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Introduction
HLA CLASS II EXPRESSION AND LIGAND-PRESENTATION
Communication between human mast cells and CD4+ T cell through 
antigen-dependent interactions. 
The HLA-class II ligandome of B cells is highly conserved on N- and 
C-terminal residues outside the peptide-binding cleft. 
HLA-DQA1*01:03/DQB1*06:03, an HLA-DQ molecule associated 
with autoimmune resistance, presents a unique peptide repertoire. 
TOWARDS A MOLECULAR BASIS FOR THE CONNECTION BETWEEN 
HLA, RHEUMATOID ARTHRITIS AND AUTOANTIBODIES
An investigation of the value of an ACPA multiplex assay in an early 
arthritis setting. 
Fine-mapping the HLA locus in rheumatoid arthritis and other rheu-
matic diseases: Identifying causal amino acid variants? 
The protective effect of HLA-DRB1*13 alleles during specific phases 
in the development of anti-citrullinated protein antibody positve 
rheumatoid arthritis.  
Crossreactivity to vinculin and microbes provides a molecular basis 
for HLA-based protection against rheumatoid arthritis. 
The HLA-DRB1*14:02 allele predisposes indigenous North American 
populations to rheumatoid arthritis based on a unique molecular 
mechanism.
Presentation of citrullinated neo-epitopes is not unique to HLA-SE 
alleles: Arginine to citrulline conversion also enhances peptide 










































Genetics of rheumatoid arthritis: What have we learned?
Immunogenetics. 2011 Aug;63(8):459-466
and
HLA and rheumatoid arthritis: How do they connect?







THE ADAPTIVE IMMUNE SYSTEM
During life, every day, we encounter many different micro-organisms including 
potentially pathogenic bacteria, viruses, fungi and parasites. The immune system is 
critically important in the defence against these pathogens.
The immune system has many different components. These include a wide variety 
of immune cells, but also non-cellular effector mechanisms. The immune system 
can be roughly subdivided in two components: the innate and the adaptive immune 
system. Upon primary infection, the innate immune system is the first to act. The 
response is generally fast and unspecific. After a few days the adaptive immune 
system comes into play. This response is highly potent and extremely specific. In 
addition, after clearance of the pathogen, the adaptive immune system establishes 
memory resulting in a highly potent and fast specific immune response upon secon-
dary infection.
The large specificity of the adaptive immune system is mainly established by two 
cell typed, the B and T cells. These lymphocytes express B or T cell receptors, highly 
specific receptors with a very large diversity. B and T cells differ in the way they 
recognize their antigen. B cells recognize their antigen in its native form. Antigen-re-
cognition combined with different activation signals allows for B cell activation and 
their differentiation in antibody secreting plasma cells. T cells can provide these 
activation signals and are therefore critically important for the generation of potent 
antibody responses. In addition. T cells also have other effector functions including 
killing of infected cells and the production of inflammatory cytokines. In contrast 
to B cells that recognize native antigens, T cells only recognize processed antigens 
presented by antigen presenting molecules, predominantly by human leukocyte 
antigens (HLA) [1].
Due to the potency and specificity of adaptive immune response, B and T cells have 
to be strongly educated to distinguish self from non-self. Nevertheless, autoim-
mune diseases (AID), diseases characterized by a failure of the immune response 
to distinguish self from non-self, are highly prevalent in the western world. In the 
United States, the prevalence was estimated between 5-8% of the population [2]. B 
and T cells are implicated in the development of most of these AID.
HUMAN LEUKOCYTE ANTIGENS
HLA molecules present processed antigens to T lymphocytes. In the presence 
of foreign proteins, e.g. during infection, foreign peptides are presented by HLA 
molecules. Recognition of such HLA-peptide complexes by T cells results in T cell 
activation and its accompanying effector mechanisms. HLA molecules can be 
subdivided in two subclasses: HLA class I and class II molecules. HLA class I molecules 
present peptides derived from an intracellular source. T lymphocytes that are 
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specific for antigens presented by HLA class I molecules are distinguished by the 
expression of CD8, hence their name CD8+ T cells. HLA class II molecules present 
peptides derived from an extracellular source. T lymphocytes that are specific for 
HLA class II molecules express CD4, hence their name CD4+ T cells. The classical HLA 
class II molecules are named HLA-DQ, HLA-DR and HLA-DP and are composed of 
an alpha and a beta chain. Peptides are presented at a site of interaction between 
these two chains [3].
The genes encoding for HLA molecules are located in a region in chromosome 6 
(Figure 1). The region has high linkage disequilibrium (LD) and the genes are highly 
polymorphic, resulting in a large variety of HLA molecules. Polymorphic residues 
are mainly located at sites important for antigen presentation resulting in large 
differences in peptide repertoire between different HLA molecules [4, 5].
Expression
HLA class I and HLA class II molecules differ in their expression pattern. HLA class I 
molecules are expressed by nearly all nucleated cells. In contrast, the expression of 
HLA class II molecules is more tightly regulated. Under physiological conditions, HLA 
class II molecules are predominantly expressed by professional antigen-presenting 
cells, including B lymphocytes, dendritic cells and macrophages. In inflammatory 
conditions, including in AID, other tissue cell types can also present HLA class II 
molecules [6].
Tolerance and autoimmunity
T cell are highly specific and potent. Therefore, it is very important to prevent 
their activation in response to processed self-antigens. In the thymus, precursor T 
cells are educated to distinguish self from non-self [7]. HLA molecules play a very 
important in role this process. Nevertheless, the HLA locus is the most important 
risk factor for the development of most AID [8]. Understanding the role of HLA 
molecules in the development of AID will likely offer very important insights in the 
AID pathogenesis.
RHEUMATOID ARTHRITIS
Rheumatoid arthritis (RA) is a chronic systemic AID characterized by extensive 
inflammation of the synovial joints. About 1% of the western population is affected 
by this disease resulting in a large disease burden. In the past decades seminal 
work was performed on the drivers of the inflammatory process, resulting in the 
development of a whole range of therapeutics that have greatly enhanced the 
quality of life of RA patients. Despite the identification of crucial pathways and the 
implementation of novel therapeutics, little is known about the factors driving the 







RA is considered an autoimmune disease. Autoantibodies are an important 
hallmark of RA and several classes of autoantibodies have been described that 
precede the development of RA. These autoantibodies include rheumatoid factor, 
anti-citrullinated protein antibodies (ACPA) and the recently identified anti-
carbamylated protein antibodies [10, 11].
ACPA are of particular interest as these autoantibodies are highly specific for RA 
and can be found in about 50% of early RA patients. This makes ACPA an important 
early clinical biomarker and ACPA-status was therefore recently added to the new 
criteria used for the classification of RA patients [12]. In addition, ACPA+ RA patients 
present with a faster rate of joint destruction. ACPA can therefore also be used as a 
biomarker for patients with a more severe disease phenotype and could be used to 
select those patients eligible for a more aggressive treatment [13].
Upon comparing ACPA+ with ACPA- RA patients, it was noted that these patient-
groups do not only differ in clinical phenotype but also in genetic and environmental 
risk factors [14, 15]. It is therefore believed that these are two distinct disease 
subsets with a different underlying pathogenesis.
Citrullination
In 1964, it was first shown that RA patients harbour very specific antibodies, 
which were called anti-perinuclear factor or anti-keratin antibodies [16-18]. In a 
search for synovial targets to which these autoantibodies bind, fibrinogen and 
vimentin were identified [19, 20]. Proteins can undergo many types of post-
translational modifications (PTMs). In 1998, it was demonstrated that the described 
autoantibodies only target citrullinated antigens, hence their name anti-citrullinated 
protein antibodies [21-23]. Citrullination is a physiological process catalysed by a 
family of enzymes called peptidylarginine deiminases (PADI1-4). These enzymes 
convert the positively charged amino acid (aa) arginine to a novel uncharged aa 
called citrulline. This process is linked to several aspects of cell biology including 
apoptosis, necrosis, netosis and histone modifications. PADI enzymes require 
relatively high concentrations of calcium for their activity allowing citrullination of 
the extracellular matrix when they are released from (dying) cells [24, 25].
Several data indicate an important role for citrullination in ACPA+ RA. Genome-wide 
Figure 1: Schematic representation of the HLA locus. Scheme shows the different genes located in the 
class-I and class-II region of the HLA locus. Genes that encode classical HLA class I and class II mole-
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association studies identified single nucleotide polymorphisms (SNPs) in the region 
encoding the PADI4 gene that are associated with an increased risk to develop ACPA+ 
RA[26]. Also, smoking, the most important environmental risk factor, is described 
to associate with an increased PADI2 expression in bronchoalveolar lavage cells 
and bronchial mucosal biopsy sections [27]. Finally, it was recently shown that RA 
patients can carry autoantibodies specifically targeting PADI-enzymes, which can 
enhance the activity of these enzymes allowing them to function at lower calcium 
concentrations enabling enhanced citrullination of the extracellular matrix when 
they are released from (dying) cells [28].
Pathogenicity of ACPA
Because of the clear association between the rate of joint destruction and ACPA 
positivity, it has been suggested that ACPA may directly contribute to synovial 
inflammation. ACPA producing B cells are enriched in the synovial fluid, which 
suggests local production of ACPA in the synovial fluid and a direct role for ACPA 
and/or ACPA-producing B cells in synovial inflammation [29, 30]. The number of 
different ACPA isotypes is a predictor of radiographic damage [31]. As different 
isotypes can recruit different immune-effector mechanisms, this suggests that 
ACPA can contribute to damage using multiple different effector pathways. For 
example, stimulation of osteoclast precursors, cells involved in the degradation 
of bone, with ACPA has been reported to result in increased osteoclastogenesis 
and was suggested to explain the association between ACPA and more severe joint 
destruction [32, 33]. This was also confirmed in mice since injecting mice with 
experimental arthritis with ACPA aggravates arthritis severity [34].
Many antibody effector mechanisms are implicated in the recruitment and 
activation of inflammatory cells. For instance, ACPA can form immune complexes 
with citrullinated proteins, which can activate inflammatory cells and induce the 
production of TNF-alpha [35, 36]. Also, it was reported that ACPA are particularly 
good in activating the complement system and complement-mediated recruitment 
of inflammatory cells could therefore be an important effector mechanism of ACPA 
[37-39]. These data suggest that ACPA is not merely a biomarker for a more severe 
disease phenotype, but could be directly involved in the inflammatory process.
The antigens targeted by ACPA
Since the identification of the molecular nature of the antigens targeted, much work 
has been performed on identifying potential citrullinated proteins recognized by 
ACPA. Unfortunately, this is hampered by the characteristics of the ACPA response. 
The ACPA repertoire is highly diverse as it displays reactivity against many different 
citrullinated proteins. This is explained both by the polyclonality of the ACPA 
response and by several reports that showed that ACPA molecules can directly 






citrullinated proteins identified within the synovial compartment and recognized by 
ACPA is now known including proteins like collagen, vimentin, fibrinogen, enolase, 
fibronectin, vinculin and histones [19, 43-46]. It is therefore likely that a plethora 
of citrullinated proteins are recognized by ACPA in the synovial compartment that 
could all conceivably contribute to synovial inflammation. However, due to the high 
degree of ACPA cross-reactivity, it is difficult to identify those citrullinated antigens 
that play a critical role in the initiation or development of ACPA+ RA.
Characteristics of the ACPA response
The presence of ACPA can precede RA onset by up to ten years, without any 
clinical signs of arthritis [47, 48]. Interestingly, by comparing the characteristics of 
ACPA before and after disease onset, it has become clear that the ACPA response 
is, on average, not the same between these subjects. In RA patients, ACPA are 
increased in level, use more isotypes, display a different glycosylation pattern and 
are more cross-reactive towards different citrullinated epitopes. Interestingly, the 
“maturation” of the ACPA response takes place before disease onset. Prior to the 
start of clinical symptoms a sharp rise in ACPA levels, isotype-usage and epitope 
recognition-profile is observed [49].
These findings are in line with the notion that before disease onset the ACPA-
response undergoes a “second hit”, which suggests a role for a matured ACPA 
response in the onset and the pathogenesis of ACPA+ RA. As an “immature” ACPA 
response can be identified in serum up to ten years before disease onset, this 
provides a potentially interesting therapeutic window for interventions preventing 
maturation of the ACPA response. In a search for such interventions, it is important 
to understand the progression from ACPA positivity without disease in healthy 
subjects to ACPA+ RA.
HLA MOLECULES IN RA
Genetic risk
The most important genetic risk factor for RA is the HLA class II locus (Figure 1). 
Importantly, it was shown that this locus is strongly associated with ACPA+ RA, not 
with ACPA- RA. It was estimated that about 20% of the genetic variance in ACPA+ 
RA patients is explained by SNPs in the HLA locus. All the other known loci together 
account for less than 5% of the genetic variance (unpublished data).
Susceptibility
In 1976, it was first shown that the presence of HLA-DRB1*04 strongly predisposes 
to RA [50]. The HLA-DRB1 gene is in LD with genes encoding the alpha and the beta 
chain of HLA-DQ (HLA-DQA1 and HLA-DQB1) and these genes are inherited together 
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novel statistical approach leading to the formation of an “HLA-SE version 2.0” hypo-
thesis. Variations encoding amino-acids 11 and 13 of the HLA-DRB1 chain explain, 
statistically, most of the genetic risk followed by “SE aa” 71 and 74. Based on these 
four amino acid positions, RA patients can be subdivided in 16 groups, each with 
their own genetic risk-profile [54]. The three groups with the highest odds ratios still 
harbor HLA-DR-DQ haplotypes encoding the SE alleles derived from HLA-DRB1*01, 
DRB1*04 and HLA-DRB1*10 alleles.
Notably, HLA-DRB1*04 positive RA patients are also HLA-DQ3 positive and it has 
also been proposed that the predisposing effect of HLA-DR4 can be explained by 
its LD with genes encoding for HLA-DQ3 [55]. The HLA-DR/HLA-DQ linkage makes 
it difficult to identify which of the two molecules is responsible for the association 
with RA. Therefore, it is still unclear whether the HLA-DQ-genes in linkage with the 
HLA-DR encoding SE genes can be excluded from the association with ACPA+ RA.
Protection
In addition to HLA-DRB1 alleles that contribute to RA susceptibility, other HLA-DRB1 
alleles confer protection against the disease. HLA-DRB1*13 alleles are most strongly 
associated with protection, but only from ACPA+ RA. Interestingly, these alleles can 
also protect in the presence of SE alleles [56]. The dominant role of these protective 
alleles could suggest that these alleles work on a similar pathway. Likewise, protec-
tion can be transferred from a mother carrying a protective allele to a child lacking 
in haplotypes. In 1986, the shared 
epitope (SE) hypothesis was pos-
tulated [51]. This hypothesis 
assumes that the HLA association 
is explained by polymorphisms in 
the HLA-DRB1 chain. Upon com-
paring different HLA-DRB1*04 
alleles it was observed that these 
alleles differ mostly in aa position 
70-74 [52]. Haplotypes encoding 
predisposing HLA-DRB1 alleles 
share the sequences QRRAA, 
QKRAA and RRRAA at these posi-
tions and hence are collectively 
called HLA-SE alleles (Figure 2). It 
was postulated that this sequence 
directly influences peptide pre-
sentation or T cell recognition 
[51, 53]. Recently, the association 
of individual amino acids with 
ACPA+ RA was revisited by using a 
Figure 2: HLA-DR4 molecule with the SE sequence 
in positions 70-74. The crystal structure of HLA-
DRB1*04:01/DRA1*01:01 complexed with a human 
collagen II-derived peptide (dark grey circles) shows 
the peptide binding groove created by the helical 
structures of the HLA-DR beta and alpha chain 






such allele, indicating that protection is an active and dominant process [57].
HLA involvement in ACPA positivity or in ACPA positive disease?
As mentioned above, the presence of ACPA can be found up to ten years before disease 
onset. This suggests that the progression to ACPA+ RA involves two “hits”. Initially 
individuals are healthy and ACPA negative. After the “first hit” they become positive 
for ACPA. Then, presumably after a “second hit”, individuals progress from ACPA 
positivity to ACPA+ RA, which is accompanied by a maturation of the ACPA response.
The HLA class II locus is strongly associated with ACPA+ RA and understanding 
this association would provide important insights in disease pathogenesis. 
The association suggests an involvement of antigen-specific CD4+ T cells. 
This is strengthened by genome-wide association studies that identified 
many genes involved in the regulation of adaptive immune responses 
(Figure 3) [58]. In understanding the HLA class II association it is important 
to understand if this locus contributes to either the first or the second “hit” 
thought to accompany ACPA-positivity or ACPA-positive disease, respectively.
As antigen-experienced CD4+ T cells are critically important for the generation 
of mature antibody responses, it seems likely that activated antigen-experienced 
(self-reactive) CD4+ T cells are involved in the maturation of the ACPA response. 
Importantly, recent evidence suggests that the HLA class II locus is not associated with 
the risk to become ACPA+, but with the risk to progress from ACPA+ to ACPA+ RA [59, 
60]. This supports the hypothesis that the HLA class II locus is not directly involved
in the formation of ACPA responses, but rather in its maturation, possibly via T cells 
providing help to ACPA producing B cells before the precipitation of disease (Figure 4).
THESIS OUTLINE
The general aim of this thesis was to provide a better understanding of the role of 
HLA class II dependent antigen presentation in both physiological conditions as well 
































Figure 3: List of ACPA+ RA susceptibility genes
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as in rheumatoid arthritis. To achieve this aim, our studies were separated in two 
parts.
In PART I, we focused on the expression of HLA class II molecules and the 
characteristics of the ligands presented by HLA class II molecules, starting with 
the observation that human mast cells can present HLA class II molecules on their 
surface (Chapter 2). Potentially this expression could play a role in rheumatoid 
arthritis as mast cells are frequent cells in the synovium [61]. The nature of peptides 
presented by HLA class I molecules have recently been extensively characterized 
[62]. In Chapter 3, we have now performed highly similar analyses in the context of 
HLA class II with a focus on HLA-DR3. HLA-DR3 is one of the most common HLA-DR 
molecules and associated with different autoimmune diseases including thyroid 
autoimmunity and ACPA negative RA [63, 64]. In Chapter 4, we have characterized 
peptides eluted from HLA-DQ6.3. This particular HLA-DQ molecule is in tight linkage 
disequilibrium with HLA-DRB1*13:01 and is strongly associated with protection 
from autoimmune diseases including RA and narcolepsy [56, 65].
In PART II, we studied the association between HLA class II, RA and citrullination. 
As discussed, the HLA locus is primarily a risk factor for ACPA+ RA. Several tests 
are now available to determine ACPA-positivity using model antigens (e.g. anti-
CCP-2/3) [11]. In Chapter 5, we have examined a novel ACPA multiplex-test in 
comparison to the conventional tests [66]. In Chapter 6, we provide an opinion 
on recent genetic advances in identifying causal variants within the HLA locus 
associated with ACPA-positive rheumatoid arthritis. To study the contribution of 
protective and predisposing alleles in the ACPA+ RA it is important to determine 
in time where these alleles modulate risk. This has previously been performed 
for the predisposing alleles and in Chapter 7 we have expanded this to protective 
HLA-DRB1*13 alleles. In Chapter 8, we provide a detailed molecular basis for the 
contribution of protective and predisposing HLA class II molecules in the HLA-RA 
connection. We have also studied an alternative hypothesis that assumes that 
Figure 4: Schematic representation of the progression from healthy to ACPA+ RA. The HLA class II locus 
associates with the progression from ACPA positivity to ACPA+ RA. During this “2nd hit” the ACPA 
response matures as showed by isotype expansion, increased ACPA titers and epitope spreading. 
Together it supports a role for the HLA class II locus in the maturation of ACPA.
RAHealthy
ACPA+ACPA+
1st hit 2nd hit
1. isotype expansion
2. increased ACPA ters
3. epitope spreading







the HLA-RA connection is explained by the presentation of shared (citrullinated) 
antigens by HLA-SE alleles [67]. In Chapter 9, we studied the ability of different 
SE-positive HLA class II molecules to present citrullinated antigens. In Chapter 10, 
we expanded these analyses to SE-negative HLA-DR and HLA-DQ molecules. Finally, 
in Chapter 11 we discuss the implications of the results and future directions.
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ABSTRACT
Mast cells are immune cells residing in tissues, where pathogens are first encoun-
tered. It has been indicated that mast cells might also be involved in setting the 
outcome of T cell responses. However, little is known about the capacity of human 
mast cells to express MHC class II and/or to capture and present antigens to CD4+ 
T cells.
To study the T cell-stimulatory potential of human mast cells, CD34+ stem cell-de-
rived mast cells were generated. These cells expressed HLA-DR when stimulated 
with IFN-γ, and, importantly, presented peptide and protein for activation of anti-
gen-specific CD4+ T cells. The interplay between mast cell and T cell led to increased 
HLA-DR-expression on mast cells. Mast cells were present in close proximity to T 
cells in tonsil and expressed HLA-DR and CD80, indicating their ability to present 
antigens to CD4+ T cells in T cell areas of human lymph nodes.
Our data show that mast cells can present native antigens to human CD4+ T cells 
and that HLA-DR expressing mast cells are present in tonsil tissue, indicating that 
human mast cells can directly activate T cells and providing a rationale to study the 
potential of mast cells to prime and/or skew human T cell responses.






Mast cells are most well-known because of their role in IgE-mediated immune res-
ponses as they express the high affinity FcεRI. Mast cells are present at strategic 
locations of the environment/host interface where they can encounter pathogens. 
Therefore, they have been implicated in the regulation of adaptive immune res-
ponses as well as in the regulation of T cell immunity.
Secretion of TNF by skin mast cells was shown to be essential for lymph node hyper-
trophy and T cell recruitment during bacterial infection [1]. Furthermore, mast cells 
were shown to be capable of migrating from the skin to the draining lymph nodes 
in murine models of contact hypersensitivity and UV radiation [2, 3]. In the draining 
lymph nodes, the secretion of chemokines by mast cells has been implicated in the 
recruitment of T cells [2, 4]. These studies, therefore, indicate that mast cells can be 
involved in the regulation of T cell trafficking towards lymphoid organs, suggesting 
that mast cells may have a role in the induction of primary and/or local memory T 
cell responses. Indeed, anti-CD3-stimulated T cells displayed enhanced prolifera-
tion and cytokine secretion in the presence of mast cells, indicating that mast cells 
are capable of enhancing T cell responses [5-7].
A first direct demonstration that mast cells can also present antigens to T cells came 
from mouse studies showing that OVA-specific TCR-transgenic CD8+ T cells can be 
activated by mast cells via MHC class I [8, 9]. Likewise, using OVA-specific TCR-trans-
genic CD4+ T cells, it was demonstrated in vitro that mouse mast cells can also 
activate MHC class II-restricted T cells when loaded with OVA-peptide, but were 
less efficient in presenting OVA-protein [10, 11].
Thus far, little information is available on the antigen-presenting capacity of human 
mast cells. Human mast cells have also been shown to express MHC class II, espe-
cially after incubation with IFN-γ, which suggests their capacity to present antigen 
to CD4+ T cells [12-14]. Indeed, activation of T cell hybridomas with superantigens 
by these cells has been reported [14]. However, T cell activation by superantigen 
does not require the presentation of antigenic peptides by MHC-molecules or the 
processing of protein via endogenous pathways.
Human mast cells have been reported to be present in the interfollicular area in 
tonsil [7], indicating they may be involved in the activation of T cell responses in 
lymphoid organs. However, it is unknown whether these mast cells possess the 
required molecular make-up, such as HLA-DR and costimulatory molecules, to 
present antigen and activate T cells in lymphoid organs.
As it is unclear whether human mast cells are able to process and present native 
antigen to CD4+ T cells, we aimed to study the interaction between these cells. 
Our data show that human mast cells can present both peptide and entire protein 
antigens to CD4+ T cells, using two different antigen-specific CD4+ T cell responses 
as read-out. Interaction of CD4+ T cells with mast cells led to the enhanced expres-
sion of HLA class II molecules on mast cells via release of IFN-γ by T cells. In addition, 
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we show that human mast cells, analyzed ex vivo from tonsil, are present in T cell 
areas where they express HLA-DR and CD80. Together, these data indicate that 
antigen-specific mast cell-T cell interactions could contribute to the outcome of 
immune responses in the human.
MATERIALS AND METHODS
Mast cells 
Buffy coats from healthy volunteers were obtained from the blood bank (Sanquin, 
The Netherlands). PBMCs were isolated using a standard Ficoll procedure, after 
which CD34+ hematopoietic stem cells were isolated with CD34 microbeads 
(Miltenyi Biotec). Isolated CD34+ stem cells were differentiated into mast cells using 
serum-free medium (StemPro 34 + supplement, Gibco) with 30 ng/mL IL-3, 100 ng/
mL IL-6 and 100 ng/mL Stem Cell Factor (SCF) at 50.000 cells/mL as described [15, 
16]. Half of the medium was replaced weekly with serum-free medium containing 
100 ng/mL IL-6 and 100 ng/mL SCF. All recombinant cytokines were obtained from 
Peprotech. After 6-8 weeks, the purity of mast cells was determined by flow cyto-
metric analysis of CD117 (c-kit), FcεRI and CD203c and intracellular tryptase. The 
purity of mast cells ranged from 90-99%.
CD4+ T cell clone 
An adenovirus-specific CD4+ T cell clone (M2.11) was used to determine antigen 
presentation by mast cells [17]. This clone recognizes a peptide derived from 
hexon protein II, in the context of HLA-DRB1*03:01. Mast cells from blood of HLA-
DRB1*03:01 positive donors were generated as described above. Mast cells were 
incubated with 5 μg/mL peptide for 24 hours, or 1-50 μg/mL protein (22.2 kDa 
polypeptide fragment D from hexon protein II [17]) for 6-72 hours, before coculture 
with the CD4+ T cells. Before coculture with the T cell clone, mast cells were tho-
roughly washed to remove all soluble protein or peptide. Subsequently, the mast 
cells were added to the CD4+ T cells in a 1:1 ratio in RPMI with 10% human serum 
and 100 ng/mL SCF at 200.000 cells/mL. After 1 hour, 5 μg/mL brefeldin A was 
added and incubated overnight. To determine the effects of activation of the T cell 
clone on the mast cells, the cells were cultured without brefeldin A for the indicated 
timepoints.
Blocking antibodies and isotype controls for HLA class II (BD Pharmingen, clone 
Tü39, 10 μg/mL) were added to the mast cells, and incubated for 1 hour at 37 
°C before the mast cells were added to the T cells. Blocking antibodies remained 
present during the coculture. Blocking antibodies and isotype controls for IFN-γ 
(eBioscience, clone NIB42, 20 μg/mL) were added to the cocultures directly.





CD4 T cell bulk responses against recall antigens 
Polyclonal CD4+ T cell bulks were generated by activation of PBMCs with the recall 
antigens tetanus toxoid at 0.75 Lf/mL (Netherlands Vaccine Institute), tuberculin 
purified protein derivative 0,5 μg/mL (Netherlands Vaccine Institute) and Candida 
albicans 0,005% (HAL allergy) in IMDM/5% human serum for 7 days, after which 
antigen presentation by autologous mast cells was evaluated. Mast cells or auto-
logous PBMCs were incubated with the recall antigens mentioned above for 16 
hours, before coculture with autologous bulk CD4+ T cells. After this incubation, 
the cells were thoroughly washed to remove all soluble protein. Autologous PBMCs 
were used as positive control and were allowed to adhere to the plate at 37°C for 
2 hours, after which non-adherent cells were removed. Subsequently, the CD4+ T 
cells were added to the antigen presenting cells in IMDM/5% human serum at 2 x 
106 cells/mL. After 1 hour, 10 μg/mL brefeldin A was added and incubated over-
night.
Tonsils 
Human tonsils were obtained after tonsillectomy. A portion of these tissues were 
fixed with 4% formaldehyde in PBS, stored in 70% ethanol and embedded in paraffin 
for immunofluorescent staining of sections. The remaining part of the tonsils was 
washed with RPMI with 10%FCS, and cut into small pieces. Subsequently, the tonsils 
were dispersed through a 70 um filter to get single-cell suspensions. Cells were 
frozen until flow cytometric staining and acquisition. This study was performed in 
accordance with the declaration of Helsinki and local ethical guidelines.
Immunofluorescence 
Tonsil tissues were treated as previously described to deparaffinize and retrieve 
antigens with EDTA [18]. Slides were incubated with 8 μg/mL goat anti-human 
tryptase, 26.5 μg/mL rabbit anti-human CD117, 60 μg/mL rabbit anti-human CD3 or 
matching isotype controls for 1 hr at room temperature. After washing, slides were 
stained with 2 μg/mL donkey α-goat AF 568 and 2 μg/mL donkey α-rabbit AF 488 
for 1 hr at room temperature. After washing, slides were covered with Vectashield 
containing DAPI (Vector laboratories) to stain nuclei. Slides were analysed on a Zeiss 
Axio ScopeA1 microscope.
Flow cytometry 
For detection of HLA-DR and costimulatory molecules expression by cultured mast 
cells, cells were incubated with fluorochrome-conjugated antibodies recognizing 
CD117, CD203c, HLA-DR, CD80 and CD86 or matching isotype controls. Intracellular 
staining of tryptase was performed as described [19].
For detection of expression of HLA-DR and costimulatory molecules on tonsil mast 
cells, cells were incubated with fluorochrome-conjugated antibodies recognizing 
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CD117, CD203c, FcεRI, HLA-DR, CD86 and CD80 or matching isotype controls for 
each of these antibodies. Just prior to flow cytometric acquisition, 0.2 uM DAPI was 
added for exclusion of dead cells.
For intracellular cytokine staining by CD4+ T cells, the cells were incubated with 
fluorochrome-conjugated antibodies recognizing CD3 and CD4, after which they 
were permeabilized using CytoFix CytoPerm Kit (BD Biosciences). To gate out any 
remaining monocytes in the CD4+ T cell bulks, antibodies to CD14 were added as 
well. After washing, cells were incubated with PE-labeled anti-IFN-γ, TNF-alpha or 
matching isotype control. Cells were taken up in 1% paraformaldehyde until flow 
cytometric acquisition.
Flow cytometry was performed on FACS Calibur (BD) or LSR II (BD). Analysis was 
performed using FACS Diva (BD) and FlowJo software.
Statistical analysis 
Results are expressed as mean + SEM. Statistical analysis was performed using SPSS 
PASW 17.0 and GraphPad Prism 4. For differences between two groups, student’s 
T tests were performed. P values of <0.05 were considered statistically significant.
RESULTS
Human peripheral blood-derived mast cells express HLA-DR when stimulated 
with IFN-γ
Human mast cells were generated from CD34+ stem cells. Typical flow cytometry 
plots identifying mast cells by combined expression of CD117, CD203c (Ectoenzyme 
E-NPP3), FcεRI and intracellular tryptase are shown in Figure 1A, indicating that the 
six-week culture results in mature (CD117+ tryptase+) mast cells. No expression 
of the DC markers DC-SIGN and CD1c (BDCA-1) was found on our cultured mast 
cells (data not shown). Only low, but detectable, levels of HLA-DR were detected on 
resting mast cells (Figure 1B-C).
Because it was previously shown for mast cell-lines that IFN-γ could induce expres-
sion of HLA class II, we evaluated whether this could lead to upregulation of HLA-DR 
on our cultured mast cells as well. Incubation with 50 ng/mL IFN-γ for 24 h induced 
upregulation of HLA-DR (Figure 1B-C). No induction of expression of HLA class II 
was found after stimulation with TLR ligands, anti-IgE or recombinant IL-4 (data not 
shown). These results indicate that in the presence of IFN-γ, mast cells can acquire 
the expression of HLA class II, and possibly the ability to present antigen to CD4+ 
T cells. Of the costimulatory molecules tested (CD80, CD86, ICOSL, OX40L, CD40L, 
CD40), we found expression of CD80 but not CD86 or any of the other markers, as 
assessed by flow cytometry (Figure 1D-E).
Together, these data indicate that human mast cells can express molecules required 
for stimulation of CD4+ T cells.





Human mast cells can present peptide and protein to CD4+ T cells
To evaluate the potential of human mast cells to present antigen to CD4+ T cells, 
mast cells were pre-incubated with an adenovirus-derived peptide or hexon IID 
protein. Subsequently, mast cells were cocultured with an adenovirus-specific T 
cell clone recognizing the particular peptide. As shown by intracellular cytokine 
staining, mast cells pre-incubated with peptide, in contrast to control mast cells, 
were capable of inducing robust cytokine production by the T cells (Figure 2A-B). 
The capacity of mast cells to induce T cell responses with the peptide was compa-
rable to that of PBMCs. Importantly, mast cells pre-incubated with the hexon IID 
protein were also capable of activating T cells, indicating the capacity of mast cells 
to take up, process and present native protein antigen to CD4+ T cells (Figure 2A-C). 
Figure 1. Expression of HLA-class II and costimulatory molecules by human peripheral blood-de-
rived mast cells. (A) Representative flow cytometric plots of mast cell characterization after 6-8 
week differentiation showing expression of CD117, intracellular tryptase, FcERI and CD203c. His-
tograms show gated live cells based on FSC/SSC characteristics as shown in the first panel. (B, C) 
Mast cells were cultured in the presence of 50 ng/mL IFN-γ for 24 hours, after which expression 
of HLA-DR was assessed. (D, E) Expression of CD80 and CD86 in resting mast cells. (B, D) Repre-
sentative examples of mast cells gated as CD117+ CD203c+. (C, E) Summaries (mean ± SEM) of 
independent mast cell cultures (n=3). Expression (MFI ratio) is indicated as MFI of the marker of 
interest (e.g. HLA-DR) divided by the MFI of the matching isotype control. Asterix in (C) indicates sig-
nificant (p<0.05) increase in IFN-γ treated cells compared with ctr mast cells, using student’s T test.
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Presentation of protein antigens by mast cells appeared rather efficient as 5 μg/
mL protein, equivalent to 225 nM, was still able to activate adenovirus-specific T 
cells. Furthermore, although there was no difference between the T cell responses 
induced by mast cells compared with PBMCs when they were incubated with 
peptide, mast cells were more efficient than PBMCs in inducing T cell responses 
with the protein antigen (Figure 2C) Similar results were obtained when T cell-de-
rived cytokine levels in supernatant were measured by ELISA (data not shown).
Figure 2. Antigen presen-
tation by human mast cells 
leads to activation of ade-
no-virus-specific T cells. (A) 
Representative flow cytome-
tric plots of TNF-alpha (TNFa) 
and IFN-γ (IFNg) production by 
gated CD3+CD4+ T cells after 
o/n coculture with mast cells 
preincubated with medium 
(ctr), adenovirus-specific 
peptide or protein, in the 
presence of brefeldin A. (B 
and C) Summary of T cell acti-
vation after preincubation 
of mast cells with peptide 
and protein. Each dot shows 
an independent mast cell 
culture or PBMCs donor (n 
= 18 and n = 9 for peptide 
and protein, respectively). 
P values comparing the 
indicated conditions were cal-
culated using student’s t-test. 
(D, E) Cytokine production by 
T cells after preincubation of 
mast cells with blocking HLA 
class II antibodies (n=3). (E) 
Data are shown as mean ± 
SEM pooled from (n=3) inde-
pendent mast cell cultures





To confirm that these T cell responses were HLA class II-dependent, mast cells were 
next incubated with blocking HLA class II- or isotype control antibodies. CD4+ T cell 
responses induced by mast cells pre-incubated with hexon IID protein were almost 
completely inhibited by HLA class II-blocking antibodies, compared with the respec-
tive isotype control (Figure 2D-E), further confirming that the mast cells stimulated 
the T cells via HLA class II.
Figure 3. Antigen presentation by human mast cells to autologous bulk CD4+ T cells.
Polyclonal CD4+ T cell bulks were generated by activation of PBMCs with the recall antigens tetanus 
toxoid, tuberculin purified protein derivative and Candida albicans for 7 days. Autologous mast cells or 
adherent PBMCs preincubated with medium (ctr) or these recallantigens (memory mix) were cultured 
o/n with the bulk T cells in the presence of brefeldin A. Flow cytometric plots of TNF-alpha (TNFa) 
production by T cells in 3 independent experiments are shown. T cells were gated based on FSC/SSC 
characteristics, CD14/CD117-negativity, CD4+ and CD3+ as shown in top panel.
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Although the data presented above indicate that human mast cells can present 
protein antigens to T cells, they do not show whether also polyclonal T cells can be 
activated by mast cells. To determine whether polyclonal T cells, rather than cloned 
T cells potentially harboring a high avidity TCR to the peptide-MHC complex, are also 
activated by mast cells, we next generated CD4+ bulk T cells expanded for one week 
Figure 4. Induction of HLA class II on mast cells 
through IFN-γ production by CD4+ T cells. (A, B) 
Representative flow cytometric plots and summary 
of HLA-DR expression by mast cells preincubated 
with medium (ctr) or adenovirus-specific peptide 
(pept), after coculture with or without adenovi-
rus-specific CD4+ T cells for the indicated time 
periods (n=2). (C, D) Representative flow cytome-
tric plots and summary of HLA-DR expression by 
mast cells after coculture for 48 hrs with adenovi-
rus-specific CD4+ T cells in the presence of isotype 
control antibodies (mIgG1) or blocking antibodies to 
IFN-γ (n=3). Mast cells are gated as CD203c+ cells as 
shown in Figure 1. Data are shown as mean ± SEM 
pooled from (n=3) independent mast cell cultures.
with pooled tetanus toxoid, tuberculin and 
candida albicans. Subsequently, autologous 
mast cells were incubated with these recall 
antigens and used as APCs for polyclonal 
bulk T cells. Mast cells were capable of acti-
vating autologous polyclonal CD4+ T cells, 
confirming their T cell-activating capacity 
(Figure 3). The response by CD4+ T cells 
that was induced by mast cells was compa-
rable to or better than our positive control, 
autologous adherent PBMCs.
Together, these results indicate that human 
mast cells are capable of taking up and pro-
cessing native proteins for presentation to 
CD4+ T cells in the context of HLA class II.
CD4+ T cells can modulate mast cells via 
IFN-γ
As the interaction between antigen-presen-
ting cells and T cells can be bi-directional, 
the potential of CD4+ T cells to modulate 
MC phenotype was analysed. To this end, 
mast cells pre-incubated with peptide 
were cocultured with adenovirus-specific 





CD4+ T cells to evaluate potential effects 
of T cell activation on the mast cells. As 
shown in Figure 4A-B, the expression 
of HLA-DR by mast cells was enhanced 
when T cells were activated by mast cells 
pre-incubated with peptide. Mast cells 
cultured without T cells, or mast cells 
not pre-incubated with peptide did not 
show an increase in HLA-DR expression. 
Upregulation of HLA-DR was inhibited 
by blocking IFN-γ, ranging from 14-100% 
inhibition as compared with the isotype 
control (Figure 4C-D). These data indicate 
that the effect of activated T cells res-
ponsible for HLA class II-upregulation on 
mast cells was mainly mediated via IFN-γ. 
Together, these results show that mast 
cells cannot only activate T cells, but also 
that CD4+ T cells can modulate mast cells 
by upregulation of HLA class II, indicating 
a bidirectional interplay between mast 
cell and T cell.
Human tonsils contain HLA-DR+ mast 
cells
To evaluate whether HLA-DR+ mast cells 
can also be found in vivo in T cell areas 
of lymphoid organs, tonsil sections were 
stained for mast cells. Mast cells were 
identified as CD117+ Tryptase+ dou-
ble-positive cells and were found in all 
(n=6) tissues analysed (Figure 5A). All 
tryptase+ cells expressed CD117, whereas 
also some CD117+ tryptase- cells could 
be identified, indicating that CD117 alone 
cannot uniquely define tonsillar mast 
cells. Tryptase+ mast cells were most 
often found in T cell areas characterized 
by abundant expression of CD3, and were 
commonly observed in close proximity to 
CD3+ T cells (Figure 5B-C). These results 
indicate that mast cells are present in T 
A. Mast cell identification in tonsil










B. Tonsil mast cells in T cell areas
10 μm
Figure 5. Mast cells are present in T cell areas 
of human tonsil. (A) Mast cells in tonsils are 
characterized as tryptase (tryp) + CD117+ 
double-positive cells. (B, C) Double-stai-
ning of tryptase and CD3. (B) Mast cells are 
mainly found in T cell areas of the tonsil. “F” 
indicates the B cell follicles; “T” indicates the 
T cell area, defined by expression of CD3. 
Arrowheads show Tryp+ mast cells present in 
the T cell area. (C) Mast cells are often found 
in close proximity to T cells. Arrowheads show 
examples of Tryp+ mast cells in close contact 
with CD3+ T cells. Original magnifications: 
20x (A and B) and 40x (C). (A-C) Images are 
representative examples of fluorescent stai-
nings of tonsils from 6 independent donors.
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cell areas of lymphoid organs and at locations allowing T cell-mast cell interactions.
Nonetheless, as evaluated by immunofluorescent stainings of tonsil sections, 
we could not detect HLA-DR on these tryptase+ mast cells (data not shown). As 
HLA-DR expression might be relatively low on tonsillar mast cells, the detection of 
its expression might be obscured by the high HLA expression of other APCs which 
are abundantly present in tonsil. Therefore, we also analyzed mast cells in tonsil 
cell suspensions using a more sensitive flow cytometric technique with antibodies 
recognizing CD117, CD203c, FcεRI, HLA-DR and costimulatory molecules (Figure 6). 
Mast cells were identified by their expression of high levels of CD117 and were 
further characterized by expression of the mast cell markers CD203c and FcεRI 
(Figure 6A-B), and absence of the DC markers DC-SIGN and CD1c (data not shown). 
HLA-DR expression was found on mast cells of all 6 donors analyzed, both when 
analyzed as percentage or mean fluorescence (Figure 6C-D). The relative immunof-
luorescence was approximately 10-fold lower than on other HLA-DR+ cells in the 
tonsil, which is in line with the difficulty to detect HLA-DR on mast cells in a convin-
cing manner by staining of tonsil sections.
The expression of costimulatory molecules by tonsillar mast cells was also evalu-
ated (Figure 6E-F). Although only low levels of CD86 were found, all four donors 
analyzed showed significant expression of CD80 compared with the isotype control, 
confirming the data obtained from mast cells cultured from blood (Figure 1C).
Together, these results show that mast cells expressing HLA-DR and costimulatory 
molecules are present in human tonsil, and that the majority of these mast cells are 
located in close proximity to T cells, arguing for mast cell-T cell interaction in human 
lymph nodes.
DISCUSSION
In this article we show for the first time that cultured human mast cells are capable 
of presenting native protein antigens to CD4+ T cells. The interaction between 
mast cells and CD4+ T cells modulated the mast cell phenotype, indicating that 
both cell types can influence each other in an antigen-dependent manner. Further-
more, the interaction between these cell types may be physiologically relevant 
as the presence of mast cells in proximity to T cells was also shown in lymphoid 
organs. A clear inherent limitation of our study is that we are unable to show the 
ability of mast cells to present antigen in vivo. Likewise, there were some diffe-
rences between the cultured mast cells and their in vivo counterparts. Whereas 
the cultured mast cells readily expressed HLA-DR after coculture with the T cells, 
the tonsil-resident mast cells already expressed HLA-DR when evaluated directly 
ex vivo. This difference might be explained by the exposure of mast cells to IFN-γ 
either in the tonsil or in the periphery by either T cells or innate IFN-γ-producing 
cells such as NK-cells. Nonetheless, as the phenotype of mast cells for the other 





Figure 6. Mast cells in tonsil express 
HLA-DR and CD80. (A, B) Mast cell 
characterization in total tonsil cell sus-
pensions by CD117, FcεRI and CD203c 
(n=6). Live cells were gated based on FSC/
SSC characteristics and DAPI-negativity 
and their expression of CD117 or isotype 
control are shown in the dotplots. Histo-
grams show expression of FcεRI and CD203c by gated CD117hi cells as shown in the dotplots. (C, D) 
Expression of HLA-DR by mast cells characterized as in A (n=6). (E, F) Expression of CD80 and CD86 
by mast cells characterized as in (A) (n=4). Expression (MFI ratio) in (D) and (F) is indicated as MFI 
of the marker of interest (e.g. HLA-DR, CD80) divided by the MFI of the matching isotype control. 
Dotted lines in (D) and (F) indicate absence of expression of the indicated marker compared with the 
isotype control (MFI ratio = 1). Data shown are representative of tonsils from 4-6 independent donors.
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markers evaluated (CD117, tryptase, CD80) was comparable, we believe that the 
cultured mast cells are a good representation of their counterparts in vivo, and that 
the biological effects observed in vitro are conceivably present in vivo as well.
The presentation of antigen to CD4+ T cells by human mast cells may serve to sti-
mulate T cells in diverse locations, such as lymphoid organs and peripheral tissues. 
As mast cells can produce a different set of cytokines than other antigen-presen-
ting cells [20-22], our findings could potentially have important implications for the 
skewing of T helper cells and maybe even for the outcome of naïve T cell-priming in 
lymph nodes. Since both cultured and tonsil-resident mast cells express HLA class 
II and CD80, their potential in stimulating naïve CD4+ T cells cannot be excluded. 
Skin mast cells have been shown to migrate from infected/allergic areas to draining 
lymph nodes in the mouse [2, 3]. Nonetheless, mouse mast cells, although able to 
activate memory T cells, were not able to prime naïve CD4+ T cells, probably due to 
the lack of costimulatory molecules [10, 11]. As mast cells only comprised approxi-
mately 0.02-0.04% of total tonsil cells as shown in figure 6, and as their expression 
of HLA class II molecules was much lower than that of other professional antigen 
presenting cells such as DCs, we do not consider it likely that mast cells play a crucial 
role in priming of T cells in primary immune responses. In contrast, we consider it 
more likely that they might be more important in activation of secondary T cells in 
either lymph node or peripheral tissue. Especially, the latter is an intriguing possi-
bility as mast cells are present at several strategic locations where pathogens are 
first encountered. It could be very beneficial to the host to swiftly activate effector 
memory T cells that are known to reside in tissues [23], by mast cells that are well 
known for their immediate and strong actions upon activation. Furthermore, mast 
cells could produce several cytokines upon activation through activation via IgE and 
TLR, which may have an impact on T cell activation or skewing.
In addition, CD4+ T cells could also influence mast cells, for example by inhibiting 
or modulating their reactivity. As murine mast cells were shown to specifically 
enhance activation of CD4+ Tregs through MHC class II [10], such T cell-mast cell 
interactions could also function to inhibit mast cell responses, such as observed in 
a murine model of anaphylaxis [24]. The expression of MHC class II by mast cells 
depended on the production of IFN-γ by T cells in this study, showing the ability of 
T cells to influence mast cell phenotype. Therefore, interaction between mast cells 
and T cells might direct the responsiveness of both cell types, allowing for optimal 
control of both cell populations.
We have not shown how the mast cells have taken up antigen for presentation to T 
cells in our study. However, we observed no enhancement of antigen presentation 
when protein antigens were targeted to the FcεRI on the mast cells via hapten-spe-
cific IgE and hapten-coupled protein (data not shown). The lack of enhancement 
of presentation by Fc-receptor-targeted antigens by human mast cells contrasts 
findings obtained in mice, as two studies reported enhanced antigen presentation 
by Fc receptor-mediated uptake [11, 25]. Nonetheless, another study using murine 





mast cells indicated decreased antigen presentation when antigen was routed to 
IgE/FcεRI, possibly because antigens were protected from proteolytic degradation 
and subsequent presentation as peptide in MHC [10]. Further research into this 
aspect is required, but our data indicate that Fc-receptor mediated uptake and pre-
sentation of Ig(E) bound antigen by human mast cells, if present, is likely to be less 
efficient as compared with the ability of DCs to take up and present immune com-
plexed antigens [26].
In conclusion, our results show that cultured human mast cells can function as 
antigen presenting cells, by uptake and processing of protein, and subsequent pre-
sentation to CD4+ T cells via HLA class II. Furthermore, expression of HLA class II and 
CD80 is found on mast cells isolated from human tonsil, where they are found in 
close proximity to T cells. In addition, the interaction between mast cells and
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CD4+ T cells led to changes in the mast cell phenotype in an antigen-specific manner, 
indicating an intimate interaction between these two distinguished cell types.
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The HLA-class II ligandome of B cells is highly 
conserved on N- and C-terminal residues 
outside the peptide binding cleft. 





Presentation of peptide-ligands on HLA class II molecules to CD4+ T cells plays an 
important role in adaptive immunity. HLA class II molecules typically present ligands 
between 11 and 20 amino acid (aa) residues in length. The part of the peptide inter-
acting with the HLA molecule is highly conserved at anchor-positions interacting 
with the peptide-binding pockets. As these peptides are generated by the action 
of specific proteases, we questioned if the N- and C-terminal side of the peptide, 
outside the peptide-binding cleft, is also conserved.
To study this we identified over 13 270 HLA-DRB1*03:01 ligands from EBV-trans-
formed B cells, the largest data set of ligands isolated from a single HLA-class II 
molecule. We provide a detailed characterization of these ligands and studied N- 
and C-terminal conservations. To do this, we selected for peptides of at least 15 
aa residues (n=7 593) and determined the frequency of aa residues at the N- and 
C-terminal side of the peptide relative to their frequency in the human proteome. 
Using this approach, we could demonstrate conservations of aa residues at both 
termini. Conserved residues are distinct from residues conserved at the p1 and 
p9 anchor residues. We identified similar conservations in a second set of ligands 
eluted from HLA-DQ2/DQ8 (n=480) and a set of HLA-DR ligands available through 
public databases (n=924).
Together, these data show that the HLA class II ligandome of B cells is conserved on 
the N- and the C-terminus. We propose that these conservations are the result of 
the action of specific proteases involved in antigen-processing.
INTRODUCTION
HLA class II molecules are heterodimers of an alpha and a beta chain and present 
peptide-ligands on the surface of professional antigen-presenting cells to CD4+ T 
cells[1, 2].
Activated CD4+ T cells play an essential role in the specific immune system and can 
have multiple effector mechanisms including the priming of CD8+ T cell responses 
and helping B cells in the production of antibodies. In addition these T cells can also 
produce effector molecules including many different cytokines that can shape the 
immune response. A proper CD4+ T cell response is crucial for the immune system 
to combat infections, but also plays an important role in anti-tumor responses[3-5].
CD4+ T cells can also play a detrimental role. In allergy CD4+ T cells targeting aller-
gens are important for class-switching towards an IgE response[6]. In autoimmunity, 
CD4+ T cells are described to be important effector cells as they could cause tissue 
damage, can prime autoreactive CD8+ T cell responses and can be involved in the 
production of autoantibodies[3]. Likewise, the HLA class II locus is a very important 
risk factor for many different autoimmune diseases[7]. Finally, the HLA-system and 





CD4+ T cells play an important role in allograft rejection[8].
Since the early 90s many groups have studied the peptide binding repertoire of 
MHC class II molecules[9-11]. From these studies it became clear that this reper-
toire strongly differs from HLA class I molecules. For instance, HLA-class II ligands 
are highly heterogeneous in size and are found in nested sets. Also, these ligands 
are the result of lysosome degradation of proteins[12]. The identification of HLA 
class II ligands was used to determine amino acid (aa) conservations in the different 
peptide-binding pockets of individual HLA class II molecules, which could be used 
to predict potential T cell epitopes.
Presented HLA class II ligands are generated upon antigen-processing by specific 
proteases (e.g. cathepsins) in the endosomal or lysomal compartments. Pep-
tide-ligands are generally presented in a linear configuration with 9 amino acids 
interacting with the HLA molecule. Within, these 9 aa residues, p1, p4, p6, p7 
and p9 residues are highly conserved as these anchor-residues interact with the 
peptide binding pockets. The characteristics of these pockets differ between HLA 
class II molecules, thereby allowing each HLA molecule to present a distinct peptide 
binding repertoire. As these ligands are generated by specific proteases, we questi-
oned if this would be reflected in aa conservations on the N- and C-terminal side of 
the presented ligandome.
We now performed an in-depth analysis of the ligandome of HLA-DRB1*03:01[13], 
one of the most prevalent HLA-DR molecules in Caucasians[14]. The large number 
of identified ligands (n=13 270) allowed us to accurately determine the frequency 




The tandem mass spectra were matched against the IPI human database (version 
3.87) using the Mascot search engine (version 2.2.04, Matrix Science, London, UK) 
with a precursor mass tolerance of 2 ppm, with methione oxidation as a variable 
modification and a product ion tolerance of 0.5 Da. Peptides were identified based 
on a false-discovery rate (FDR) of 1%. The GRAVY index of each peptide was cal-
culated using the Protein GRAVY sequence manipulation suite. The pI values of 
the identified peptides were calculated using the ExPASy “Compute pI/Mw” tool. 
To generate motifs, the minimal core sequences found within nested sets were 
extracted and the resulting list of peptides were aligned using MEME where motif 
width was set to 9–15 and motif distribution set to ‘one per sequence’. Icelogo 
(version 1.2) was used to generate the peptide binding motif and the presented 




To establish the HLA-DRB1*03:01 ligandome, we isolated HLA-DR3:peptide com-
plexes from EBV-transformed B cell line DUCAF. This resulted in the identification 
of the largest set of HLA-class II derived ligands (13 270 unique ligands with a false 
discovery rate of 1%) ever described from a single HLA-class II molecule. This set of 
ligands allows us to perform a detailed characterization of the HLA-class II ligandome.
To quantify the variety of identified ligands, we calculated for all identified ligands 
their theoretical isoelectric points (pI) and their gravy index, a measure of hydrop-
hobicity (Figure S1A-B). These analyses showed us that we have identified a wide 
variety of ligands with large differences in hydrophobicity and in pI. Hydrophilic 
ligands are slightly disfavored as previously described for HLA-class I ligands [17].
Characteristics of the HLA-DRB1*03:01 ligandome
We next studied the identified ligands in more detail. These analyses were only per-
formed on ligands with a best mascot ionscore above 60 (still leaving 4926 unique 
ligands), thereby further limiting false-positive results. In Figure 1A, we analyzed 
the length of the ligands and confirmed previous results showing MHC class II 
ligands are heterogeneous in size with 91% of the ligands between 12 and 20 aa in 
length [10, 11].
We next characterized the protein sources of the identified ligands. In Figure 1B, we 
studied the position in the protein of which the ligand was derived by looking at the 
start or stop position relative to the protein length. Interestingly, the ligands were 
derived from sequences throughout the length of the protein without an obvious 
bias. Ligands derived from the end of the protein are slightly underrepresented in 
the ligandome.
The 4926 ligands that we identified were derived from 1188 different proteins. 
When we plotted the number of ligands against the different proteins, we found 
up to 69 unique ligands derived from a single protein. In Figure 1C the number 
of ligands per protein are plotted. For 90% of the proteins, less than 10 unique 
ligands were found. As previously described, certain proteins, including different 
HLA proteins, were clearly overrepresented[10]. It was previously demonstrated 
for HLA-class I ligands, that the number of ligands per protein correlated with the 
length of the protein[17]. This is conceivable as longer proteins theoretically yield 
contain more different ligands. However for HLA-DRB1*03:01 ligands, we did not 
observe an association between protein length and the number of ligands that 
were identified (Figure 1D).
The HLA-DRB1*03:01 peptide-binding motif
In contrast to HLA-class I molecules, HLA class II molecules have an open confi-





guration allowing the accommodation of a wide variety of peptide lengths[2, 10, 
11]. The part of the peptide that interacts with the HLA molecules is only 9 aa in 
length[2], but HLA-class II derived ligands usually present in nested sets of ligands of 
different length with the same 9 aa core sequence. An analysis of the association of 
the number of ligands versus protein length is therefore largely influenced by these 
nested sets. To correct for this bias, we determined the minimum core sequences 
by removing all length variants. This resulted in the identification of 1175 ligand-


























































































































Figure 1: Characteristics of HLA-DRB1*03:01 ligands. (A) Distribution of the peptide-length of eluted 
DUCAF-DR3-ligands. Ligands were selected based on a BMI ≥ 60. (B-C) Plots depict the start (B) or stop 
position (C) of the ligands as a percentage of the total protein length versus the percentage of identi-
fied core-sequences. (D) Plot depicts the number of proteins as a function of the number of peptides 
identified per protein. (E) Plot depicts the protein length as function of the number of peptides by 
which the protein is represented.
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core sequences for HLA-DRB1*03:01. For 74% of the proteins we identified a single 
ligand-core sequence (Figure 2A). Interestingly, again there was no obvious corre-
lation between protein length and the number of ligand-cores/protein (Figure 2B).
To determine the peptide binding motif of HLA-DRB1*03:01, we aligned all ligand-
core sequences with MEME and subsequently compared the frequency of amino 
acids at different positions interacting with the peptide binding pockets with the 
frequency of these amino acids in the human proteome with Icelogo. This approach 
led to the identification of the peptide binding motif of HLA-DRB1*03:01 (Figure 
2C). As previously shown, HLA-DR molecules have an hydrophobic anchor in p1 
(Figure 2D). Likewise, we observed a clear preference of isoleucine, leucine, valine, 
phenylalanine and tyrosine residues in p1. In p4, we can observe a strong prefe-
rence for aspartic acid and the highly related asparagine residue, likely caused by a 
combination of size and charge of this particular pocket (Figure 2E). In pocket 6 and 
9, both electronegative pockets, we observed a preference for respectively lysine or 
arginine and tyrosine residues (Figure 2F-G).
Figure 2: Characteristics of HLA-DRB1*03:01 core-ligands. (A) Figure depicts the number of proteins 
as a function of the number of core-peptides identified per protein. There is a gradual decrease in 
the number of core-peptides by which a protein is represented. (B) The protein length is depicted as 
function of the number of core-peptides by which the protein is represented. To determine the pep-
tide-binding motif, identified cores were aligned using MEME to identify nonamers. The frequency of 
aa residues in the human proteome was used as a reference to study aa conservations. (C) Visualiza-
tion of the peptide binding motif by ICELOGO. Positively associated residues (P>0.05 at each relative 
position) are shown above the X-axis and negatively associated residues are shown below. Residue 
height is proportionate to prevalence. (D-H) Plots depict enriched or deprived aa residues on the p1 


























































































































































Figure 3: Frequency of aa residues on the N- and C-terminus of HLA-DRB1*03:01 ligands. Plots depict 
the frequency of the depicted aa residues at the ligands N- and C-terminal residue (designated “N” 
and “C”) or the adjacent residues (designated “N+1” and “C-1”) For this analysis HLA-DRB1*03:01-li-
gands with a length of >15 aa were selected.
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The HLA-DRB1*03:01 ligandome of B cells is conserved on the N- and C-terminus
HLA-class II ligands are generated upon lysosome degradation of proteins and are 
therefore the result of the action of specific proteases and peptidases[18]. We the-
refore proposed that the action of these proteases/peptidases would be reflected in 
conservations of particular aa residues in the N- and C-terminal peptide-positions. 
To analyze this, we selected ligands of ≥15 aa in length to make sure that we are not 
analyzing p1 and p9 residue conservations and we next determined the frequency 
of individual amino acid (aa) residues in the peptides N- and C-terminal residues in 
four different positions: the two N-terminal residues (designated N and N+1) and 
the two C-terminal residues (C-1 and C). Figure 3 shows aa residues that differ more 
than two-fold in frequency between the different positions. Importantly, these data 
provide a first indication that aa residues on the N- and C-terminus of HLA class II 
ligands are not randomly distributed.
To further study potential conservations, we next compared the frequency of the aa 
residues presented in Figure 3 with their frequency in the human proteome using 
IceLogo. Using this approach, we show a more than two-fold increase in aspartic 
acid and a more than two-fold decrease in proline and glutamine on the N-ter-
minus (Figure 4A). Likewise, on the C-terminus, we observed a more than two-fold 
decrease in methionine and isoleucine (Figure 4B). We also focused on the peptide 
position adjacent to the N- or C-terminal position and could demonstrate a clear 







































































































































Figure 4: N- and C-terminal 
enrichment of aa residues 
in HLA-DRB1*03:01. Plots 
depict enriched or deprived aa 
residues on the N- (A and B) and 
C-terminal (C and D) residues of 
HLA-DRB1*03:01-ligands. For 
this analysis peptides with a 
length of >15 aa were selected. 
The frequency of aa residues 
in the human proteome (swiss-
prot means) was used as a 
reference.





relatively low occurrence of 
methionine and tryptophan 
residues. In the second last 
peptide residues (desig-
nated C-1), no aa residues 
were clearly disfavored 
(Figure 4D). Importantly, the 
described conservations are 
different from the conserva-
tions at position p1 and p9 
of the peptide binding motif 
(Figure 2), indicating that 
the conserved residues at 
position N, N+1, C, and C+1, 
are most likely projecting 
outside the HLA-molecule.
N- and C-terminal conser-
vations are a general 
feature of HLA-class II B cell 
ligandomes.
The presented data indicate 
that the N- and C-ter-
minal side of the studied 
ligandome is highly con-
served. To investigate if this 
a general feature of HLA 
class II B cell ligandomes, we 
next focused on other HLA 
class II molecules isolated 
from EBV-transformed B 
cells. Figure 5 shows N- 
and C-terminal preferences 
in two additional sets of 
ligands (480 ligands ≥15 
aa) derived from HLA-DQ 
(DQ2 and DQ8, in total 480 
ligands ≥15 aa) and HLA-DR 
(DR4, DR8 and DR13, in total 
924 ligands ≥15 aa) mole-
cules. Importantly, we can 
















































































































































































































































































Figure 5: N- and C-terminal enrichment of aa residues in diffe-
rent HLA-DR and HLA-DQ ligandomes. Plots depict enriched or 
deprived aa residues on the N- (A, B, E and F) and C-terminal 
(C, D, G and H) residues of HLA-DR- (A-D) or HLA-DQ-ligands 
(E-H). For this analysis peptides with a length of >15 aa were 
selected. The frequency of aa residues in the human proteome 
(swiss-prot means) was used as a reference.
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servations on both the N- and C-terminus and these conservations largely overlap 
between different EBV-transformed B cell lines.
The applied reference set is based on Swiss-prot means of the frequency of aa 
residues in human proteins. To further validate our findings we made use of a 
second reference set of previously published HLA class I ligands (n=35 050 ligands 
of 9 aa). HLA class I ligands are conserved in positions p2 and p9. We therefore 
selected the p4 and p5 positions (at which no conservations are expected) and used 
the aa frequencies at these positions as a reference. Importantly, using this second 
set, we can again confirm the described aa conservations on the N- and C-terminus 
of the HLA class II ligandome (Figure S2).
Together these data indicate that the identified conservations are shared between 
cell lines, suggesting that these conservations are a general feature of HLA-class 
II-ligands derived from B cell lines. The observation that similar conservations are 
found in different HLA-DR/DQ molecules further supports that these conserved 
positions are not interacting with the polymorphic peptide-binding pockets.
DISCUSSION
We show that HLA-DRB1*03:01 can present a highly diverse ligandome. The 
presented ligands are mostly between 12 and 20 aa in length and both the core 
interacting with the HLA-molecule as well as the N-terminal and C-terminal part of 
these ligands are enriched for particular aa residues.
We show that the electronegative p6 and p9 pocket and the electropositive p4 
pocket provide important constraints on the type of peptides that can be accom-
modated by HLA-DRB1*03:01. Previously it was attempted to elucidate the peptide 
binding motif of HLA-DRB1*03:01 using peptide substitutions or with small sets of 
eluted peptides[19-22]. We now constructed a detailed peptide binding motif with 
1845 core sequences that could be used in the future to predict potential DR3:T cell 
epitopes.
Our analysis demonstrate new insights into the influence of antigen-processing on 
the ligandome. Firstly, The ligands that we identified are derived from sequences 
throughout the length of the protein, indicating that the enzymes used for proces-
sing don’t bias the peptide repertoire towards epitopes from particular parts of 
the protein. Secondly, the number of different ligands or core-sequences derived 
from a particular protein is not related to protein length, which is in contrast to HLA 
class I molecules[17]. This observation could be explained by less stringent peptide 
binding motifs of HLA class II molecules. This is interesting as it suggests that smaller 
protein are equally represent in the HLA class II ligandome. How, this is achieved 
remains elusive. Thirdly, the N- and C-terminal ligand residues are conserved for 
particular aa residues. Our data suggests that this is a general phenomenon of B cell 
HLA class II ligandomes. We believe this could point to the action of specific pro-





teases/peptidases involved in antigen processing. For instance, we observe a clear 
conservation of a proline residue at p2. Similar preferences have been described for 
a member of the cathepsin-family, a family of proteases involved in antigen-proces-
sing[23]. These conservations can aid in better predicting potential T cell epitopes 
or in the design of long-peptide vaccines.
The 13 270 different ligands are now publicly available and can be used to answer 
a plethora of immunological questions regarding the role of HLA-DR3 in allergy, 
autoimmunity, infection and transplant rejection.
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SUPPLEMENTARY INFORMATION
Figure S1: DUCAF-DR3-ligandome physiochemical properties. (A) Distribution of ligands over the pI 







































































































Figure S2: N- and C-terminal enrichment of aa residues in different HLA-DR and HLA-DQ ligandomes. 
Plots depict enriched or deprived aa residues on the N- (and C-terminal residues of HLA-DRB1*03:01-, 
HLA-DR- or HLA-DQ-ligands (E-H). For this analysis peptides with a length of >15 aa were selected. 
The frequency of aa residues in position 4 and 5 of 9mer HLA class I ligands was used as a references
Position N DRB1*03:01 DR ligands DQ-ligands
DRB1*03:01 DR ligands DQ-ligands
DRB1*03:01 DR ligands DQ-ligands
DRB1*03:01 DR ligands DQ-ligands






























































































































































































































































































































































































HLA-DQA1*01:03/DQB1*06:03, an HLA-DQ 
molecule linked to autoimmune resistance, 
presents a unique peptide repertoire.
Jurgen van Heemst, Arnoud H. de Ru, Marieke Bax, George K. Papadopoulos, Peter 




HLA-DQ0603 (DQA1*01:03;DQB1*06:03) is associated with resistance to multiple 
autoimmune diseases including rheumatoid arthritis, type 1 diabetes, narcolepsy 
and myasthenia gravis. We aimed to elucidate the peptide-binding repertoire of 
HLA-DQ0603 by isolating HLA-DQ0603 molecules from B-LCL lines and subsequent 
characterization of HLA-DQ0603-bound ligands. Characteristics of the identi-
fied ligands were comparable to what was previously shown for other HLA-class 
II molecules (e.g. ligand length and localization of protein-sources). After pepti-
de-alignment we obtained the peptide-binding motif of HLA-DQ0603. We found 
that HLA-DQ0603 presented a unique peptide-binding repertoire that differed from 
previously identified peptide-binding motifs of closely related HLA-DQ6 molecules. 
Differences were mainly in pocket 1 and pocket 6 and can be translated to struc-
tural differences between different HLA-DQ molecules. This motif allows for more 
precision in the identification of disease-linked epitopes.






The Human Leukocyte Antigen (HLA) class II locus is the primary risk factor for many 
different autoimmune diseases (AID), including multiple sclerosis (MS), rheumatoid 
arthritis (RA), type 1 diabetes (T1D), narcolepsy and Myasthenia Gravis (MG) [1-5]. 
These HLA associations with autoimmunity suggest an important role for anti-
gen-specific T cells during pathogenesis. For most of these autoimmune diseases 
the antigens recognized by such autoimmunogenic T cells are unclear.
The HLA class II locus contains genes that are in strong linkage disequilibrium [6]. 
As a result, these genes inherit together in haplotypes making it difficult to geneti-
cally pinpoint the causative gene. In addition, this locus can play a dual role. Certain 
haplotypes can be associated with susceptibility, while others are neutral or even asso-
ciated with resistance. Most haplotypes are differentially associated with multiple 
autoimmune diseases. For example, the HLA-DRB1*04-DQB1*03:01-DQA1*03:02 
haplotype is strongly associated with risk for RA, yet protective in T1D [7-9]. 
However, other haplotypes display a similar effect throughout different autoim-
mune diseases. The haplotype HLA-DRB1*13:01-DQB1*06:03-DQA1*01:03 is of 
particular interest as it is strongly associated with resistance to different autoim-
mune diseases including RA [7, 10], T1D [9, 11-13], MG [14] and narcolepsy [15]. 
The underlying immunological pathways are currently elusive.
The ligandome of HLA-DRB1*13:01 was previously characterized [16], but the 
peptide-binding repertoire of HLA-DQ0603 (HLA-DQB1*06:03/DQA1*01:03) is 
unknown. We therefore aimed to elute naturally processed ligands and to charac-
terize the peptide-binding repertoire for this HLA-DQ molecule.
MATERIALS AND METHODS
Ligand isolation from affinity-purified HLA class II molecules. HLA-DQ0603-mo-
lecules were isolated from DRB1*13:01-DQB1*06:03-DQA1*01:03 homozygous 
EBV-transformed B lymphoblastoid cell line APD. Approximately 2x109 cells were 
grown in IMDM supplemented with L-glutamine and 10% FCS. Subsequently, the 
cells were harvested, washed with PBS, and the cell pellet was stored at -80°C. 
The cells were lysed with 50 ml of lysis buffer (50 mM Tris, 150 mM NaCl, 5 mM 
EDTA, 0.5% Nonidet P-40, and protease inhibitors (Complete inhibitor mix; Roche)) 
to remove the nuclei and insoluble material. The lysate was centrifuged for 60 min 
at 10,000g. It was subsequently precleared for 60 min with Sepharose beads and 
mixed with SPV-L3 coupled sepharose beads. After 60 min of gentle mixing, the 
beads were washed in 10 bead volumes of lysis buffer followed by washing with 20 
mM Tris-HCl, 120 mM NaCl (pH 8.0), followed by washing with 20 mM Tris-HCl, 1 
M NaCl (pH 8.0), 20 mM Tris-HCl (pH 8.0), and finally with 10 mM Tris-HCl (pH 8.0). 
Subsequently, the HLA-peptide complexes were eluted with 25 ml of 10% acetic 
Chapter 460
acid in water. All purification steps were performed at 4°C. High molecular mass 
material (HLA molecules) was removed by filtration through Centriprep filtration 
units with a cutoff value of 10 kDa. Ligands were identified as previously described. 
Briefly, ligands were fractionated on a C18 reverse phase HPLC system and analyzed 
by tandem mass spectrometry.
Peptide identification by mass spectrometry (MS) Ligands were characterized by an 
online nano-HPLC-MS system. The nano-HPLC column was connected to the needle 
of the electrospray source of the mass spectrometer. The mass spectrometer 
was run in data-dependent MS/MS mode during ligand elution. All tandem mass 
spectra produced in this way were searched against the human IPI database with 
the database search program MASCOT version 2.4 (Matrixscience). All reported hits 
were assessed manually, and ligands with best MASCOT ionscores <50 were dis-
carded.
Peptide binding motif. The peptide binding motif of HLA-DQ0603 was constructed 
by aligning all the identified ligands and subsequent identification of the most likely 
nonamers. Aa frequency at each of the positions in the nonamer were compared to 
the frequency of these aa residues in the human proteome.
RESULTS
Characterization of the peptide-binding repertoire of HLA-DQ0603
The presence of HLA-DQ0603 is tightly associated with autoimmune resistance. 
Figure 1A shows the sequence of the HLA-DQB1*06:03 chain and a comparison 
with HLA-DQB1*06:02 and *06:04. Figure 1B shows a schematic representation 
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Figure 1: Characteristics of the HLA-DQ0603 molecule. (A) Sequences of HLA-DQB1*06:03 in com-
parison to HLA-DQB1*06:02 and *06:04. (B) Schematic representation of aa involved in shaping 
the different peptide-binding pockets of HLA-DQ0603 (DQB1*06:03/DQA1*01:03). Amino acids are 
colored according to their properties (white = hydrophilic, light-gray = hydrophobic, dark-gray = acidic, 
black = basic). Numbering below the amino-acids indicate their positions in the DQA1 (gray) or DQB1 
(black) chain.





of the residues involved in shaping the various peptide-binding pockets of HLA-
DQB1*06:03. Most notable is the β57D residue. The presence of β57D is strongly 
associated with T1D risk and it was described that this residue forms a salt-bridge 
with α76, thereby enhancing the stability of the peptide-MHC complex [17].
To examine the peptide-binding repertoire of HLA-DQ0603, we isolated HLA-DQ 
molecules from an EBV-transformed HLA-DQ0603 homozygous B cell line. Ligands 
derived from these HLA-DQ molecules were characterized. In total we identified 
698 unique ligands. Most of the identified ligands were derived from HLA mole-
cules (23%) as was previously described for ligands derived from other HLA class II 
molecules [18].
The ligands ranged in length between 7 and 20 amino acids. 94% of the ligands 
ranged between 12 and 18 aa in length as was previously shown for other HLA class 
II molecules (Figure 2A) [18, 19]. As HLA class II molecules are flexible in the size of 
ligands that can be accommodated, nested peptide-sets can be frequently found. 
These sets include different ligands with a shared core-sequence but of a different 
length. When we discard these length variants, 303 core sequences were identified. 
For 71% of the core sequences we found only a single length variant. For the remai-
ning 29% we found up to 37 different length variants (Figure 2B). We also studied 
the localization of the proteins from which the identified ligands were derived. 
About 60% of the ligands were derived from the endocytic pathway, the remainder 





































































































Figure 2: Characteristics 
of identified ligands. (A) 
Graph depicting the distri-
bution of peptide length 
in the identified ligands. 
(B) Graph depicting the 
number of length variants 
identified for the different 
core ligand-sequences. 
(C) Graph depicting the 
percentage of peptides 
derived from a cytosolic 
or an endocytic source. (D) 
Graph depicting the diffe-
rent sources from which 
the identified peptides 
were derived. PM = plasma 
membrane, Lyso/Endo = 
lysosome or endosome, ER 
= endoplasmatic reticulum.
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from the cytosolic pathway (Figure 2C). Most ligands were derived from the plasma 
membrane, which includes all the HLA-derived ligands. The second most abundant 
source is the cytosol (Figure 2D. Peptide-localizations were comparable to what was 
previously shown for other HLA class II molecules [20, 21].
The peptide-binding motif of HLA-DQ0603
To determine the peptide-binding motif of HLA-DQ0603 from the eluted ligands, 
we performed both manual and automated ligand alignment, both resulting in 
similar results. Figure 3 shows the results from automated ligands alignments. 
The presence of aa residues in positions interacting with the various pepti-
de-binding pockets were compared to the frequency of that particular aa in the 
human proteome. In the aa residues predicted to interact with pocket 1, there 
are clear preferences for asparagine, serine, threonine, leucine and isoleucine 
residues, all small to medium sized amino acid residues (Figure 3A). In pocket 4, 
a serine, threonine, alanine and valine are enriched. These are all small amino 
acid residues (Figure 3B). Residues in p6 are enriched for acidic residues and 
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Figure 3: Peptide-binding motif of HLA-DQ0603. (A-E) Ligands derived from HLA-DQ0603 were aligned 
and the frequency of aa at positions interacting with pockets were compared to their distribution in 
the human proteome. Plots depict enrichment for amino acids at positions predicted to interact with 
pocket 1 (A), pocket 4 (B), pocket 6 (C), pocket 7 (D) and pocket 9 (F) of HLA-DQ0603 Aa color conven-
tions are as in Figure 1. (F) Summary of the peptide-binding motif of HLA-DQ0603.





proline (Figure 3C). In pocket 7, ring-shaped aa histidine and proline are preferred 
(Figure 3D). Finally, pocket 9 prefers the small amino acid residues alanine and 
serine (Figure 3E). The corresponding binding motif is summarized in Figure 3F.
DISCUSSION
This is the first report characterizing the peptide-binding repertoire of HLA-DQ0603, 
an HLA-DQ molecule tightly associated with autoimmune resistance. Using naturally 
eluted ligand sequences we have also established its peptide-binding motif. This 
allows for a comparison with other previously characterized HLA-DQ molecules.
HLA-DQ0602 (DQB1*06:02-DQA1*01:02) is of particular interest. This HLA-DQ 
molecules is tightly linked with susceptibility for narcolepsy [15, 22]. This HLA-DQ 
molecule is highly related to the HLA-DQ0603 (Figure 1A). Both HLA-DQ molecules 
differ only in two amino acid positions: β9 that shapes peptide-binding pocket 9 
and β30 that shapes peptide-binding pocket 6 [23]. The difference in β9 is relatively 
a minor difference (phenylalanine in DQB1*06:02 and tyrosine in DQB1*06:03). 
In contrast, the difference in β30 (tyrosine in DQB1*06:02 and a histidine in 
DQB1*06:03) would result in a more positively charged p6 pocket. Likewise, if we 
compare the peptide-binding motif of HLA-DQ0602(24;25) and HLA-DQ0603, we 
Molecule Name Sequence
Hypocretin Hcrt 3-11 LPSTKVSWA
(O43612) Hcrt 6-14 TKVSWAAVT
Hcrt 83-91 LLQASGNHA
Hcrt 89-97 NHAAGILTL
Hypocretin receptor 1 HcrtR1 88-96 LSLADVLVT
(AAL47214) HcrtR1 125-133 LQAVSVSVA
HcrtR1 300-308 LMVVLLVFA
Hypocretin receptor 2 HcrtR2 63-71 IVFVVALIG







Table 1: List of predicted epitopes that bind to HLA-DQB1*06:02 but not to HLA-DQB1*06:03.
Chapter 464
cannot identify differences in the p1, p4, and p9 residues, but we do find large dif-
ferences in the p6 residues. HLA-DQ0602 is reported to prefer leucine, isoleucine 
and valine residues, all medium-sized hydrophobic residues [24, 25]. In contrast, 
we showed a preference for acidic residues in the p6 pocket of HLA-DQ0602, which 
can be directly explained by an β30Y→H substitution. An understanding of these 
differences allows for predicting candidate narcolepsy epitopes. In Table 1, we have 
summarized candidate epitopes from three narcolepsy candidate autoantigens 
(hypcretin and hypocretin receptor 1 and 2) that we predict to selectively bind to 
HLA-DQ0602 and not to DQ0603 and that can therefore be attractive candidate 
epitopes. Indeed, Hcrt3-11 was previously crystallized in the context of HLA-
DQB1*06:02 and was presented in the predicted register [26].
The peptide-binding motif of HLA-DQ0604 (DQB1*06:04-DQA1*01:02) has also been 
established [25]. This allele is associated with T1D susceptibility. HLA-DQB1*06:03 
differs from HLA-DQB1*06:04 in three different positions: β86 (A→G) that shapes 
the p1 pocket, β57 (D→V) that is involved in peptide-MHC stability and β70(G→R) 
that is involved in TCR recognition [17, 23, 27] (Figure 1A). β86 renders the p1 pocket 
more spacious allowing the accommodation of large residues [25]. Together, these 
comparison illustrates how small differences in the structure of HLA-DQ molecules 
are translated in large differences in the peptide-binding repertoire. This study 
shows that HLA-DQ0603 presents a unique peptide-binding repertoire, distinct 
from highly related HLA-DQ6 molecules, likely resulting in distinct T cell repertoires 
that could explain HLA-DQ0603-mediated autoimmune resistance.
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ABSTRACT
Introduction. Recently, arrays have become available that allow the simultaneous 
analysis of several anti-citrullinated protein antibody (ACPA) reactivities using 
distinct citrullinated peptides. Such assays are designed for exploratory studies. The 
interpretation of positive antibody reactivity’s can best be made if the diagnostic 
and prognostic value of a multiplex array in an early-arthritis setting is known and 
if the multiplex-positive patients who are negative according to 3 commonly used 
commercial ACPA assays are characterized.
Methods. Using Thermo Scientifics’ ImmunoCap ISAC system, a multiplexed array 
that determines reactivities to 11 citrullinated peptides, we analysed serum/
plasma of 195 healthy controls and 1282 early arthritis patients from two indepen-
dent cohorts: the Leiden Early Arthritis Clinic (n=1013) and the IMPROVED (n=269). 
Findings were compared to results primarily of the anti-CCP2 assay, but also to 
CCP3 and anti-MCV assays. The associations between ACPA reactivities and patient 
characteristics, risk factors (shared epitope, smoking) and disease outcomes (pro-
gression of undifferentiated arthritis to RA and severity of joint destruction) were 
assessed.
Results. 31% of anti-CCP-2-negative RA patients displayed reactivity towards citrul-
linated peptides in the multiplex assay. These patients had a positive signal towards 
a more restricted peptide repertoire than anti-CCP-2-positive RA patients (median 
= 1 versus 5). Within anti-CCP-2-negative patients, ACPA reactivity as detected by 
multiplex array was not significantly associated with known risk factors, clinical or 
prognostic parameters. The frequency of sera from anti-CCP-2-negative RA patients 
that were positive for the multiplexed peptides was comparable to the frequency in 
non-RA arthritic patients (27%).
Conclusions. Additive citrulline peptide reactivities detected by the current mul-
tiplex system did not reach significant power to be RA-specific. The presence of 
residual citrulline reactivities detected by the multiplex-system used in arthritis 
patients that are negative in commercial ACPA assays need to be interpreted with 
caution.






Rheumatoid Arthritis (RA) is a systemic inflammatory disease characterized by 
extensive inflammation of synovial joints[1]. RA patients frequently present with 
autoantibodies, of which the anti-citrullinated protein antibodies (ACPA) are of 
particular interest. These autoantibodies are highly specific for RA and specifically 
target proteins that have undergone a post-translational modification that converts 
arginine to citrulline residues. ACPA can be used to predict the development of RA 
as these autoantibodies can be detected up to ten years prior to disease onset[2, 
3]. Furthermore, ACPA can subdivide RA patients in distinct diseases subsets. These 
subsets differ substantially in clinical outcome and with regard to underlying genetic 
and environmental risk factors[4-6]. 
Several commercial tests are available that use specific citrullinated antigens to 
determine ACPA positivity. The most widely used tests are anti-citrullinated cyclic 
peptide 2 (CCP-2), anti-CCP-3 and anti-mutated citrullinated vimentin (anti-MCV)[7, 
8]. Anti-CCP-2 has been used in most studies and has long been the standard test 
to determine reactivity to citrullinated peptides, although the sequence identity 
has not been disclosed [9]. It has been postulated that because commercial anti-
CCP-tests employ peptide-sequences that are, most likely, not derived from human 
proteins, these tests do not detect part of the citrullinated-peptide reactivities[10]. 
Therefore, arrays have been developed to do exploratory studies on a large number 
of peptides. This could be important to enhance understanding of disease as well 
as identify antibody systems that are predictive of disease characteristics which can 
occur in a number of different diseases such as exocrine gland dysfunction which is 
associated with anti-SSA antibodies. 
Recently, arrays have become available that can determine citrullinated peptide 
reactivities towards a wide variety of natural citrullinated antigens in a relatively 
high-throughput setting[10, 13]. Intriguingly, these arrays showed the presence of 
reactivities against citrullinated peptides within anti-CCP-2-negative RA patients. 
This raised the question what a positive signal in such an array means and to guide 
subsequent exploratory studies, we determined whether a positive signal in a mul-
tiplex assay has an additive value over commercial assays determining the presence 
of ACPA and whether these patients share the characteristics of RA patients positive 
in commercial ACPA assays.
We aimed to perform a detailed characterization of the value of multiplex 
ACPA-testing in an early-arthritis setting by studying the characteristics of anti-CCP-
2-negative patients that are positive or negative for additional citrulline reactivities. 
We studied clinical parameters and the presence of genetic and environmental risk 
factors using a previously validated multiplex chip-based array, the ImmunoCAP 
ISAC system[13-16]. Using this array, we measured reactivity against 11 different 
citrullinated peptides derived from fillagrin, type II collagen, alpha-enolase, fibri-




Citrullinated peptide reactivities were assessed on baseline plasma samples of 
arthritis patients (n=1013) included in the Leiden Early Arthritis Clinic (EAC). This 
Dutch cohort was initiated in 1993 and includes patients with a recent onset of 
arthritis (symptom duration < 2 years) from the Leiden area[17, 18]. Definitive diag-
noses were determined after 1 year of follow-up by an experienced rheumatologist. 
In the current analysis 564 patients fulfilled the ACR1987 criteria for RA. Patients not 
fulfilling the RA criteria, who had no other definite clinical diagnosis, were classified 
as undifferentiated/unclassified arthritis (UA, n=297). The remaining 149 patients 
were classified as non-UA/non-RA patients. 135 out of 149 patients were anti-CCP-2 
negative and these presented with a wide variety of diagnoses (Table S1).
We also assessed citrullinated peptide reactivities in baseline serum samples of 269 
patients that were included in the IMPROVED study and that fulfilled the ACR1987 
criteria for RA at the time of inclusion [19]. The IMPROVED study (ISRCTN11916566) 
was a randomized controlled trial investigating the effect of different treatment 
regimens in early arthritis.
Genotyping of the HLA-DRB1 region in order to determine the number of RA-as-
sociated Shared Epitope (SE) alleles was available for 500 patients (EAC only)[20]. 
Within the EAC, radiographs were taken at baseline and at yearly follow-up visits for 
7 years. In total 2340 sets of hands and feet radiographs of 463 RA patients were 
scored using the Sharp- van der Heijde scoring methods (SHS) by one experienced 
reader with known time-order (intra-class correlation coefficient 0.91) [21]. 
Patient samples were compared to serum samples of 195 healthy controls. These 
controls lived in the Leiden area and were matched to the patients for age and 
gender. 
The study was performed in accordance with the declaration of Helsinki and pro-
tocols were approved by the Leiden University Medical Center ethics committee. 
Informed consent was obtained.
Citrullinated peptide assays
Anti-CCP-2 was measured on the Immunoscan RA Mark 2;Eurodiagnostica, Arnhem, 
The Netherlands with a cut-off of 25 arbitrary units in all patients. Anti-CCP-3 and 
anti-MCV were measured in 454 EAC RA patients by respectively Quanta lite CCP 
3.1 IgG/IgA (INOVA Diagnostics Inc., San Diego, CA, USA) and Orgentec Diagnostika 
GmbH (Mainz, Germany) with a cut-off of 20 arbitrary units. Cut-offs were set using 
manufacturer’s instructions. IgM-RF was determined by routine diagnostic labora-
tory screening in 614 RA patients (EAC and IMPROVED).
Antibody responses to citrullinated peptides were measured with the ImmunoCAP 
ISAC system (Thermo Scientific) that contains 11 different citrullinated peptides and 
their arginine counterparts: CCP1, CitC1 (CII355-378cit3), CEP1, Fibα36-50, Fibα621-





635, Fibβ36-52, Fibβ60-74, Fibβ563-583, Fibβ580-600, Vim2-17 and Vim60-75 as 
described elsewhere [13-16, 22]. We excluded 4% of the tested samples from the 
analyses as antibody responses could not be accurately determined due to high 
background signals or unspecific reactivity towards streptavidin. 
For cut-off calculations, the citrulline-specific signal was used (difference in fluo-
rescence intensity between the citrullinated peptide and the arginine-containing 
peptide). The cut-off was established as the mean plus two times the standard devi-
ation (SD) of the citrulline-specific signals in 195 healthy control sera. For CitC1 ( a 
peptide derived from collagen type II) we used the citrulline signal without subtrac-
ting the arginine signal as this is a non-linear peptide and have independent but 
exclusive reactivities to the arginine counterpart [23]. 
For reasons of sample availability, plasma of EAC patients and serum of IMPROVED 
patients and healthy controls was used for the multiplex assay. For several indivi-
duals (n=59) both serum and plasma with 92% reproducibility (data not shown).
Statistical analysis 
Linear regression was performed to study the association between log-transformed 
median anti-CCP-2 levels and the number of peptides recognized in the multiplex 
array. Differences in anti-CCP-2 levels between groups were analysed with the 
Mann-Whitney test.
To determine the association between the risk factors HLA-SE, smoking and RA, 
unconditional logistic regression analysis was performed to calculate odds ratio’s 
(ORs) and 95% confidence intervals (CIs). Multiplex-negative RA patients (either anti-
CCP-2-negative or –positive) were used as the reference category and compared 
with multiplex-positive RA patients (again in both categories: anti-CCP-2-positive 
or anti-CCP-2-negative). Similarly the association between multiplex-positivity or 
anti-CCP-2-positivity and progression to RA was assessed. To study progression, we 
used selected patients that are classified as undifferentiated arthritis (UA) patients 
at baseline and we assessed the development of RA in the first year of follow-up 
using the ACR1987 criteria for RA. 
To study biological interaction between smoking, HLA-SE and multiplex-positivity 
in anti-CCP2 negative RA patients was performed as described elsewhere[24]. To 
analyse the rate of joint destruction, a multivariate normal regression model for 
longitudinal data with log-transformed SHS as response variable was used as previ-
ously described[25]. This method analyses al repeated measures at once and takes 
advantage of the correlation between these measurements. Analyses were adjusted 
for age, gender and different inclusion periods as proxy for treatment strategy [17]. 
Anti-CCP-2-negative RA patients were used as reference and compared with anti-
CCP-2-positive RA patients. We also used anti-CCP-2-negative multiplex-negative 
and anti-CCP-2-negative multiplex-positive RA patients as a reference and these 
were compared with respectively anti-CCP-2-negative multiplex-positive and anti-
CCP-2-positive multiplex-positive RA patients. The beta (β) indicates the relative 
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fold increase in radiographic joint damage per year.
 
RESULTS
The presence of citrulline-reactivities by multiplex assay in RA patients.
Before embarking on determining the diagnostic value of a prototype multiplex 
array in an early arthritis setting, we first wished to validate the assay by compa-
ring the results in the Leiden population of RA-patients to previously published 
data using other sets of RA-patients. We used a multiplex-array to measure reac-
tivities against the arginine and citrulline variants of 11 different antigens. All 
citrullinated peptides were recognized by a proportion of RA patients in the EAC 
and the IMPROVED cohort (Figure 1A). In 8% of the tested healthy controls, citrul-
line-reactivities were present and 13/15 multiplex-positive controls recognized a 
single citrullinated peptide (Figure 1B). In RA patients, citrulline reactivities were 
observed in the majority of patients (64% in EAC, 75% in IMPROVED) and positive 
patients were generally positive for more than one peptide (79% in EAC and 84% in 
IMPROVED, Figure 1C). Notably, the frequency of anti-CCP-2-positive RA patients is 
higher in the IMPROVED than in the EAC (65% vs 51%), probably explained by the 
different inclusion criteria. 
We next focused on anti-CCP-2-positive RA patients. The multiplex chip-based-array 
detected citrullinated peptide reactivities in 274/285 (96%) anti-CCP-2-positive EAC 
RA patients (Figure 2A). Percentages were comparable in the IMPROVED cohort 
(169/174, 97%) and with anti-MCV- or anti-CCP-3-positive EAC RA patients (241/273 
(88%) and 234/261 (90%) respectively). The number of recognized citrullinated mul-
tiplex peptides associated with median anti-CCP-2 antibody levels (Figure 2B, R2 = 
0.86, P < 0.0001) as has also been reported for ACPA fine specificities determined 
by ELISA[26]. Likewise, the 4% of anti-CCP-2-positive multiplex-negative RA patients 
displayed lower anti-CCP-2 levels. (Figure 2C, P=0.009). These data show that nearly 
all anti-CCP/MCV-positive RA patients are positive in the multiplex-array. The small 
multiplex-negative subgroup represents patients with lower anti-CCP-2 levels.
Most importantly, the test characteristics described above are comparable to pre-
viously published data, indicating that the multiplex array reproducibly detected 
reactivities against commonly used citrullinated peptide tests in RA patients.
Multiplex-positive anti-CCP-2 negative RA patients
Recent reports using multiplex-platforms with citrullinated peptides also showed 
positive response in anti-CCP-2-negative RA patients[10, 13, 26]. To determine 
whether this could also be found in the Leiden RA population, we next analysed 
the multiplex-array reactivity in the anti-CCP-2-negative RA population. In the EAC, 
31% (86/279) of the anti-CCP-2-negative RA patients tested positive in the multiplex 
assay versus 34% (31/91) in the IMPROVED (Figure 3A). Similar percentages were 





found in anti-CCP-3-negative (29%, 56/193) or anti-MCV-negative (27%, 49/181) 
RA patient populations. These findings are also comparable to previously reported 
observations using similar assays in other sets of patients.
Diagnostic value of the multiplex-array in an early arthritis setting.
The finding that a substantial proportion of ACPA-negative RA patients, as deter-
mined by 3 commercial assays, shows reactivity in the multiplex assay is intriguing 
and prompted us to determine whether this assay has an additive value over 
“conventional” ACPA-testing in an “early arthritis setting”. We next analysed multi-
plex-positivity in EAC patients with a form of arthritis other than UA or RA (so-called 
non-RA, n=149). 30% (45/149) of non-RA patients were multiplex-positive. In anti-
CCP-2-negative (135/149) non-RA patients, 27% (37/135) was multiplex-positive, 
without a predilection for a particular diagnosis (Figure 3B). Similar findings were 
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Figure 1: Citrulline-reactivities in RA patients and healthy controls. A. Plot depicts the frequency of 
positive RA patients in the EAC (n=564, in black) or the IMPROVED (n=269, in white) and healthy 
controls (n=195, in grey) for the different tested citrullinated peptides. B. Percentage of healthy 
controls plotted against the number of citrulline-reactivities. C. Percentage of RA patients (EAC in 
black, IMPROVED in white) plotted against the number of citrulline-reactivities. 
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made when the anti-CCP-3 and anti-MCV-assays were used to determine the 
presence of ACPA.
The findings described above were reflected in the sensitivity and the specificity 
(in relation to the original ACR 1987 criteria) of the multiplex assay (63.8% and 
63.7%) in comparison with the anti-CCP-2 ELISA (51% and 87%). To calculate the 
sensitivity and specificity, all 446 patients in the EAC without RA were taken into 
account. These patients had either UA or another form of arthritis. The positive 
likelihood-ratio (LR+) for the multiplex is lower (1.76 versus 4.02 for anti-CCP2), 
whereas the LR- is similar (0.57) (Figure 3C-D). These analyses were performed 
using the ACR1987 criteria for RA since the EULAR/ACR2010 criteria includes anti-
CCP-2 status, thereby introducing potential circular reasoning. 
The diagnosis of non-RA patients was initially assessed after 1 year by an expe-
rienced rheumatologist. To rule out the possibility that the multiplex-positive 
non-RA patients were misdiagnosed or that they developed RA later in time, we 
re-assessed their diagnosis, radiographs and medication use at their last visit. Two 
non-RA patients were now classified with RA. Taking these findings into considera-
tion and assuming that these 2 patients were initially misdiagnosed, the sensitivity 
of the multiplex assay increased from 63.7% to 64.1%. 
All analyses described above have been performed using the same cut-off 
(mean+2xSD of the citrulline-specific signal in healthy controls). However, using 
several different cut-offs did not change the outcome/conclusions of the studies 
(data not shown).  
Together these data illustrate that a large subset of anti-CCP/MCV-negative arthritis 











































Figure 2: Multiplex-positivity correlates with anti-CCP-2 levels. A. Percentage of anti-CCP-2 positive RA 
patients (n=285) in the EAC that are positive or negative in the multiplex array. B. Median anti-CCP-2 
levels plotted against the number of recognized peptides. A linear regression was used to determine 
the degree of correlation. C. Anti-CCP-2 levels in multiplex negative (n=11) and positive (n=274) RA 
patients. Each dot represent an EAC patient. Median anti-CCP-2 levels were compared using a Mann-
Whitney test.





Characteristics of anti-CCP-2-negative RA patients positive or negative for 
citrullinated peptide reactivities.
As the multiplex assay was designed to identify antibodies and antibody patterns 
to formulate new hypothesis regarding of value for understanding etiology, patho-
genesis , prognosis, and prediction, we wished to investigate whether the multiplex 
assay could be useful to stratify anti-CCP-2-negative RA patients into different 
subsets using other outcome parameters. There were no statistical differences in 
baseline characteristics between multiplex-negative and –positive EAC patients, 
although female anti-CCP-2-negative patients were more often multiplex-positive 
(P = 0.04, Table S2). Taking into account the large number of comparisons per-

















No 390 56 446






















0 10 20 30 40
Nr of patients
Figure 3: Multiplex-positivity in anti-CCP-2 negative RA patients is not RA specific. A. Percentage of 
anti-CCP-2 negative RA patients (n=279) in the EAC that are positive (n=86) or negative (n=193) in 
the multiplex array. B. Pie diagram summarizes the percentage of multiplex positive (n=37, grey) 
and negative (n=98, white) anti-CCP-2 negative non-RA/UA patients (n=135). Bar diagram plots 
the number of patients that are multiplex positive and negative with different diagnoses. C-D. The 
ACR1987 criteria were used to calculate the sensitivity and specificity of the anti-CCP-2 test (C, E) and 
of the multiplex-array (D, F).
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Citrullinated-peptide repertoire recognized by anti-CCP-2-negative, multiplex-
positive RA-patients. 
We next analysed in more detail the reactivity patterns of sera from multiplex-po-
sitive anti-CCP-2 negative sera. Multiplex-positive anti-CCP-2 negative subjects 
(either RA, healthy and non-RA) recognized mostly one peptide (Median=1 in 
anti-CCP2-negative vs. 5 in anti-CCP-2 positive) as previously reported[13]. 
85% of the anti-CCP-2-negative sera in the EAC that are positive for a single peptide 
are positive for Fibα36-50 or Fibβ563-583 (122/143), Table S3). As the fraction of 
anti-CCP-2-negative multiplex-positive patients largely relies on these two pepti-
de-reactivities, we studied these in more detail (Figure S1). Anti-CCP2-negative 
patients with reactivities towards Fibβ563-583, were mostly positive just above the 
cut-off (Figure S1). This was not unique for this peptide as this was also observed 
for other citrullinated peptide reactivities. Fibα36-50 was the exception with a 
Shared epitope
No, n (%) Yes, n (%) OR (95% CI) P-value
CCP2- 140 (57) 107 (43) REFERENCE
CCP2+ 54 (21) 199 (79) 4.82 (3.26-7.14) P < 0.001
CCP2-Multiplex- 93 (55) 78 (46) REFERENCE
CCP2-Multiplex+ 47 (60) 29 (39) 0.74 (0.42-1.28) P=0.28
CCP2-Multiplex+ 47 (62) 29 (38) REFERENCE
CCP2+Multiplex+ 51 (21) 192 (79) 6.10 (3.50-10.64) P < 0.001
Ever smoker
No, n (%) Yes, n (%) OR (95% CI) P-value
CCP2- 274 (78) 78 (22) REFERENCE
CCP2+ 301 (69) 138 (31) 1.61 (1.17-2.22) P = 0.004
CCP2-Multiplex- 183 (79) 54 (21) REFERENCE
CCP2-Multiplex+ 90 (79) 24 (21) 0.90 (0.53-1.56) P = 0.71
CCP2-Multiplex+ 90 (79) 24 (21) REFERENCE
CCP2+Multiplex+ 281 (71) 125 (29) 1.67 (1.01-2.74) P = 0.004
Table 1: Association of risk factors HLA-SE and smoking with multiplex-positivity in anti-CCP-2-nega-
tive RA patients. Statistical comparison of the frequency of smokers and HLA-SE alleles in anti-CCP2 
positive vs anti-CCP2 negative RA patients and within multiplex-positive RA patients. 





substantial number of anti-CCP2-negative RA patients who tested clearly positive 
(Figure S1), although recognition of this peptide was not RA-specific. After removal 
of these two peptides from the analysis 15% of anti-CCP-2-negative RA patients 
were multiplex-positive versus 5% of non-RA patients. This also led to a decreased 
sensitivity (54%) but an increased specificity (81%) of the multiplex assay. 
Risk factors and anti-CCP-2-negative RA patients positive or negative for 
citrullinated peptide reactivities
Previously, it was shown that the presence of anti-CCP2-antibodies associates 
with HLA-SE alleles and smoking[5, 6]. Indeed, we found an increased frequency 
of HLA-SE alleles (43% vs 79%, OR = 4.82, P < 0.001) and smoking (22% vs. 32%, 
OR = 1.57, P = 0.004) in anti-CCP-2-positive versus -negative RA patients (Table 1). 
In contrast, in the anti-CCP-2-negative subset, we found no difference in the fre-
quency of HLA-SE alleles (46% vs. 39%, OR = 0.74, P = 0.28) and smokers (21% vs. 
21%, OR = 0.90, P = 0.71, Table 1) between multiplex-negative and -positive RA 
patients. We did observe an increased frequency of HLA-SE alleles and smoking in 
multiplex-positive anti-CCP-2-positive RA patients compared to multiplex-positive 
anti-CCP-2-negative RA patients (79% vs. 38% and 29% vs. 21%, Table 1). 
We also studied IgM-RF, which co-occurs with anti-CCP-2 (29% in anti-CCP-2-ne-
gative and 91% in anti-CCP-2-positive RA, P < 0.001), but, again, no increased 
frequency of IgM-RF was found in the subgroup of anti-CCP2-negative multiplex-po-
sitive RA patients compared to multiplex negative patients (25% versus 33%)[27]. 
These findings were replicated with anti-MCV- and anti-CCP-3 (data not shown).
Together, these data show that anti-CCP/MCV-negative multiplex-positive RA 
patients cannot be distinguished from anti-CCP/MCV negative multiplex-negative 
RA patients using the read-outs described. 
Correlation of multiplex array positivity with clinical outcome in anti-CCP-2-
negative patients. 
Next, we wished to study whether the multiplex-assay aids in the prognosis of 
clinical outcome. In the EAC cohort, it is known that anti-CCP-2-positive UA patients 
have an increased risk to progress towards RA in the first year of follow-up as 
compared to anti-CCP-2-negative UA patients (30% versus 68%, Figure 4A). Within 
the anti-CCP-2-negative subset, positivity in the multiplex-array was not associated 
with progression (30% in multiplex negative vs 30% in multiplex positive). Accor-
dingly, multiplex-positive UA patients that are anti-CCP-2-positive have a higher risk 
to progress than multiplex-positive anti-CCP-2-negative UA patients (71% versus 
30%, Figure 4A).
Likewise, with regard to joint damage anti-CCP-2-positive RA patients had 11% 
more joint destruction per year (β = 1.11, CI = 1.08-1.14, P < 0.001), which accu-
mulated over 7 years of follow-up (Figure 4B). There was no significant association 
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with joint destruction over time when multiplex-negative anti-CCP-2-negative and 
multiplex-positive anti-CCP-2-negative patients were compared. (β = 1.02, CI = 0.99-
1.06, P = 0.15, Figure 4C). In line with this observation, within the multiplex-positive 
RA subset, anti-CCP-2-positive patients have more joint destruction over time than 
anti-CCP-2-negative RA patients. (β = 1.09, CI = 1.05-1.13, P < 0.001, Figure 4D). 
Together, these data show no added clinical value of the multiplex-array, using 11 
citrullinated peptides, over the existing anti-CCP-2-test with regard to clinical phe-
notype or outcome of disease. 
DISCUSSION




P < 0.001 P = 0.15 P < 0.001
 Progression to RA   
 No n (%) Yes n (%) OR (95% CI) P-value 
CCP2- 311 (70) 132 (30) REFERENCE  
CCP2+ 45 (32) 97 (68) 5.08 (3.38-7.64) P < 0.001 
     
CCP2-Multiplex- 222 (70) 93 (30) REFERENCE  
CCP2-Multiplex+ 89 (70) 39 (30) 1.05 (0.67-1.64) P = 0.84 
     
CCP2-Multiplex+ 89 (68) 39 (30) REFERENCE  
CCP2+Multiplex+ 37 (29) 91 (71) 5.61 (3.28-9.60) P < 0.001 
 















































Figure 4: Multiplex positivity in anti-CCP-2 negative RA patients does not correlate with clinical 
outcome. A. Scheme depicts the number of patients that are diagnosed with UA at baseline. Patients 
were followed for one year to study their progression towards RA. B. Median SHS during 7 years of 
follow-up in anti-CCP-2 negative (N=1010) and positive (N=1330) RA patients. C. Median SHS during 7 
years of follow-up in anti-CCP-2 negative RA patients that are multiplex negative (N=729) or positive 
(N=281). D. Median SHS during 7 years of follow-up in multiplex positive RA patients that are anti-CCP2 
negative (N=281) or positive (N=1282). N depicts the number of radiographs.





ferent citrullinated peptides for detection of ACPA, in an early arthritis setting. The 
multiplex-array can identify most RA patients that are positive in the conventional 
ACPA tests. A large subgroup of RA patients that are negative in commercial ACPA 
tests, including anti-CCP-2/3 and anti-MCV, are positive for one or more reactivities 
in the multiplex-array. These reactivities have potential to discover new autoanti-
body systems or lead to understanding of auto-immune reactions in RA. However 
on a group level, these “additional” identified reactivities does not contribute with 
more clinical information. Furthermore, patients that are multiplex positive but 
CCP2-negative differ from CCP-2-positive RA patients in ACPA risk factors (HLA-SE 
and smoking), the presence of IgM-RF and in clinical parameters (UA to RA progres-
sion and joint destruction), but do not differ from anti-CCP-2-negative patients. 
The fact that the current analysis made use of a single platform is a limitation. 
Nonetheless, findings are in line with results obtained by other platforms[10, 26, 
28]. Using a bead-based multiplex-platform containing 16 different citrullinated 
antigens Wagner et al. found that at least 10% of anti-CCP-2 negative RA patients 
were ACPA-positive. In this study ACPA-positive was much more stringently defined 
(positive for >2 antigen-reactivities with positive defined as mean + 3x the standard 
deviation of the signal in healthy controls). Consistent with our findings, they also 
described that anti-CCP-2-negative RA patients that are positive for citrulline-reacti-
vities recognize a more restricted peptide repertoire[10]. Likewise, this observation 
was also confirmed in another study describing a surface plasmon resonance based 
multiplex platform[25].
Multiplex assays are designed to investigate the presence of antibodies to a large 
number of targets in a high throughput manner and with very small amounts of 
samples. The assay presently contains a large number of different peptides, which 
are derived from native proteins. It is not clear, however, whether antibodies to the 
peptides selected in the array in fact crossreact to native citrullinated proteins in 
vivo. It has been shown that antibodies to citrullinated type II collagen both bind 
joints in vivo, and induces arthritis in mice, but the presently included peptide 
contains two citrullines that block many antibodies reactive with single citrullines 
present on type II collagen in cartilage [29-30]. Thus, it is not clear, whether any of 
the selected peptides attract antibodies that have functional relevance in vivo. On 
the other hand this can also be said regarding the CCP-2 test as well, since in this 
case the sequence is not publically known and therefore no arginine-control can 
be used. Possibly the test contains several peptides that have been selected to give 
the highest specificity for RA. Thus, neither of the used test give any information on 
possible pathogenic or regulatory influence of the respective antibody reactivities.
In this study we have focused on the clinical relevance of citrulline reactivities in anti-
CCP-2-negative RA patients. To the best of our knowledge, only one other report 
has focused on the clinical relevance of citrulline reactivities in anti-CCP-2-negative 
patients. Pratt et al studied the predictive value of reactivity towards citrullinated 
antigens in an ELISA platform with regard to UA to RA progression and found that 
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none of the tested reactivities was as good as anti-CCP-2 in predicting progression. In 
line with our observations, reactivities to a set of citrullinated peptides in anti-CCP-
2-negative UA patients were not associated with disease progression[28]. Although 
our findings are in line with results from other platforms, future work should focus 
on comparing citrulline reactivities in independent cohorts of anti-CCP-2 negative 
RA patients side-by-side on different platforms. To improve multiplex-platforms, 
this work should be directed towards identifying those citrullinated peptides that 
have an additive value and are specific for RA or a specific phenotypical aspect such 
as the anti-SSA antibodies. Most importantly, such specified clinical characteristics 
should be linked with functional knowledge of the detected antibodies. It is needed 
to both improve these platforms with more relevant peptides and to validate them 
using large cohorts of healthy controls, RA patients and disease controls. Future 
studies will also be useful to analyse the relationship of each reactivity with risk 
factors and prognosis, and to investigate the functional role of these autoantibody 
specificities in the disease process. This could facilitate the incorporation of the 
most meaningful reactivities in new future assays
Our data indicate that the positive signals found in anti-CCP-2 negative sera using 
the current multiplex-system, should be interpreted with caution. The detected 
signals are dependent on the particular assays of peptides bound to solidphase, 
known to twist the conformation and increase variability and false positive signals 
as compared with assaying protein-protein interactions. In addition, for most of 
the positive signals for detection of citrullinated peptides, the signal is just above 
the cut-off. False positive signals may therefore contribute to the observation that 
citrulline reactivities in anti-CCP/MCV-negative RA patients are not associated with 
any of the known risk factors for ACPA-positive disease. Another limitation is that 
the peptide composition of the array is limited and the truly relevant citrullinated 
peptides or proteins are not present. This is especially relevant since the number 
of non-fibrinogen peptide positive, anti-CCP-2 negative, multiplex-positive patients 
are low thereby making it impossible to analyse these reactivities. In fact, an incre-
asing number of citrullinated peptides, not used in the present array, are reported 
to have potential pathogenic properties in the development of arthritis [29,31].  
 
CONCLUSIONS
Our data indicate that residual reactivities to a wide range of citrullinated joint 
antigens as measured in the current multiplex-system are unable to subdivide anti-
CCP-2-negative RA patients into clinically different patient subsets. Nonetheless, it 
is clear that anti-CCP-2-negative RA patients are clinically heterogeneous and there 
is a need for biomarkers for disease phenotypes within disease like RA but also 
across different diseases. This would require different studies in patient cohorts 
with detailed phenotypical characteristics which are selected in non-biased ways 





[32]. An improved multiplex-assay could potentially accomplish this.
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Figure S1: Citrulline reactivities to Fibα36-50 and Fibβ563-583. Citrulline-reactivities towards Fibβ563-
583 in anti-CCP-2 positive (n=285) and anti-CCP-2 negative (n=279) RA patients and non-RA patients 
(n=149) in the EAC. B. Citrulline-reactivities in arbitrary units (AU) towards Fibβ563-583 in anti-CCP-2 
positive (n=174) and anti-CCP-2 negative (n=92) RA patients in the IMPROVED. C. Citrulline-reactivities 
towards Fibα36-50 in anti-CCP-2 positive (n=285) and anti-CCP-2 negative (n=279) RA patients and 
non-RA patients (n=149) in the EAC. D. Citrulline-reactivities towards Fibα36-50 in anti-CCP-2 positive 
(n=174) and anti-CCP-2 negative (n=92) RA patients in the IMPROVED. The dotted line indicates the 
cut-off. Reactivities are plotted in arbitrary units (AU). Each dot indicates a unique individual.
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Group Multiplex-negative Multiplex-positive Total
Reactive arthritis 6 (6%)  4 (11%) 10 (7%)
Gout 16 (16%)  6 (16%) 22 (16%)
Pseudogout 1 (1%) 0 (0%) 1 (1%)
Spondyloarthritis including 
psoriatric arthritis
45 (46%) 13 (35%) 58 (43%)
Osteoarthritis 15 (15%) 6 (16% 21 (16%)
Lyme arthritis 1 (1%) 0 (0%) 1 (1%)
Paramalignant arthritis 0 (0%) 4 (11%) 4 (3%)
Sarcoidosis 0 (0%) 1 (3%) 1 (1%)
Mixed connective tissue 
disease, vasculitis
1 (1%) 0 (0%) 1 (1%)
Other systemic autoimmune 
diseases
5 (5%) 0 (0%) 5 (4%)
Remitting seronegative 
symmetrical synovitis with 
pitting edema
8 (8%) 2 (8%) 10 (7%)
Rest 0 (0%) 1 (3%) 1 (1%)
Total 98 (100%) 37 (100%) 135 (100%)
Table S1: Diagnoses of anti-CCP2-negative non-RA patients (n=135) as assessed by an experienced 
rheumatologist after 1 year of follow-up stratified for multiplex-positivity.












Anti-CCP2 titer in AU/ml, mean (SD) 13 (9) 12 (10) 0.53
                                        median (IQR) 20 (3-21) 20 (1-20) 0.73
Age in yrs, mean (SD) 60 (17) 59 (17) 0.67
Female gender, n (%) 47 (55) 131 (68) 0.04
HAQ, median (IQR) 1.0 (0.6-1.6) 1.0 (0.6-1.6) 0.76
         mean (SD) 1.1 (0.7) 1.1 (0.7) 0.92
CRP in mg/ml, mean (SD) 27 (30) 35 (42) 0.72
                        median (IQR) 15 (6-37) 23 (6-48) 0.46
SHS, mean (SD) 9 (11) 8 (9) 0.36
         median (IQR) 6 (2-12) 4 (2-11) 0.19
ESR in mm/h, mean (SD) 35 (23) 33 (27) 0.54
Symptom duration at baseline in months, 
mean (SD)
6 (12) 5 (9) 0.58















Table S3: Peptides recognized by anti-CCP-2-negative EAC patients that are positive in the multiplex 
assay for a single epitope (n=143).
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Fine-mapping the HLA locus in rheumatoid 
arthritis and other rheumatic diseases: 
Identifying causal amino acid variants. 
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ABSTRACT
Purpose of review To provide an update on- and context of the recent findings 
obtained with novel statistical methods on the association of the Human leucocyte 
(HLA) locus with rheumatic diseases.
Recent findings Novel SNP fine-mapping data obtained for the HLA locus have indi-
cated the strongest association with aa positions 11 and 13 of HLA-DRB1 molecule 
for several rheumatic diseases. On the basis of these data, a dominant role for 
position 11/13 in driving the association with these diseases is proposed and  the 
identification of causal variants in the HLA-region in relation to disease-susceptibi-
lity implicated.
Summary The human leukocyte antigen (HLA) class II locus is the most important 
risk factor for several rheumatic diseases. Recently, new statistical approaches have 
identified previously unrecognized amino acid positions in the HLA-DR-molecule 
that associate with anti-citrullinated protein antibody negative and positive rheu-
matoid arthritis. Likewise, similar findings have been made for other rheumatic 
conditions such as giant cell arteritis and systemic lupus erythematosus. Interes-
tingly all these studies point towards an association with the same amino acid 
positions: amino acid position 11 and 13 of the HLA-DR beta chain. As both these 
positions influence peptide binding by HLA-DR and have been implicated in antigen 
presentation, the novel fine-mapping approach is proposed to map causal variants 
in the HLA-region relevant to RA and several rheumatic diseases. If these interpre-
tations are correct, they would direct the biological research aiming to address the 
explanation for the HLA-disease association. Here, we provide an overview of the 
recent findings and evidence from literature that, while relevant new insights have 
been obtained on HLA-disease associations, the interpretation of the biological role 
of these amino acids as causal variants explaining such associations should be taken 
with caution.






Rheumatoid Arthritis (RA) is a chronic systemic inflammatory disorder predomi-
nantly affecting synovial joints. In the past pivotal pathophysiological insight has 
been obtained by the identification of the anti-citrullinated protein antibodies 
(ACPA), a group of autoantibodies specifically directed to citrullinated proteins[1]. 
ACPA are highly specific for RA and directed against antigens that are also expressed 
in the inflamed joint[2]. 
It is now clear that RA represents two main syndromes, ACPA-positive- and ACPA-ne-
gative disease, that are most likely etiologically distinct as different genetic risk 
factors are underlying the two distinct disease phenotypes. This was first evidenced 
by the finding that different Human Leukocyte Antigen (HLA)-genes are predispo-
sing to either ACPA-positive or ACPA-negative disease, and boosted by the results 
of Whole Genome Association (WGA)-studies[3-5]. In the recent past, the genetics 
of RA has undergone a revolution through the identification of several novel genetic 
risk factors. Although the identification of genetic regions triggering human disease 
represents a major step forward, one of the biggest challenges to date is to eluci-
date the biological pathways underlying these associations to obtain a thorough 
understanding of disease pathogenesis. At least 20% of all genetic variance contri-
buting to RA is explained by the HLA class II region, which is considerably more than 
that of all known non-HLA common genetic variants together[6]. Thus, the HLA-re-
gion is by far the most important known genetic risk factor for RA. Nonetheless, the 
biological pathway(s) causing this association is/are still unknown. Therefore, one 
of the major questions in the field is how the HLA class II region is contributing to 
disease pathogenesis, how the immune response underlying the disease is gene-
rated and which role it is playing in disease induction and progression. 
HLA-class II-proteins present antigenic peptides to T-cells, which will result in T-cell 
activation and induction of antigen-specific immune reactions. Activated T-cells 
can mediate a plethora of effects including provision of help to B-cells necessary 
for antibody isotype-switching, affinity-maturation and memory B-cell-forma-
tion. Although the association between HLA and RA is known for over 30 years, 
the biology explaining this association and the nature of the presented antigen 
is poorly understood. One of the prevailing ideas to date is the notion that the 
HLA-molecules that predispose to RA have an enhanced ability, in comparison to 
the HLA-alleles that do not predispose to ACPA-positive disease, to present citrulli-
nated epitopes[7-8]. The HLA-molecules associating with RA are generally referred 
to as HLA-Shared-Epitopes (HLA-SE) as the HLA-DR-molecules encoded by the 
predisposing HLA-haplotypes share a common sequence in the peptide-binding 
groove of the molecule[9]. Through the ability of the HLA-SE-molecules to present 
citrullinated antigens, these molecules are best suited to activate T-cells reactive 
to citrullinated antigens, thereby facilitating the induction of T-cell responses that 
can provide help to B cells recognizing the same antigens. Whether this hypothesis 
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is correct is not known, but it has been shown that the pocket in the HLA-anti-
gen-binding groove (the P4-pocket) that is, in part, shaped by the SE-sequence, is 
able to accommodate citrulline, but not arginine, the amino acid from which cit-
rulline is formed. Nonetheless, it is not known whether these findings apply for all 
HLA-SE-molecules or for all citrullinated epitopes. To better understand the contri-
bution of the HLA-SE-alleles in ACPA-positive RA, more refined insights the HLA-RA 
connection is important. Obviously, a similar notion applies for other rheumatic 
diseases where the contribution of the HLA-region to disease pathogenesis is also 
not well understood.
FINE MAPPING THE HLA LOCUS
The HLA locus is complex as it contains many genes that can be highly poly-
morphic[10]. Also, this region is characterized by extensive linkage disequilibrium 
(LD) making it difficult to identify the responsible genes and/or causal variants. 
Recent studies have revealed relevant new insights into the association of the 
HLA-region with rheumatoid arthritis and several other  rheumatic diseases[4, 8-12]. 
By fine-mapping of the HLA locus and imputation of amino acids (aa) sequences of 
HLA-molecules from SNP genotype data, HLA-genetics have been made feasible in 
large groups of patients and controls. This allowed new insights into the HLA-asso-
ciation for many different diseases (detailed description in [4]).
Analysis of the association of individual imputed amino acids (aa) throughout the 
HLA-locus revealed specific positions in the HLA-DRB1-allele that associated best 
with disease. As the identified HLA-variants are part of peptide-binding grooves, 
these new findings were proposed to map causal variants in the disease-associating 
HLA-molecules. This approach has now been applied to both ACPA-negative[11, 12] 
and ACPA-positive RA [4, 11, 13], but also to other rheumatic diseases including 
Systemic Lupus Erythematosus (SLE) and Giant Cell Arteritis (GCA)[14-15]. Previ-
ously, dominant risk genotypes of these diseases were documented on the basis of 
conventional HLA-genotyping. Susceptibility to ACPA-negative RA was shown to be 
associated with HLA-DRB1*03[3, 11], whereas ACPA-positive RA and GCA are most 
strongly associated with HLA-DRB1*04[16, 17]. SLE susceptibility in Koreans was 
reported to be linked to HLA-DRB1*15[18]. 
Intriguingly, the novel SNP fine-mapping data obtained for the HLA locus showed 
the strongest association with aa positions 11 and 13 of HLA-DRB1 for all these 
rheumatic diseases (summarized in Table 1). Importantly, positions 11 and 13, 
which are in tight LD, are critically relevant for shaping several peptide-binding 
pockets: Aa position 11 is involved in shaping peptide-binding pocket 6, whereas aa 
position 13 affects the shape of pocket 4[19]. Peptide-binding pockets are part of 
the peptide-binding groove of the HLA-molecule that are involved in epitope-pre-
sentation. The interpretations of these combined findings often imply a dominant 





role for position 11/13 in driving the association with disease or implicate the iden-
tification of causal variants in the HLA-region in relation to disease-susceptibility. 
For instance, when these aa positions where found in association with SLE, it was 
concluded that these aa positions at the epitope-binding groove of HLA-DRβ1 are 
responsible for most of the association between SLE and MHC. Likewise, when it 
was shown that the variants that associate with RA are the same variants that asso-
ciated with risk for development of follicular lymphoma, the presence of a common 
HLA-DR antigen-driven mechanism for the pathogenesis of follicular lymphoma (FL) 
and RA was suggested[20].  
PERSPECTIVE
If the interpretations, such as the one mentioned above, are correct, it would have 
an important impact on the design of experiments aiming to address the biological 
explanation for the HLA-disease association. For example, in the case of RA, less 
efforts should be devoted to the elucidation of the role of the shared epitope, but 
instead, the contribution of aa position 11/13 should be scrutinized. Aa positions 
11 is not part of pocket 4 and does not interact with SE-residues. Therefore, these 
findings would imply that, at the molecular level, two different mechanisms might 
be operative that contribute to the development of ACPA-positive RA. Similar impli-
cations would apply for other rheumatic diseases. To better understand the possible 
contributions of these aa associations and the findings generated by the described 
method, we reviewed variation between HLA-DRB1-alleles in closer detail. 
An aa position can only be significantly associated with a disease if the particular 
position is polymorphic. HLA-DR molecules are heterodimers consisting of an alpha 
and a beta chain. For HLA-DR all the variation between donors is found in the beta 
chain. Figure 1A schematically depicts the variation in the HLA-DR b1 domain per 
amino acid of the top-15 most prevalent HLA-DRB1 chains present in the Cauca-
sian population (together covering 91% of the variation in Caucasians[21]). Black 
dots indicate aa residues that are involved in shaping the peptide-binding pockets. 
As illustrated, most variation in HLA-DRB1 resides in residues critically engaged 
Pos1 Pos2 Pos3 Reference
ACPA- RA 11/13 - - [9, 10]
ACPA+ RA (Caucasians) 11/13 71 74 [6, 9, 11]
ACPA+ RA (Asians) 11/13 57 74 [11]
Giant cell arteritis 11/13 - - [13]
Systemic Lupus Erythematosus 11/13 26 - [12]
Table 1: Summary of amino acid positions associated with risk to develop rheumatic diseases.
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in shaping peptide-binding pockets. The finding that the statistically significant 
amino-acid positions are those involved in peptide presentation is therefore not 
surprising and does not, per se, support a more important pathophysiological role 
of these particular amino acid positions compared to other non-associated posi-
tions. 
HLA-crystallization and peptide-elution studies have shown that peptide-binding 
pockets are shaped by the combination of multiple different (polymorphic) amino 
acids (schematically depicted in Figure 1B) and that the combination of all these 
amino acids will eventually determine the size, charge and hydrophobicity of each 
peptide-binding pocket and thereby the ligands that can be presented by the 
HLA-molecule [22-27]. It is therefore surprising that aa positions 11 and 13 are so 
strongly associated with different rheumatic diseases compared to other aa posi-
tions that are also involved in shaping these pockets as one could assume that, 
in case a particular pocket is crucial to the presentation of a particular (set of) 
antigens, also the other aa involved in the formation of the pocket would influence 
the binding of such antigen(s). Recently, these studies were also conducted for 
non-rheumatic diseases: ulcerative colitis and FL [20, 28]. Again, aa positions 11 
and 13 were most strongly associated with risk for these two diseases. Together, 
Figure 1: Variation in the HLA-DR b1 chain. 
(A) Plot depicts the number of variants for 
each position in the HLA-DR beta chain. 
Amino acid position 11 and 13 are hig-
hlighted. Black dots indicate amino acid 
positions implicated in shaping peptide-bin-
ding pockets, gray dots indicate amino acid 
positions that are not involved in shaping 
the binding pockets. (B) Summary of the 
aa position of the HLA-DRA1 and HLA-DRB1 
chain that are involved in shaping the pep-
tide-binding pockets. Positions 11 and 13 
are highlighted in bold. (C) Scheme depic-
ting the subdivision of HLA-DR alleles on the 
basis of aa position 13 or aa position 9. (D) 
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Distribution of the aa variants at position 11 or position 13. All analyses were performed using the 15 
most frequent HLA-DRB1 alleles in Caucasians (91% of all the variation).





these findings and considerations make it conceivable that the applied approach 
does not identify causal variants as implied, but may contain a bias towards these 
two aa residues. 
Such bias could be introduced by the fact that some aa positions are more poly-
morphic than others. As depicted in Figure 1A, aa positions 11 and 13 are the most 
polymorphic amino acid positions in the HLA-DRB1-gene. It is conceivable that 
the applied approach biases towards amino acid positions that can subdivide the 
different HLA class II molecules into the largest number of groups, i.e. the most 
polymorphic amino acid positions. Thus, positions 11 and 13 are likely to be the 
best surrogate markers for defining HLA-genotype as they contain the most discri-
minative ability. This is illustrated in Figure 1C for ACPA-positive RA which is known 
to associate most strongly with HLA-DR4[29]. Stratification on position 13 gene-
rates 6 different groups on the basis of the 6 different aa that can be present in this 
position. HLA-DR4 will be in a group without other HLA-DR subtypes. Stratification 
on a less polymorphic position, e.g. position 9, subdivides the HLA class II mole-
cules in only 2 groups. HLA-DR4 will now be in a subgroup with HLA-DR3, HLA-DR8, 
HLA-DR11 and HLA-DR13 that will all dilute the risk effect of HLA-DRB1*04. The-
refore, a statistical approach based upon the presence of individual aa in certain 
positions will unlikely identify aa at position 9, as this position is relatively non-poly-
morphic. Nonetheless, in biological terms, this position shapes one of the pockets: 
pocket 9, and hence will impact HLA-ligand binding. Likewise, giant cell arteritis is 
also associated with HLA-DRB1*04 and therefore similar aa position will likely asso-
ciate with this disease although the biological basis is likely different[16]. 
For ACPA-negative RA, HLA-DRB1*03 is the major risk determinant[3, 11, 30]. Stra-
tification on the basis of aa position 13 will generate an HLA-DR3 subgroup with 
HLA-DRB1*11 and HLA-DR13, whereas stratification based on aa position 9 will 
generate a subgroup of HLA-DR3 with HLA-DR4, HLA-DR8, HLA-DR11 and HLA-DR13 
(Figure 1C). Hence, stratification on aa position 13 will again be favored over less 
polymorphic positions, e.g. position 9. Finally, SLE is most strongly associated with 
HLA-DR15 in Asians and stratification on position 13 will generate an HLA-DR15 
subgroup with DR16, whereas stratification on position 9 will generate a subgroup 
of HLA-DR15 with HLA-DR1, HLA-DR7 and HLA-DR16[18].
Stratification on aa positions 11 and 13 does not only generate the largest number 
of different groups, but also provides the best resolution due to the fact that the 
various aa variants predisposing to different rheumatic diseases are quite evenly 
distributed in size. This could further explain why these aa residues are so strongly 




The development of new methods and tools for genetic data analyses in the 
HLA-region have been rewarding as they further refined the HLA-diseases 
associations by allowing inclusion of large datasets that lacked conventional 
HLA-genotyping data. Based on the analyses described above we feel, however, 
that conclusions on the biological role of amino acid positions obtained via 
this novel fine-mapping approach should be taken with caution as it appears 
that this approach may contain a bias towards particular aa positions that, at a 
single amino acid level, best mark the associated HLA-DRB1 genotype. These 
considerations are in agreement with MHC-ligand studies that clearly show 
that the combination of all residues shaping peptide-binding pockets will even-
tually determine the type of ligands that are presented by these molecules.
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CHAPTER 7
The protective effect of HLA-DRB1*13 alleles 
during specific phases in the development 
of anti-citrullinated protein antibody positive 
rheumatoid arthritis.
Jurgen van Heemst*, Aase H. Hensvold*, Xia Jiang, Hanna W. van Steenbergen, Lars 
Klareskog, Tom W.J. Huizinga, Annette van der Helm-van Mil, Anca I. Catrina, Karin 




Objective HLA-DRB1*13 alleles are associated with protection from anti-citrul-
linated protein antibody (ACPA-)positive rheumatoid arthritis (RA). It is however 
unknown at which phase of disease development (seroconversion, ACPA matura-
tion, disease onset or outcome) these alleles are most important. We therefore 
examined the effect of HLA-DRB1*13 on the presence of ACPA (:systemic autoimmu-
nity associated with RA) in individuals with and without RA, on ACPA characteristics 
and clinical outcome measures. 
Methods The effect of HLA-DRB1*13 on the presence of ACPA with of without RA 
was assessed in the Swedish twin registry (n=10748). ACPA characteristics were 
studied in ACPA-positive RA patients from the Swedish Epidemiological Investiga-
tion of Rheumatoid Arthritis (EIRA, n=1224) and the Dutch Leiden Early Arthritis 
Clinic (EAC, n=441). Disease activity at inclusion and disease outcome (DMARD-free 
sustained remission and radiographic progression) was assessed in more than 600 
RA patients from the EAC.
Results HLA-DRB1*13 is associated with protection from ACPA-positive RA (pre-
valence 16% versus 28% in ACPA-negative RA), but not with significant protection 
(p-value 0.09) from ACPA (systemic autoimmunity associated with RA) (prevalence: 
22%). HLA-DRB1*13 is associated with lower ACPA-levels (EIRA: 447 U/ml versus 
691 U/ml, p-value: 0,0002) and decreased recognition of citrullinated vimentin and/
or alpha-enolase (EIRA: p< 0.0001). HLA-DRB1*13 is not associated with disease 
activity or outcome.
Conclusion These data suggest that HLA-DRB1*13 mainly affects the onset of 
ACPA-positive RA in ACPA-positive non-RA individuals. HLA-DRB1*13 influences 
ACPA characteristics, but not disease course after seroconversion. This implies that 
therapeutic strategies aimed at emulating the HLA-DBR1*13 protective effect may 
be most effective in ACPA-positive healthy individuals at risk for RA.






The risk of developing rheumatoid arthritis risk (RA) is influenced by both genetic 
and environmental factors, with the human leukocyte antigen (HLA) class II locus 
as the major genetic determinant [1, 2]. RA risk is mainly associated with the 
presence of HLA-DR molecules that carry the shared epitope (SE) motif, whereas 
HLA-DRB1*13 alleles (HLA-DRB1*13:01 and HLA-DRB1*13:02) are associated with 
protection against RA[3-5]. Interestingly, these alleles protect with an odds ratio of 
approximately 0,55 both in the absence and presence of SE-alleles, indicating that 
this protective effect is SE-independent [5].
Autoantibodies, in particular anti-citrullinated protein antibodies (ACPA), are an 
important hallmark of rheumatoid arthritis[6]. These autoantibodies recognize a 
broad variety of proteins that have undergone post-translational modifications con-
verting arginine to citrulline residues[7, 8]. These autoantibodies can be found up 
to ten years before RA onset and are a strong predictive factor for RA development 
[9-11]. Prior to disease onset, the ACPA-response suddenly matures with a rise in 
ACPA levels, increased isotype usage and epitope-spreading to a broader range of 
citrullinated antigens (reviewed in [12]). Moreover, the presence of ACPA is associ-
ated with a more destructive disease phenotype[13]. 
HLA class II alleles, including the SE-alleles and HLA-DRB1*13 alleles, shape the 
risk to develop RA, and are predominantly associated with ACPA-positive RA [14, 
15]. This suggests that ACPA-positive and ACPA-negative disease are two distinct 
diseases, and that these HLA-DRB1 alleles are specifically involved in the production 
of ACPA autoantibodies. Recently, several reports have investigated the contribution 
of SE-alleles during different phases of RA development. These studies suggest that 
SE plays a minor role in the development of ACPA in individuals without arthritis, 
but is more important for the transformation from ACPA-positive autoimmunity (in 
the absence of arthritis) to ACPA-positive disease[16-17]. Moreover, in ACPA-posi-
tive RA patients, SE-alleles associate with the recognition of a broader repertoire 
of fine-specificities and with specific ACPA fine-specificities, most notably epitopes 
on citrullinated α-enolase and vimentin [18-20]. However, SE-alleles do not asso-
ciate with disease outcome[21-23]. Despite the strong protective association 
between HLA DRB1*13 alleles and ACPA-positive RA, it is unknown at which phases 
of disease development these alleles exert their effect. A better understanding of 
the protective effect of HLA DRB1*13 alleles might allow the development of the-
rapeutic strategies aimed at imitating this effect. Ideally, the beneficial effect of 
these alleles could then be simulated in HLA DRB1*13-negative individuals by a 
therapeutic agent.
Therefore we now aimed to investigate the contribution of HLA-DRB1*13 during 
different phases of ACPA-positive disease. We therefore examined the effect of 
HLA-DRB1*13 on the presence of ACPA (:systemic autoimmunity associated with 
RA) in individuals with and without RA, the association between HLA DRB1*13 and 
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ACPA characteristics as well as clinical outcome measures (DMARD-free remission 




This study made use of three independent cohorts: the Swedish TWINGENE 
cohort[24, 25], the Swedish Epidemiological Investigation of RA (EIRA[26]) and the 
Dutch Leiden Early Arthritis Clinic[27].
The TWINGENE cohort was used to study the influence of HLA-DRB1*13 on ACPA-po-
sitivity in subjects without RA (i.e. in non-RA individuals). This cohort consists of 
12590 twins from the national Swedish twin registry. A twin was considered an 
RA patient if an RA diagnosis was listed in the patient’s register at least once in 
2009, or in prior years, as described previously [17]. The current analysis included 
10748 individuals on whom HLA data was available: ACPA-negative non-RA twins 
(n=10454), ACPA-positive non-RA (called: healthy) twins (n=190) and ACPA-positive 
RA twins (n=104) of whom HLA-typing was available.
The EIRA was used to study the influence of HLA-DRB1*13 on characteristics of the 
ACPA-response. This Swedish cohort recruited incident RA cases and controls from 
1996 to 2003 from the south and central regions of Sweden. All EIRA RA cases fulfil 
the 1987 ACR criteria for RA. Only HLA-genotyped, anti-CCP2 antibody positive EIRA 
RA patients were included in the current analysis (n=1224). 
The Leiden EAC was used to study the influence of HLA-DRB1*13 on the ACPA-charac-
teristics and on disease outcome measures. This cohort was initiated in 1993 and 
includes patients with a recent onset of arthritis (symptom duration < 2 years) from 
the Leiden area[27, 28]. Definitive diagnoses were determined after 1 year of fol-
low-up by an experienced rheumatologist using existing classification criteria. Of 
the 1140 fulfilling the EULAR/ACR2010 criteria for RA, HLA-typing was available for 
835 of which 441 patients were anti-CCP-2-positive. Disease characteristics such as 
the swollen joint count (SJC), score on health assessment questionnaire (HAQ), and 
joint damage as measured by Sharp-van der Heijde-score (SHS) were assessed at 
baseline and yearly thereafter[30]. 
Auto-antibodies 
Anti-CCP-2 was measured by ELISA using the Immunoscan RA Mark 2-test; (Eurodi-
agnostica, Arnhem, The Netherlands; Eurodiagnostica AB, Malmö, Sweden) with a 
cut-off as specified by the manufacturer. In the EAC and the EIRA, antibodies against 
citrullinated and native vimentin (Vim59-74 in the EAC, Vim60-75 in the EIRA) or 
alpha-enolase (linear Eno5-20 in the EAC, cyclic Eno5-21 in the EIRA) peptides, as 
well as the corresponding arginine-containing control peptides, were determined 
by in-house ELISAs as previously described[12, 18, 19, 20, 22]. 






Genotyping was performed as previously described[17, 20, 30]. In the EAC a specific 
probe was used that can detect the presence of the SE sequence, classifying HLA-
DRB1*01:01, *01:02, *04:01, *04:04, *04:05, *04:08 and *10:01 as SE-alleles. In 
the EIRA, HLA-DRB1*01:01, HLA-DRB1*01:02, HLA-DRB1*04 and HLA-DRB1*10 
were classified as SE-alleles. In the TWINGENE cohort, HLA-DRB1 gene alleles were 
imputed from genome-wide datasets.
Remission 
In the EAC, DMARD-free sustained remission was defined as previously described[31, 
32. Briefly, three criteria needed to be fulfilled: no current use of DMARDs, no 
swollen joints, and classification as DMARD-free remission by the patient’s rheu-
matologist. The absence of swollen joints had to be observed by a rheumatologist 
for at least one year after DMARD-therapy discontinuation. 
Statistical analysis 
To estimate the association of HLA-DRB1*13 with ACPA-positivity in twins with 
or without RA, a binominal logistic regression model was used to calculate odds 
ratios (ORs). Confidence intervals (CI) were adjusted due to clustering of twin data. 
P-values were estimated by Wald statistics and chi-square tests.
To determine the association of HLA-DRB1*13 with various ACPA-characteristics, 
ORs with 95% CI were calculated using logistic regression analyses with those 
negative for risk factors as reference. Stratification was performed as previously 
described [30] by analyzing the effect of HLA-DRB1*13 in both the SE-negative (x/x 
versus DRB1*13/x and DRB1*13/DRB1*13) and SE-positive stratum (SE/x versus 
SE/DRB1*13).
To analyze the rate of joint destruction, a multivariate normal regression model 
for longitudinal data with log-transformed SHS as response variable was used as 
previously described[33]. This method analyses al repeated measures at once and 
takes advantage of the correlation between these measurements. Analyses were 
adjusted for age, gender and different inclusion periods as proxy for treatment 
strategy [28].
Analysis of DMARD-free sustained remission was performed by Cox regression 
analysis, after verification that the proportional hazards assumption was satisfied. 
For patients who achieved remission the dependent variable is the “time-to-event”, 
indicating the time until reaching remission. For non-remission patients the time to 
last follow-up was used, with a maximum of 15 years. 
P-values <0.05 were considered significant. All reported p-values are two-sided. 
Analyses were performed using SPSS statistics, version 22.
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RESULTS
Influence of HLA-DRB1*13-status on the presence of ACPA in non-RA individuals 
and in RA patients
In order to investigate the effects of HLA-DRB1*13 alleles during different phases of 
RA development, we first examined whether HLA-DRB1*13 alleles prevent the first 
detectable stage of autoimmunity: the development of ACPA. To this end we used a 
cohort of 10.748 twins from the national Swedish twin registry[24, 25]. ACPA could 
be detected in 2.7% of these twins (n=294). Of those 294 ACPA-positive twins, 104 
(35%) were diagnosed with RA[17]. The HLA-DRB1*13 frequency was compared 
in ACPA-negative non-RA individuals (27,6%), ACPA-positive non-RA individuals 
(22,1%) and ACPA-positive RA patients (16,3%). There was a significant protec-
tive effect of HLA-DRB1*13 in ACPA-positive RA patients in the TWINGENE cohort 
(OR=0.51, CI=0.30-0.87, p=0.01, Supplementary Table 1) as was previously demon-
strated in other Caucasian cohorts[5]. However, there was no significant protective 
effect of HLA-DRB1*13 in ACPA-positive non-RA individuals (OR=0.74, CI=0.53-1.05 
p=0.09,) (Table 1). However, there might be a trend towards protection, which could 
indicate that HLA-DRB1*13 might exert some protective effect also in the deve-
lopment of ACPA, but mainly protects from the development of ACPA-positive RA. 
Similar associations have previously been shown for the predisposing effect of the 
SE-alleles[17]. Stratifying the HLA-DRB1*13 analysis for SE status did not change 
the results (data not shown).
HLA-DRB1*13 also protects from ACPA-positive RA in the Japanese RA case-control 
study[4]. Recently, a report was published describing a large cohort (Nagahama-co-
hort) of Japanese volunteers without autoimmune diseases that were HLA-typed 
and serotyped for ACPA[34]. We have now extracted data from this report to make 
a similar comparison and to validate our findings (Table 1). In line with our data 
TWINGENE Non-RA
ACPA- ACPA+ OR (95% CI) P-value
DRB1*13 Neg 7566 (72,4%) 148 (77,9%) REF
Pos 2888 (27,6%) 42 (22,1%) 0.74 (0.53-1.05) 0.09
NAGAHAMA Non-RA
ACPA- ACPA+ OR (95% CI) P-value
DRB1*13 Neg 2495 (80,1%) 42 (75%) REF
Pos 619 (19,9%) 14 (25%) 1.36 (0.74-2.51) 0.33
Table 1. HLA-DRB1*13 association with ACPA-positivity in non-RA patients.





from the TWINGENE cohort, HLA-DRB1*13 does not protect from the develop-
ment of ACPA in Japanese individuals without autoimmune diseases (OR=1.36, 
CI=0.74-2.51, p=0.33). When compared to the TWINGENE cohort, the Nagahama 
cohort had a lower frequency of HLA-DRB1*13 alleles (20% versus 29%) and fewer 
ACPA-positive individuals (56 versus 190). Still, the data show that also in Japan, 
the presence of HLA-DRB1*13 alleles seem to protect from the development of 
ACPA-positive RA, but not from the development of ACPA. Hence data from two 
independent cohorts supports a protective effect of HLA-DRB1*13 on the transition 
from ACPA-positive autoimmunity to ACPA-positive RA. 
Influence of HLA-DRB1*13 on ACPA levels
There are many data which have indicated that the transition from from ACPA-po-
sitive autoimmunity to ACPA-positive RA is marked by pronounced changes in the 
EIRA Anti-CCP-2 levels in U/ml
Total Median IQR Patient Nr. P-value
DRB1*13 neg 690.64 224.94-1554.56 1100 REF
pos 446.50 105.94-907.78 126 0.0002
SE-negative stratum
DRB1*13 neg 684.10 258.45-1514.04 143 REF
pos 387.00 102.00-656.09 46 0.0028
SE-positive stratum
DRB1*13 neg 651.45 183.05-1593.90 568 REF
pos 454.49 109.88-1109.85 80 0.048
EAC Anti-CCP-2 levels in U/ml
Total Median IQR Patient Nr. P-value
DRB1*13 neg 609.93 193.30-1297.80 391 REF
pos 421.54 172.61-1060.61 50 0.30
SE-negative stratum
DRB1*13 neg 545.87 191.94-1108.21 62 REF
pos 342.82 58.08-1012.72 26 0.48
SE-positive stratum
DRB1*13 neg 626.53 180.81-1340.76 220 REF
pos 500.41 221.90-1749.70 23 0.68
Table 2. HLA-DRB1*13 association with anti-CCP-2 level in ACPA-positive RA patients.
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nature of the ACPA-response. Around disease onset, the ACPA response changes: 
ACPA levels increase, the number of isotypes expand and the ACPA response 
“spreads” to other citrullinated epitopes[35]. Since HLA-DRB1*13 alleles appear 
to inhibit this transition from pre-disease to RA, we investigated whether HLA-
DRB1*13 can also shape the ACPA-response by influencing ACPA characteristics. To 
avoid skewing of the results due to the inverse association between HLA DRB1*13 
and ACPA-positive RA, we further focused our analyses on ACPA-positive RA patients 
in two independent cohorts, the Dutch Early Arthritis Clinic (EAC, n=441) and the 
Swedish Epidemiological Investigation of Rheumatoid Arthritis (EIRA, n=1224) 
cohort. 
In the EIRA, HLA-DRB1*13 alleles are associated with lower ACPA-levels (p=0.0002) 
(Table 2). Since ACPA-levels have been described to be increased in patients positive 
for SE-alleles[14], we next investigated if the effect of HLA-DRB1*13 on ACPA levels 
EIRA DRB1*13
Total negative positive OR (95% CI) P-value
Vim and/or eno Neg 272 (24.5) 54 (42.9) REF
Pos 838 (75.7) 72 (57.1) 0.42 (0.29-0.62) <0.0001
SE-negative stratum
Vim and/or eno Neg 64 (44.76) 25 (54.35) REF
Pos 79 (55.24) 21 (45.65) 0.56 (0.26-1.18) 0.12
SE-positive stratum
Vim and/or eno Neg 147 (25.88 29 (36.25) REF
Pos 421 (74.21) 51 (63.75) 0.60 (0.36-0.99) 0.047
EAC DRB1*13
Total negative positive OR (95% CI) P-value
Vim and/or eno Neg 112 (40.1) 24 (60.0) REF
Pos 167 (59.9) 16 (40.0) 0.45 (0.23-0.88) 0.02
SE-negative stratum
Vim and/or eno Neg 30 (68.2) 15 (78.9) REF
Pos 14 (31.8) 4 (21.1) 0.57 (0.16-2.04) 0.39
SE-positive stratum
Vim and/or eno Neg 59 (37.1) 9 (45.0) REF
Pos 100 (62.9) 11 (55.0) 0.72 (0.28-1.84) 0.36
Table 3. HLA-DRB1*13 association with ACPA fine-specificities towards vimentin and alpha-enolase.





is SE-independent or explained by an underrepresentation of SE-alleles in HLA-DR-
B1*13-positive individuals. To this end, the patients were stratified into an HLA-SE 
negative and -positive stratum. This revealed that ACPA-levels were decreased in 
HLA-DRB1*13-positive patients in both the SE-positive (p=0.048) and SE-negative 
(p=0.003) stratum. In the EAC, the same difference in ACPA-levels between HLA 
DRB1*13-positive and –negative patients was visible, with absolute ACPA-levels 
which were remarkably similar to the EIRA. However, the differences in EAC did 
not reach statistical significance, which may be explained by low statistical power 
(Table 2).
Together, these data indicate that HLA-DRB1*13 alleles associate with lower 
ACPA-levels independent of SE-status.
Influence of HLA-DRB1*13 on ACPA fine-specificities
A correlation between ACPA-levels and the number of recognized citrullinated 
epitopes has been reported. Based on the lower ACPA-levels in HLA-DRB1*13-posi-
tive ACPA-positive RA patients, we wondered if these patients would also have fewer 
ACPA-fine-specificities than HLA-DRB1*13-negative ACPA-positive RA patients. Since 
it has previously been shown that the presence of HLA SE-alleles in ACPA-positive 
RA patients is associated with increased presence of certain ACPA fine-specificities, 
in particular ACPAs targeting citrullinated vimentin and α-enolase, we focused on 






Age in yrs, mean (SD) 54 (15) 55 (12) 0.54
Female gender n (%) 268 (69) 29 (58) 0.14
Symptom duration at 
baseline in months (SD)
7 (10) 7 (11) 0.77
ESR in mm/h, mean (SD) 40 (29) 36 (25) 0.29
CRP in mg/ml, mean (SD) 27 (33) 26 (29) 0.71
                    median (IQR) 16 (7-35) 11 (7-30) 0.43
IgM-RF positive, n (%) 339 (87) 40 (80) 0.20
SJC, mean (SD) 9 (8) 9 (7) 0.76
HAQ, mean (SD) 1 (0.7) 0.9 (0.7) 0.52
SHS, mean (SD) 9 (12) 7 (6) 0.26
         median (IQR) 6 (2-11) 5 (3-11) 0.47
Table 4. HLA-DRB1*13 association with baseline characteristics of ACPA-positive RA patients.
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tive RA patients in HLA-DRB1*13-negative and -positive subsets and determined 
the percentage of patients positive for one or both of these fine-specificities. In 
accordance with our hypothesis, the presence of HLA DRB1*13 is associated with a 
decreased recognition of these particular fine-specificities in both the EIRA cohort 
(OR=0.42, CI=0.29-0.62, p<0.0001) and the EAC (OR=0.45, CI=0.23-0.88, p=0.02) , 
Table 3). Next, we investigated whether the observed association is SE-independent 
by performing stratification. Again the recognition of these fine specificities was 
markedly lower in the DRB1*13-positive patients in all strata and in both cohorts, 
although this only reached (borderline) significance in the SE-positive stratum in 
the EIRA (Table 3), possibly due to lack of statistical power. Serum reactivity to cit-
rullinated epitopes on collagen type II and fibrinogen was also analyzed in EIRA, 
but no associations with HLA DRB1*13 were found, similar to findings concerning 
SE-alleles. 
Together these data show that the presence of HLA-DRB1*13 may be associated 
with differences in the ACPA-profile, based on the lower ACPA-levels and dimi-
nished presence of anti- vimentin and anti-alpha-enolase-reactivities observed in 
both the EIRA and the EAC cohort.
Figure 1. HLA-DRB1*13 association with radiographic progression (A-C) and clinical remission (D-F) in 
total RA patients (A,D), ACPA-positive (B,E) and ACPA-negative RA patients (C,D).




























































































































RA patients, since the pro-
tective effect of the HLA 
DRB1*13 alleles is limited to 
ACPA-positive RA. This did 
not show any striking dif-
ferences between the two 
subgroups (Table 4). 
Concerning disease 
outcome we then assessed 
whether HLA-DRB1*13 is 
associated with radiographic 
progression or with DMARD-
free sustained remission in 
the EAC. Previously, it was 
shown that ACPA-positive 
RA patients have a more 
rapid radiographic pro-
gression over time and a 
decreased chance of achie-
ving sustained DMARD-free 
remission[13, 31]. In line 
with the decreased presence 
of ACPA in HLA DRB1*13-po-
sitive RA patients, we 
observed significantly less 
radiographic progression 
(p=0.04) and an increased 
risk for remission (p=0.007) 
in HLA-DRB1*13-positive RA 
patients when all RA patients 
were taken into account 
(Figure 1). To investigate 
whether this effect of HLA-
DRB1*13 was independent 
of the presence of ACPA, we 
stratified for ACPA-status. 
Both in ACPA-positive and 
Figure 2. HLA-DRB1*13 association with radiographic pro-
gression (A-D) and clinical remission (E-H) in ACPA-negative 
(C,D,G,H) and ACPA-positive RA patients. (A,B,E,F) in both 
SE-positive (B,D,F,H) and SE-negative (A,C,E,G) patients.
Influence of HLA-DRB1*13 on disease outcome
In order to complete our view of the role of the protective HLA DRB1*13 alleles 
in RA, we then analyzed the association of these alleles with clinical phenotype 
and disease outcome. To this end, we first compared the baseline characteristics 
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ACPA-negative RA patients, the presence of HLA-DRB1*13 was then no longer asso-
ciated with radiographic progression of with remission (Figure 1). 
To investigate whether the protective effect of HLA-DRB1*13 was dependent on 
presence/absence of HLA-DRB1 SE, we stratified ACPA-negative and ACPA-positive 
RA patients by SE and studied the effect of HLA-DRB1*13 on radiographic pro-
gression and remission (Figure 2). Again, the presence of HLA-DRB1*13 was not 
associated with radiographic progression or with remission, both in the SE-negative 
and the SE-positive stratum.
Together, these data suggest that neither risk (SE) nor protective (DRB1*13) 
HLA-DRB1 alleles influence disease outcome measures independent of ACPA-status. 
 
DISCUSSION
To enhance our understanding of HLA-mediated risk and protection in RA, it is 
essential to grasp at what point during disease evolution these alleles exert their 
effects. The contribution of the predisposing SE-alleles during different phases of 
disease has been extensively studied [16-23]. However, this is the first report that 
has studied the effect of protective HLA-DRB1*13 alleles during different phases of 
disease development and in RA. Based on our data - generated from two large popu-
lation-based cohorts comprising ACPA-positive RA as well as ACPA-positive non-RA 
individuals, and two large cohorts of ACPA-positive RA patients - we conclude that 
HLA-DRB1*13 alleles mainly influence the risk of developing ACPA-positive RA, 
rather than ACPA-positive autoimmunity (in the absence of clinical symptoms). 
Further, that HLA-DRB1*13 alleles have some modifying effects on ACPA concen-
trations and ACPA fine-specificities, but not on bone destruction or chance of 
DMARD-free sustained remission in response to treatment.
In the same twin cohort that was used in the present study, we recently des-
cribed the effect of SE-alleles on the development of ACPA-positive autoimmunity 
in non-RA individuals versus the development of ACPA-positive RA[17], and we 
could show that HLA-DRB1 SE-alleles were significantly associated with ACPA-po-
sitivity in non-RA individuals (OR=1.4), but that the HLA-DRB1 SE-association with 
ACPA-positive RA was significantly stronger (OR=7.2). Interestingly, this observation 
suggests that the most important effect of SE lies not in the evolution of anti-citrul-
line autoimmunity, but rather in determining the development of clinical symptoms 
and disease. In contrast, smoking was associated with both ACPA-positivity and 
ACPA-positive RA with equal strength (ORs approximately 1.3), indicating a more 
important role for smoking and possibly also other environmental factors in the 
initial development of ACPA. 
Our data now indicate that similar to the SE-alleles, HLA-DRB1*13 alleles also mainly 
influence the risk to develop arthritis rather than the risk of developing ACPA. 
These data support a previously postulated step-wise model for RA[17] (Figure 3) 





that proposes that genotype is relatively more important for arthritis development. 
The fact that HLA-DRB1*13 appears to mirror the effect of the SE-alleles could 
indicate that these alleles act in the same pathophysiological pathway. Previous 
observations that SE-positive subjects have a reduced risk of developing ACPA-po-
sitive RA if they carry HLA-DRB1*13 alleles further supports this possibility[3-5]. 
Unfortunately, little is known about the molecular mechanisms underlying the 
association between HLA-DRB1*13 and ACPA-positive RA. Clues might come from 
previous work that indicate that a mother carrying protective HLA-DRB1 alleles can 
transfer RA protection to her child that does not carry such protective alleles[36]. 
This observation could support a role for microchimeric cells travelling from the 
mother to the child possibly influencing thymic selection of T-cells. Alternatively, 
specific antigen-presenting characteristics of the HLA DRB1*13-molecule might be 
involved. 
In the present study, we specifically chose to examine the effects of the classical 
HLA DBR1*13 allele rather than look at specific amino acids within the HLA DR beta 
1-chain which have been described to explain most of the association between MHC 
en seropositive RA[37]. The reasons for focusing on the classical HLA DRB1*13-al-
lele were twofold. First of all, the protective effect of this allele for ACPA-positive 
RA has been well-described[4, 5], but it is unclear if this effect can be ascribed to 
certain amino acids, and if so, to which amino acids. Secondly, taking into account 
the biological and structural properties of HLA molecules, in which a large number of 
amino acids at various positions contribute to the peptide-binding groove, it seems 
wise to be cautious in inferring a causal role for a very limited number of amino 































acids. Our data support the idea that HLA-genotype plays that HLA-genotype plays 
only a modest role in established disease. Both the predisposing SE-alleles and the 
protective HLA-DRB1*13 alleles do not associate with disease outcome (e.g. clinical 
remission or radiographic progression) in ACPA-positive RA patients. These findings 
are in line with previous reports, which have also shown that the classical SE-al-
leles or distinctive predisposing amino acids (valine or leucine at HLA-DRB1 position 
11) are not associated with disease outcome independently of ACPA [23, 31, 38]. 
HLA-DRB1*13 did associate with ACPA characteristics in the sense that HLA-DR-
B1*13-positive ACPA-positive RA patients have significantly lower ACPA levels and 
are less often positive for antibody responses towards citrullinated vimentin and 
alpha-enolase.
Our study has several limitations, the most important of which is the limited power 
of the studies concerning ACPA characteristics and outcome measures (radiographic 
damage and outcome measures) in HLA DRB1*13-positive RA patients. Due to the 
strong protective effect of HLA DRB1*13 on ACPA-positive RA, there is only a very 
small number of HLA DRB1*13-carrying individuals that develops ACPA-positive RA. 
This is also illustrated by the fact that homozygosity for HLA DRB1*13 hardly ever 
occurs among ACPA-positive RA patients (n=0 in the EAC, 4 in the EIRA). This makes 
it difficult to study ACPA characteristics and disease outcome in relevant subgroups 
of patients with sufficient power. 
A further limitation is that only cross-sectional data from population-based cohorts 
(the TWINGENE sand the Nagahama study) are available to study risk factors for 
the presence of ACPA in non-RA individuals. Ideally, longitudinal data on the deve-
lopment and maturation of the autoantibody response in HLA DRB1*13-positive 
and –negative individuals would be used to reach more firm conclusions on the role 
of HLA DRB1*13 alleles during the different phases of disease development. The 
direction of the effect of HLA DRB1*13 alleles on the presence of ACPA in non-RA 
individuals differed in the TWINGENE (OR: 0.74) and Nagahama study (OR: 1.36), 
but was non-significant in both cohorts. This difference may indicate that the true 
effect might be associated with an odds ratio of approximately 1, which is in line 
with our conclusions that the HLA DRB1*13 alleles mainly affect the onset of RA in 
ACPA-positive individuals.
In conclusion, the protective HLA-DRB1*13 alleles can, like predisposing SE-al-
leles, influence ACPA characteristics, but (like SE) mainly have their effect in the 
timeframe between the development of ACPA and the onset of ACPA-positive 
disease. Previous studies have shown that ACPA can be detected more than 10 
years before disease onset[10], thereby generating a window of opportunity, where 
at-risk individuals can be serologically identified based on the presence of ACPA 
and risk (HLA-)genotype. The protective effect of HLA-DRB1*13 in this timeframe 
suggests that pathways exist which might be targeted in order to prevent the onset 
of ACPA-positive disease. Understanding the molecular basis for HLA-DRB1*13-me-
diated protection from developing ACPA-positive disease could therefore potentially 





offer new possibilities for autoantibody positive individuals at risk for RA. 
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SUPPLEMENTARY INFORMATION
TWINGENE ACPA- non-RA ACPA+ RA OR (CI) P-value
DRB1*13 Neg 7566 (72,4%) 87 (83,7%) REF
Pos 2888 (27,6%) 17 (16,3%) 0.51 (0.30-0.86) 0.01
Table S1. HLA-DRB1*13 association with ACPA-positive RA 
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CHAPTER 8
Crossreactivity to vinculin and microbes pro-
vides a molecular basis for HLA-based protection 
against rheumatoid arthritis. 
Jurgen van Heemst*, Diahann T.S.L. Jansen*, Savvas Polydorides, Antonis K. Mous-
takas, Marieke Bax, Anouk L. Feitsma, Diënne G. Bontrop-Elferink, Martine Baarse, 
Diane van der Woude, Gert-Jan Wolbink, Theo Rispens, Frits Koning, René R.P. de 
Vries, George K. Papadopoulos, Georgios Archontis, Tom W.J. Huizinga and René 
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ABSTRACT 
The HLA locus is the strongest risk factor for anti-citrullinated protein antibody 
(ACPA)+ rheumatoid arthritis (RA). Despite considerable efforts in the last 35 years, 
this association is poorly understood. 
Here we identify (citrullinated) vinculin, present in the joints of ACPA+ RA patients, 
as an autoantigen targeted by ACPA and CD4+ T cells. These T cells recognize an 
epitope with the core sequence DERAA, that is also found in many microbes and in 
protective HLA-DRB1*13 molecules, presented by predisposing HLA-DQ molecules. 
Moreover, these T cells crossreact with vinculin- and microbial-derived DERAA 
epitopes. Intriguingly, DERAA-directed T cells are not detected in HLA-DRB1*13+ 
donors, indicating that the DERAA epitope from HLA-DRB1*13 mediates (thymic) 
tolerance in these donors and explaining the protective effects associated with 
HLA-DRB1*13.
Together, our data indicate the involvement of pathogen-induced DERAA-directed 
T cells in the HLA–RA association and provide a molecular basis for the contribution 
of protective/predisposing HLA-alleles.






Rheumatoid Arthritis (RA) is a chronic autoimmune disease affecting synovial 
joints that can lead to severe disability. Pivotal pathophysiological insight has been 
obtained by the identification of Anti-Citrullinated Protein Antibodies (ACPA)[1,2]. 
These autoantibodies target proteins that have undergone a post-translational 
conversion of arginine to citrulline, catalyzed by peptidylarginine deiminases (PAD 
enzymes)[3]. ACPA are highly specific for RA, enriched in the joints of patients and 
can cross-react between citrullinated antigens that are expressed in the inflamed 
joints[4-8]. It is clear now that RA represents two main syndromes, ACPA-posi-
tive and ACPA-negative disease, each with distinct genetic and environmental risk 
factors and disease outcome[9-12]. Characteristics of ACPA (e.g. isotype usage and 
epitope spreading) indicate the involvement of CD4+ T cell help in shaping the ACPA 
response[13].
The most important genetic risk factor for ACPA+ RA is the HLA class II locus and 
risk is confined to a region with genes encoding for the beta chain of HLA-DR and 
the alpha and beta chain of HLA-DQ that are in tight linkage disequilibrium (LD) and 
inherit in haplotypes[14,15]. An understanding of the HLA class II association and 
the relative contribution of the HLA-DR and HLA-DQ locus has been lacking for the 
last 35 years.
Next to the association of the predisposing alleles to ACPA-positive disease, other 
HLA-molecules are associated with protection. These protective HLA alleles, mainly 
HLA-DRB1*13, carry the five amino acid sequence DERAA at positions 70-74 of the 
beta chain and protect also in the presence of predisposing alleles[16,17]. Intri-
guingly, protection by these alleles is transferred from mother to child, supporting 
an active protective role of these alleles, possibly via microchimeric cells influencing 
thymic selection of CD4+ T cells, and indicating a dominant role of HLA-DRB1*13 in 
disease protection[18].
HLA-derived peptides are a dominant peptide source presented by HLA class II 
molecules. We therefore proposed that the protective effect of HLA-DRB1*13 is 
explained by presentation of an HLA-DRB1*13 derived peptide in the context of 
other (predisposing) HLA class II molecules[19-21].
It was previously shown that degradation of HLA-DRB1*13 can result in the presen-
tation of a peptide with the core sequence DERAA by other HLA class II molecules 
to CD4+ T cells[22]. This could allow for the negative selection of such “DERAA 
directed” CD4+ thymocytes. Interestingly, the DERAA sequence is also found in many 
microbes and in the self-protein vinculin. Vinculin is expressed in the synovium, and 
was recently shown to be citrullinated in the synovial fluid of an RA patient[4,23]. 
Likewise, T cells directed to vinculin are found under certain infectious conditions, 
indicating that T cell tolerance to vinculin is not absolute[24,25]. Molecular mimicry 
of self-proteins with pathogenic proteins was proposed as an important mecha-
nism to break T cell tolerance[26,27]. Therefore, we postulate that upon priming 
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of DERAA directed T cells by microbes expressing DERAA-containing proteins, T 
cells crossreactive to vinculin would be able to provide help to B cells reactive to 
citrullinated vinculin. This would ultimately result in the production of ACPA. In 
HLA-DRB1*13-positive donors these T cells are conceivably deleted, leading to pro-
tection against ACPA-positive disease.
METHODS
Cells and sera
HLA-typed buffy coats from healthy volunteers were obtained from the blood bank 
(Sanquin, The Netherlands). PBMCs and sera from RA patients were derived from 
patients participating in the Leiden Early Arthritis Clinic cohort [28]. All RA patients 
fulfilled the American College of Rheumatology (formerly the American Rheuma-
tism Association) 1987 revised criteria for the classification of RA. A total of 178 
RA patients were used in the current analyses. Patient samples were compared to 
80 control samples from healthy individuals also living in the Leiden area. PBMCs 
were isolated using a standard Ficoll procedure. The protocols were approved by 
the Leiden University Medical Center ethics committee and informed consent was 
obtained.
Peptides
Peptides were synthesized according to standard Fmoc (N-(9-fluorenyl)methoxy-
carbonyl) chemistry using a SyroII peptide synthesizer (MultiSynTech, Witten, 
Germany). The integrity of the peptides was checked using reverse phase HPLC 
and MS. For vinculin ELISPOT experiments, HLA class II binding studies and T cell 
activation studies 15mer vinculin epitope VCL622-636 (VCL-DERAA; REEVFDERAAN-
FENH) was used. For ELISPOT assays against common pathogens, pathogenic 
peptides were used derived from measles virus (SSRASDERAAHLPTS), influenza A 
virus (VFEFSDERAANPIVP), human herpesvirus 7 (LAARADERAAFPDVG), Bordetella 
pertussis (SPNLTDERAAQAGVT), Staphylococcus aureus (QDMNDDERAALTMAM), 
Haemophilus influenzae (RFHGDDERAAKVYEN), Salmonella enteritidis (PLM-
MDDERAAKVYEN) and Propionibacterium acnes (EEVFTDERAARLSHV). For the 
generation of T cell lines these 8 pathogenic peptides were pooled.
Cell lines
The following EBV-transformed lymphoblastoid B cell lines were used: BSM 
(DRB1*04:01;DQA1*03:01;DQB1*03:02), BOLETH (DRB1*04:01;DQA1*03:01; 
DQB1*03:02), BM21 (DQA1*05:01;DQB1*03:01), JSM (DQA1*03:02;DQB1*03:01), 
APD (DRB1*13:01;DQA1*01:03;DQB1*06:03), BC34 (DRB1*13:02;D-
QA1*01:02;DQB1 *06:04), WT8 (DQA1*01:02;DQB1*06:02), KAS116 





(DRB1*01:01;DQA1*01:02; DQB1*05:01) and 721.82 (DR/DQ-negative). Cells were 
maintained in IMDM (Lonza) supplemented with 10% heat-inactivated FCS.
HLA class II competitive peptide binding assay
Peptide-binding assays were performed, as described previously [29]. In short, cell 
lysates from HLA- class II homozygous B-lymphoblastoid cell lines were incubated 
on SPV-L3- (anti-HLA-DQ) or B8.11.2- (anti-HLA-DR) coated (10 μg/ml) FluoroNunc 
96-well plates at 40C overnight. Titration ranges of the tested peptides (0 to 300 
μM) were mixed with a fixed concentration (0.6 μM) of biotinylated indicator 
peptide and added to the wells. Bound indicator peptide was detected using euro-
pium-streptavidin (Perkin Elmer, Boston, MA) and measured in a time-resolved 
fluorometer (PerkinElmer, Wallac Victor2). IC50 values were calculated based upon 
the observed binding of the test peptide against the fixed concentration indicator 
peptide. The IC50 value depicts the concentration of test peptide required for a loss 
of 50% of the indicator peptide signal.
Enzyme-linked immunosorbent spot assay
PBMCs were incubated in 96-well Multiscreen HA plates (Millipore) precoated with 
5 μg/ml anti-IFN-γ capture antibody (clone 1-D1K; Mabtech) at 5x105 cells/well and 
stimulated in X-VIVO medium (LONZA) with 5 μg/ml peptide or with a mix of recall 
antigens consisting of 0.75 Lf/ml tetanus toxoid (Netherlands Vaccine Institute), 0.5 
μg/mL tuberculin purified protein derivative (Netherlands Vaccine Institute) and 
0.005% Candida albicans (HAL allergy). After 24h incubation at 37ºC, plates were 
extensively washed and incubated with 0.3 μg/ml biotin labeled anti-IFN-γ detection 
antibody (clone 7-B6-1; Mabtech) for 2h at RT, with 1000x diluted ExtrAvidin-Alka-
line phosphatase (Sigma-Aldrich) for 1h at RT and with 5-Bromo-4-chloro-3-indolyl 
phosphate/Nitro blue tetrazolium (Sigma-Aldrich). Spots were analyzed using the 
BioSys Bioreader 3000pro. Circular spots with a size of 80-450μm were included.
Flow cytometry
Polyclonal CD4+ T cell lines were generated by stimulating 3 x 106 PBMCs/well in 
a 24-well plate with 5 μg/ml peptide for 7 days in IMDM supplemented with 5% 
human serum (Sanguin). After 7 days 1.5 x 106 autologous PBMCs per well were 
plated in 24-well plates for 2h. After 2h non-adherent cells were removed and 
adherent cells were pulsed with 5 μg/ml peptide and used as feeders for 106 T cells. 
After 1h, 10 μg/ml brefeldin A was added. Cells were incubated overnight and used 
for intracellular cytokine staining. The cells were incubated with fluorochrome-con-
jugated antibodies recognizing CD4, (Clone RPA-T4; BD biosciences), CD14 (Clone 
61D3; eBioscience) and CD25 (Clone M-A251; BD biosciences), after which they 
were permeabilized using CytoFix CytoPerm Kit (BD Biosciences). After washing, 
cells were incubated with PE-labeled anti-IFN-γ or matching isotype control. Cells 
Chapter 8124
were taken up in 1% paraformaldehyde until flow cytometric acquisition. Flow cyto-
metry was performed on FACS Calibur (BD biosciences) or LSR II (BD biosciences). 
Analysis was performed using FACS Diva (BD biosciences) and FlowJo software.
T cell cloning
JPT57 was generated from an HLA-DRB1*04:05/01:01;DQ8/DQ5 donor. PBMCs 
were cultured for 7 days in the presence of 10 μg/ml of VCL-DERAA peptide and 
restimulated with VCL-DERAA-pulsed antigen-presenting cells. After 1 week, cells 
were restimulated with 150 U/ml rIL-2. After two rounds of restimulation, T cell 
lines were tested for their specificity. The wells responding to VCL-DERAA peptide 
were cloned in a limiting dilution of 0.3 cells/well resulting in the isolation of clone 
JPT57.
D2C18 was generated from an HLA-DRB1*04:01;DQ2/DQ8 positive donor. CD4+ T 
cells and CD14+ monocytes were isolated from PBMCs using antibodies bound to 
magnetic beads from respectively Dynal and Miltenyi. CD4+ T cells were labeled 
with 1μM CFSE (Invitrogen) and incubated in a 2:1 ratio with CD14+ monocytes 
with 30 μg/ml PathMix. After 6 days, CD3posCD4posCD25posCD14negDAPInegCFSElow cells 
were sorted by FACS aria (BD). Isolated CD4+ T cells were rested in medium contai-
ning 20 IU/ml rIL-2 (Peprotech). After 3 days, cells were cloned in a limiting dilution 
of 0.3 cells/well resulting in the isolation of CD4+ T cell clone D2C18.
T cell activation 
To determine IFN-γ production by T cell clones in response to peptide stimulation, 
50.000 T cells were incubated in a 1:1 ratio with B-LCL lines pulsed with 10 μg/
ml of peptide for 3-6h. After 3 days, supernatant was collected and an IFN-γ ELISA 
(eBioscience) was used to determine the concentration of IFN-γ. For measurement 
of T cell proliferation, 50.000 T cells were incubated in a 1:1 ratio with radiated 
(3000RAD) autologous PBMCs pulsed with 10 μg/ml of peptide for 3-6h in IMDM 
supplemented with 5% human serum. After 3 days, cells were cultured for 16–20h 
with [3H]thymidine (0.5 μCi/well). 3H incorporation was measured by liquid scintil-
lation counting (1450 MicroBeta TriLux; PerkinElmer). Blocking experiments were 
performed by preincubating APCs for 1h with anti-DQ (SPVL3), anti-DR (B8.11.2) 
and anti-DP (B7.21) blocking antibodies.
Detection of anti-citrullinated vinculin antibodies
Citrullinated vinculin was generated by incubation of 50 μg vinculin protein 
(Sanbio) in a volume of 200 μl containing 0.1 M Tris-HCl pH 7.6, 0.15 M CaCl2, and 
10 U PAD4 (Sigma) for 4 h at 37 °C. Unmodified vinculin-protein was generated 
by incubation of vinculin with PAD4 without CaCl2. Citrullinated and unmodified 
vinculin were loaded onto 10% SDS-polyacrylamide gels and transferred onto 
blotting membranes. Blots were blocked, washed and incubated in 1:500 diluted 





serum overnight at 4°C. The sera were either ACPA-positive or ACPA-negative as 
determined by ELISA. Blots were incubated with HRP-labeled rabbit anti-human 
IgG (Dako) and visualized with chemiluminescence (ECL, Amersham). To analyze 
reactivity to vinculin by a monoclonal ACPA (anti-cFIB1.1, citrullinated fibrinogen), 
vinculin- or citrullinated vinculin-coated Nunc plates were incubated with 5 μg/ml 
anti-cFIB1.1 for 2h at room temperature [30]. Bound antibody was detected using 
HRP-labeled rabbit anti-human IgG (Dako) and visualized with ABTS. Peptide-ELISA 
was performed as described previously using biotinylated peptides coated on strep-
tavidin precoated plates [31].
B cell activation by JPT57 cells
B cells were isolated from PBMCs of HLA-DQ8 positive healthy donors or ACPA 
positive RA patients by magnetic anti-CD19 beads (Invitrogen). B cells were cultured 
in IMDM supplemented with 10% FCS, penicillin, streptomycin and glutamax. From 
healthy subjects, 30,000 B cells were co-cultured with different number of JPT57 
cells in the presence of 5μg/ml anti-IgM (JacksonImmunoresearch Laboratories) 
and with 10 μg/ml VCL-DERAA or 1 μg/ml PHA in round-bottom 96-well plates. 
After 7 days, IgG production by B cells was determined using a total IgG ELISA 
(Bethyl laboratories). From RA patients, 20,000 B cells were pulsed with 10 μg/ml 
VCL-DERAA peptide and co-cultured with 20,000 JPT57 cells in the presence of 5 
μg/ml anti-IgM in round-bottom 96-well plates. After 7 days, ACPA production was 
determined by ELISA measuring reactivity against the CCP2-peptide in individual 
wells (EuroDiagnostica).
Energy minimization
Molecular simulations of HLA-DQ8(A1*0301/B1*302) and –DQ7.3 (A1*0302/
B1*0301) complexed with various peptides, experimentally shown to bind to these 
molecules, were carried out as previously described using the Discover Suite (pro-
grammes InsightII and Discover) of Accelrys (San Diego, CA, release of 2005) on a 
Silicon Graphics Fuel instrument, using a minimization approach previously des-
cribed [32], i.e. one thousand steps of the steepest gradient method, followed by 
one thousand steps of the conjugate gradient method. Records of the energy of 
every step showed a continuous decrease in energy without any local minima and 
an energy asymptote for the last 300-400 steps of the conjugate gradient method. 
The base molecule was the crystal structure of HLA-DQ8 (A1*0301/B1*0302) with 
bound the insulin B11–23 peptide [33]. The region HLA-DQβ105-112 for which full 
coordinates were not available in the original data, was constructed by molecular 
replacement of the respective region from HLA-DR1 [34], after superposition of 
the β-plated sheet regions of the two molecules in the α1β1 domains. The binding 
registers of the vinculin and the bound microbial peptides were decided from the 
binding of truncated peptides as well as Arg-substituted peptides in presumed 
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anchor positions; energy minimization of successive registers confirmed the regis-
ters predicted from the binding data. The rotamers for the peptide residues were 
chosen from a library of rotamers provided by the software data base, in order 
to have no molecular clashes with the residues of HLA-DQ8. Minimizations were 
carried out either at pH 5.4 (endosomal pH) or 7.4 (extracellular). There are no simi-
larly charged residues (e.g. Glu-Glu) with their charged groups so close to each other 
as to require that one of the residues be uncharged. Occasionally runs were per-
formed on a Silicon Graphics Octane instrument with previous releases of the same 
software with very similar results. Figures are drawn using the WebLabViewer v.3.5 
and DSViewerPro software of Accelrys, the latter currently freely available on the 
































































Figure 1. Citrullinated vinculin is a novel autoantigen targeted by ACPA. (a) Western blot of native and 
citrullinated vinculin protein, stained with serum of an ACPA-positive or an ACPA-negative RA patient. 
(b) ELISA of vinculin or citrullinated vinculin protein coated plates stained with ACPA monoclonal 
antibody anti-citFib1.1. Two-sided statistical analysis was performed using a student’s t-test with ** 
indicating P < 0.001. (c) ELISA of citrullinated vinculin peptides VCL-CIT285277-293, VCL-CIT622614-651, 
VCL-CIT823815-831 in serum of anti-CCP2 positive (n=140) versus anti-CCP2 negative (n=38) RA patients. 
Plot depicts the percentage of patient sera positive for one or more citrullinated vinculin peptides. 
(d) Heatmap depicting all patients positive for one or more citrullinated vinculin epitopes and their 
serum reactivity towards different citrullinated epitopes derived from vimentin, fibrinogen and alp-
ha-enolase. Red = positive, green = negative, black is undetermined.





level of the peptide backbone and parallel to the HLA-DQ β-sheet floor is visualized 
with atomic charges coloured accordingly (red, acidic; blue basic, and with appro-
priate scales of grey for cases in between). In the supplementary figures, the α1β1 
domains of the modelled HLA-DQ molecules in complex with given bound peptides 
are depicted in van der Waals surface representation, with color and depiction con-
ventions identical to those for the other figures. Several visible residues from the 
HLA-DQ molecule in contact with the antigenic peptide and potential contact with 
a cognate TCR in canonical orientation are shown in stick form with a transparent 
surface (atomic color code: oxygen, red; nitrogen, blue; hydrogen, white; carbon, 
geen; sulfur, yellow). The antigenic peptide in the groove is shown in space-filling 
form.
Molecular Dynamics Simulations
The simulated system included the entire DQ8 molecule and the 13-residue peptide 
with the vinculin sequence Glu-Glu-Val-Phe-Asp-Glu-Arg-Ala-Ala-Asn-Phe-Glu-Asn, 
placed in a periodically replicated octahedral water box. The simulations were con-
ducted with the molecular mechanics program CHARMM, version c37b2 [35]. The 
initial coordinates of all protein heavy atoms and the peptide mainchain heavy 
atoms were taken from the crystallographic structure of the DQ8:insulin complex 
(PDB entry 1JK8) [33]. The peptide side chain initial conformations were optimized 
with the program PROTEUS [36]. An additional control simulation studied the 
DQ8:insulin complex; the initial coordinates of the protein and peptide were taken 
from the corresponding crystal structure (PDB entry 1JK8) [33].
Protein atomic parameters were taken from the CHARMM36 all-atom force field 
[37, 38]. The interaction energies of selected peptide – protein residue pairs were 
computed by post-processing the MD trajectories in the GBSA approximation, as in 
[39] with the GBSW Generalized Born model [40, 41].
RESULTS
Citrullinated vinculin is a novel target for ACPA
We speculate that the protective effects of HLA-DRB1*13 on the development of 
ACPA-positive RA are related to a T cell response reactive to a sequence that is 
commonly present in the HLA-DRB1*13 molecule, micro-organisms and self-pro-
teins that are targeted by ACPA. Indeed, a 5-amino-acid long HLA-DRB1*13-derived 
sequence (DERAA) is present in many micro-organisms and a few self-proteins. Of 
these self-proteins, the citrullinated protein vinculin attracted our attention. There-
fore, we first analyzed whether citrullinated vinculin is recognized by ACPA. To this 
end, we citrullinated vinculin in vitro with PAD enzymes and tested both native and 
citrullinated vinculin for recognition with serum of an ACPA-positive RA-patient. We 
observed citrulline-specific recognition of vinculin by serum of an ACPA-positive RA 
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patient, but not with an ACPA-negative patient (Figure 1A). We further confirmed 
that citrullinated vinculin is a target of ACPA using an ACPA monoclonal antibody 
(Figure 1B) [30].
Recently, several reports showed the presence of citrullinated vinculin in the 
synovial fluid of ACPA+ RA patients. In addition, three sites of in vivo citrullina-
tion on this protein were identified: Arg285, Arg622 and Arg823 [4,23]. When we 
studied antibody responses to these citrullination sites, we could show recognition 
by 34% of tested sera from ACPA+ RA patients versus 5% of sera from ACPA- patients 
(Figure 1C). Sera of ACPA+ RA patients are highly (cross-)reactive towards multiple 
citrullinated antigens. Indeed, when we quantified responses to citrullinated alp-
ha-enolase, fibrinogen, vimentin, and myelin basic protein in patient sera that react 
to citrullinated vinculin peptides, we could readily demonstrate additional reactivi-
ties indicating that ACPA are not exclusively directed against citrullinated vinculin 
as expected (Figure 1D). Together, these data show that citrullinated vinculin is a 
self-protein recognized by RA autoantibodies in a citrulline-dependent fashion.
Vinculin is an autoantigen recognized by T cells from HLA-DRB1*13-negative 
donors
We next wished to determine whether the DERAA-sequence from vinculin is 
recognized by human CD4+ T cells. To this end, PBMCs were stimulated with a 
15-mer vinculin–peptide (VCL622-636, REEVFDERAANFENH) (VCL-DERAA) for 24h. 
We observed a clear reactivity towards this epitope as determined in an IFN-γ-






























































































a. Figure 2. Citrullinated vinculin is a 
novel autoantigen targeted by CD4+ 
T cells in HLA-DRB1*13 negative 
donors. (a) IFN-γ ELISPOT of PBMCs 
from healthy individuals stimulated 
for 24h with VCL-DERAA peptide 
REEVFDERAANFENH or with a mix of 
recall antigens (tetanus, tuberculin, 
candida). Donors were stratified 
based on HLA-DRB1*13:01 status. 
(b) IFN-γ ELISPOT of PBMCs of HLA-
DRB1*13:01 carriers, HLA-DRB1*04 
carriers and HLA-DRB1*13:01/
DRB1*04 donors, stimulated for 24h 
with VCL-DERAA peptide or with 
a mix of recall antigens. Each dot 
represents a unique donor. Two-
sided statistical analyses of ELISPOT 
data were performed using a Mann-
Whitney U test with * indicating P < 
0.05.





associated with protection against ACPA-positive RA [17]. We hypothesize that 
HLA-DRB1*13 protects against ACPA-positive disease by affecting the generation of 
DERAA directed T cells. Therefore, we stratified donors for HLA-DRB1*13:01 status. 
We observed a striking difference in IFN-γ producing cells depending on HLA-DR-
B1*13:01-status. The lack of reactivity in HLA-DRB1*13:01-positive donors was 
not due to a hampered ability of such donors to respond to T cell antigens as we 
observed strong response to microbial antigens in both HLA-DRB1*13:01 carriers 
and non-carriers when stimulated with recall antigens (Figure 2A). We further 
confirmed this finding in PBMCs stimulated for 4 days (Figure S2). The differential 
ability of HLA-DRB1*13:01-positive donors to respond to VCL-DERAA is most likely 
not due to a general deficiency to present the VCL-DERAA-epitope as these donors 
were heterozygous and thus expressed other HLA-molecules that could potenti-
ally present VCL-DERAA. Nonetheless, to further confirm that HLA-DRB1*13:01 
affects the ability to generate VCL-DERAA directed T cell responses, we repeated 
the experiments in a set-up stratified for HLA using PBMCs from HLA-DRB1*04-, 
HLA-DRB1*13:01- and HLA-DRB1*04/*13:01 heterozygous donors. A significant 
reduction in IFN-γ producing cells was observed in both HLA-DRB1*13:01 carriers 
and DRB1*04/*13:01 heterozygous donors as compared to HLA-DRB1*04 carriers. 
Again, no difference was observed for recall antigens (Figure 2B). These data indicate 
that the lack of detecting VCL-DERAA directed T cells is not explained by the ina-
bility of HLA-DRB1*13 molecules to present VCL-DERAA, but rather the result of a 
dominant effect associated with the presence of HLA-DRB1*13.
Thus, vinculin is an autoantigen recognized by circulating VCL-DERAA directed CD4+ 
T cells. In HLA-DRB1*13:01 carriers these T cells are absent. This effect, like the pro-
tective effects of HLA-DRB1*13:01 on the development of ACPA-positive RA, was 
present in a dominant fashion, consistent with the notion that HLA-DRB1*13 affects 
the generation of DERAA directed T cells, possibly during thymic selection.
Presentation of the Vinculin-DERAA epitope is restricted to RA predisposing 
HLA-DQ molecules
HLA-DRB1 alleles predisposing to ACPA-positive RA in the Caucasian population are 
collectively called HLA shared epitope (SE) alleles [14,15,42]. The most common 
HLA-SE alleles are HLA-DRB1*04:01 and HLA-DRB1*01:01. Using HLA-DR binding 
assays, we examined the ability of VCL-DERAA to bind to these HLA-molecules, but 
we could not detect any binding of VCL-DERAA to these alleles (Figure 3A, Figure 
S 3A-B). The HLA class II region is known for its strong LD. Genes that encode for 
the HLA-DR-beta chains are inherited in haplotypes with genes that encode for the 
alpha and beta chain of HLA-DQ. The predisposing HLA-SE alleles are in tight LD 
with HLA-DQ5 (DQA1*01;DQB1*05:01), HLA-DQ7.3 (DQA1*03:02;DQB1*03:01) 
and HLA-DQ8 (DQA1*03:01;DQB1*03:02) (Figure 3B-C). In Figure 3C the distribu-
tion of HLA-DQ molecules in SE+ healthy donors is depicted, showing that these 
donors are HLA-DQ5, HLA-DQ7.3 or HLA-DQ8 positive. We therefore next studied 
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the binding of VCL-DERAA to these HLA-DQ alleles and observed binding of the 
VCL-DERAA-peptide to HLA-DQ5, DQ7.3 and DQ8 (Figure 3A, Figure S3C-E). These 
data indicate that VCL-DERAA can be presented by HLA-DQ molecules in LD with 
predisposing HLA-SE alleles.
To obtain an indication whether the VCL-DERAA can be presented by more HLA 
molecules, we also studied the ability of additional HLA-DR and HLA-DQ molecules 
encoded by HLA-haplotypes that protect or have no influence on the development 
of ACPA-positive RA. We could not detect binding of VCL-DERAA to these HLA class 
II alleles (Figure 3A, Figure S3F-K). Likewise, using an IFN-gamma ELISPOT, VCL-
DERAA directed T cells were absent in donors negative for predisposing HLA-DQ 
molecules (data not shown).
These data indicate that HLA-DQ-molecules that predispose to ACPA-positive 
disease present the VCL-DERAA-peptide, whereas the analyzed HLA-DQ and HLA-DR 
molecules not associated with disease do not present VCL-DERAA.
HLA-DQ restricted recognition of VCL-DERAA by T cells
To further confirm the presence of VCL-DERAA directed T cells and their HLA-res-
triction, we isolated CD4+ T cell clone JPT57, that was specific for VCL-DERAA. As 



























































HLA-SE+ ACPA+ RA pts
Figure 3. Presentation to vin-
culin-DERAA directed T cells is 
restricted to RA predisposing 
HLA-DQ molecules. (a) Affinity of 
VCL-DERAA for associated HLA 
class II molecules. Affinity was 
determined by a competitive 
binding assay using a high affinity 
biotinylated peptides. Results are 
depicted as IC50 value, the con-
centration of test-peptide (μM) 
where 50% of biotinylated peptide 
is bound. Experiments were per-
formed at least three times and 
the average IC50 value between 
the different experiments is shown. 
(b) Schematic representation of 
the linkage disequilibrium between 
the HLA-DRB1, HLA-DQA1 and 
HLA-DQB1 gene in studied haplo-
types associated or not associated 
with susceptibility to ACPA+ RA. 
(c) Distribution of HLA-DQ mole-
cules in ACPA+ RA patients positive 
for HLA-DR shared epitope alleles 
(n=31).





IFN-γ when stimulated with the VCL-DERAA-peptide.
When cultured with B cells from ACPA-positive RA patients pulsed with the VCL-
DERAA epitope, the clone not only upregulated CD40L, but also enhanced the 
production of ACPA in culture, indicating that such T cells have a phenotype compa-
tible with the ability to provide “help” to ACPA producing B cells (Figure S5).
To further confirm that HLA-DQ-molecules present the VCL-DERAA-peptide, we sti-
mulated the clone with VCL-DERAA pulsed HLA-typed APCs pre-incubated with HLA 
class II blocking antibodies (Figure S6). In concordance with the binding studies, 
anti-HLA-DQ antibodies abrogated T cell recognition. Interestingly, we observed 
that JPT57 can recognize VCL-DERAA, presented by both HLA-DQ7.3 and HLA-DQ8 
suggesting that this this epitope is presented in a similar binding register by these 
HLA-molecules (Figure S7).
Together, HLA-class II presentation and T cell recognition of VCL-DERAA was res-
tricted to HLA-DQ molecules that are associated with RA susceptibility.
Identification of microbe-specific T cells targeting DERAA epitopes
We next investigated the presence of the DERAA sequence in micro-organisms. A 
Blast search showed that DERAA is found in 66% of bacteria and 12% of viruses 
(Figure 4A). This large number represents a major challenge to identify potential 
“cross-reactive micro-organisms”. To select for relevant micro-organisms, we res-
tricted the search to those micro-organisms that can cause disease or symptoms 
in humans and are present in the western world. This approach left us with 219 
candidate sequences. We then synthesized 8 DERAA-containing peptides from 
common recall microbes including several bacteria (P. acnes, S enteritidis, B. per-
tussis, S. aureus) and viruses (measles virus, influenza A and human herpesvirus 7). 
Interestingly, all of these peptides were presented by HLA-DQ7.3 and DQ8 mole-
cules showing that these HLA molecules can efficiently accommodate both the 
VCL-DERAA epitope as well as microbe-derived DERAA epitopes (Figure 4B).
To determine whether these microbial-derived epitopes are recognized by human 
T cells, we generated T cell lines by stimulating PBMCs from 3 healthy HLA-DQ8 
positive donors for 7 days with a pool of the 8 pathogen-derived peptides (PathMix). 
Next, we determined the presence of PathMix specific CD4+ IFN-γ producing T 
cells. As shown in Figure 4C, such T cells were readily detectable. Using limiting 
dilutions, we isolated T cell clone D2C18, further confirming the presence of “micro-
bial-DERAA-directed” T cells (Figure S8). Next, we also analyzed the presence of 
“microbial-DERAA directed” T cells by ELISPOT directly ex vivo, allowing the analyses 
of more donors at higher throughput. Interestingly, PBMCs from HLA-DRB1*13:01 
carriers displayed a significantly reduced reaction against these peptides, indicating 
that the presence of HLA-DRB1*13 also affects the formation of T cell responses 
against DERAA-epitopes from microbes (Figure 4D).
Together, these data indicate that HLA-DQ alleles associated with ACPA-positive 
RA efficiently present both VCL-DERAA and microbe-derived DERAA epitopes and 
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that microbe-specific T cells directed to DERAA epitopes are readily detected. The 













































































































































































Figure 4. Identification of pathogen-specific T cells targeting DERAA epitopes in HLA-DRB1*13 negative 
donors. (a) Frequency of bacteria or viruses positive for a DERAA containing protein as identified using 
the NCBI BLAST. List of all bacteria or viruses in blast database was and for three random sets of 50 
bacteria/viruses a blast search for DERAA was performed. Error bars indicate the standard deviation 
between the three analyzed sets. (b) Competitive binding of pathogen-derived DERAA epitopes to 
HLA-DQ7.3 or HLA-DQ8. Binding experiments were performed at least three times and plots show 
pooled experiments, the error bars show the variation between the different experiments. (c) Flow 
cytometry staining of PathMix-directed T cell lines restimulated with PathMix pulsed or unpulsed 
APCs. Plots are gated on CD14neg/CD4pos/CD25pos T cells. (d) ELISPOT of PBMCs of healthy indivi-
duals of HLA-DRB1*13:01 donors (n=5) and HLA-DQ7.3/DQ8 donors (n=8) stimulated for 24 h with 
DERAA containing peptides and recall antigens. Error bars indicate the variation between different 
donors.





Molecular modelling of HLA-DQ:VCL-DERAA complexes allows for predicting 
cross-eactive microbes
The data presented above demonstrate the presence of microbial- and VCL-DERAA 
directed T cells, but do not show if a single TCR can react with both epitopes. 
To facilitate the search for possible “crossreactive” DERAA-epitopes out of all 
microbe-derived DERAA-sequences, we first determined the binding register of 
VCL-DERAA using HLA class II binding assays with N- and C-terminally truncated 
and amino-acid substituted VCL-DERAA peptides as detailed in Figure S9-13. 
Together these experiments support VFDERAANF (anchors in bold) as the core 
binding register for both HLA-DQ7.3 and HLA-DQ8. All-atom molecular dynamics 
(MD) simulations showed that residues Val625 (P1), Glu628 (P4) and Phe633 (P9) 
make numberous intermolecular polar and non-polar interactions in the respec-
tive pockets. In Figure 5A-F we highlight key intermolecular interactions between 
the VCL-DERAA epitope and the HLA-DQ8 molecule. A detailed discussion of the 
MD results and a quantitative assessment of the intermolecular interactions can be 
found in the supplementary data (Figure S14-15 and Table S1). The MD simulations 
also indicated that the long protruding side-chains of Glu623 (P-2) Glu624 (P-1), 
Phe626 (P2), Asp627 (P3), Arg629 (P5), Asn632 (P8), Glu634 (P10) and Asn635 (P11) 
are exposed to solved and could potentially interact with crossreactive TCRs (Figure 
5G). Subsequently we also further confirmed the obtained model using a second 
type of molecular modelling: energy minimization, that further confirmed possible 
TCR contact residues (Figure S16-17).
To functionally confirm whether a TCR would indeed interact with (some of the) 
potential TCR contact residues within the VCL-DERAA-peptide, we next deter-
mined how the epitope is recognized by the VCL-DERAA-directed T cell clone JPT57. 
Phe626 (P2) interacts with the JPT57 TCR as its removal results in a large decrease 
in recognition without affecting HLA-DQ8 binding. (Figure 5H, Figure S11). C-ter-
minal truncations resulted in a large decrease in T cell recognition after removal of 
Glu634 (P10), showing that this residue is also important for JPT57 TCR interaction 
(Figure 5I). Thus, the data obtained using the VCL-DERAA directed T cell clone as 
a functional read-out, are in line with the HLA binding and molecular modeling 
studies indicating the sequence VFDERAANFE (anchors in bold) as the minimal 
epitope required for activation of JPT57. Next, we performed alanine substitutions 
within the minimal epitope to remove critical TCR interacting residues. Substitu-
ting Asn632 (P8) and Phe633 (P9) dramatically impacted T cell recognition, without 
affecting the binding affinity of VCL-DERAA (Figure 5J-K).
Together, these data indicate VFDERAANF (anchors in bold) as the most likely core 
binding register for HLA-DQ7.3 and HLA-DQ8 and Asn632 and Phe633 as important 
residues for JPT57-TCR recognition.
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water molecules as small spheres. Hydrogens are omitted, with the exception of the extra hydrogen 
in protonated αGlu31. (g) TCR view of the DQ8:VCL-DERAA complex.The peptide mainchain is shown 
in licorice; Domains α and β are shown in a surface representation, colored, respectively, in blue and 
red.Sidechains P-2E, P-1E, P2F, P3D, P5R, P8N, P10E and P11N are facing toward the TCR binding site. 
The P2F and αPhe58 sidechainsand the nonpolar moiety of P5Rform a nonpolar cluster, that faces 
toward the TCR binding site; the average P2F ring - αPhe58 ring distance is ~ 8 Å. (h-j) IFN- ELISA on 
supernatant of T cell clone JPT57 stimulated with unpulsed HLA-DQ8 positive APCs and N-truncated 
(h), C-truncated (i) or alanine-substituted (j) VCL-DERAA peptides. (k) Competitive binding of the VCL-
DERAA peptide, and alanine substituted VCL-DERAA peptides to HLA-DQ8. Binding experiments were 
performed at least three times and plots show pooled experiments, the error bars show the varia-
tion between the different experiments. Experiments involving JPT57 were performed three times 
and show a representative experiment. Two-sided statistical analysis was performed using a student’s 




































































































































































Figure 5 Molecular modeling of HLA:VCL-
DERAA complexes identifies critical TCR 
contact residues. (a-c) Non-polar contacts 
between the VCL-DERAA peptide and 
HLA-DQ8 in pockets P1 (a), P4 (b) and 
P9 (c). Protein residues are depicted in a 
surface representation, in distinct colors. 
(d-f) Hydrogen bonds between the VCL-
DERAA peptide and HLA-DQ8 in pockets 
P1 (d), P4 (e) and P9 (f). Peptide and 
protein groups are shown, respectively, in 
thick and thin licorice representation, and 





TCR crossreactivity between vinculin and bacterial antigens
Identifying microbes that crossreact with vinculin was challenging due to the large 
number of potential candidates. Therefore, we used the data presented above to 
determine if a single TCR can crossreact both to DERAA-sequences from microbes 
and the self-protein vinculin. As we identified the Asn632 and Phe633 at P8 and 
P9 respectively, as important for JPT57-TCR interactions, we used the molecular 
modeling to predict which viral and bacterial epitopes are likely to bind to HLA-DQ8 
and harbor P8Asn or P9Phe and are thus likely to crossreact with JPT57. From the 
15 peptides identified (Table S2), three were able to activate JPT57 in a T cell sti-
mulation assay at concentrations similar to those used for the vinculin-peptide. 
These epitopes were derived from Campylobacter coli, Lactobacillus curvatus and 
Lactobacillus sakei and cross-reacted with JPT57 in an HLA-DQ dependent manner 
Figure 6 TCR crossreactivity of vinculin and bacterial DERAA epitopes. (a) IFN-γ ELISA on supernatant 
of T cell clone JPT57 stimulated with HLA-DQ8 positive B-LCLs and alanine-substituted VCL-DERAA 
peptides. This experiment was performed three times, the plot shows a representative experiment. 
Two-sided statistical analysis was performed using a student’s t-test with * indicating P < 0.05 and ** 
indicating P < 0.001. (b-c) Competitive binding of HLA-DQ7.3 (b) and HLA-DQ8 (c) to a non-binding 
negative control peptide, an unbiotinylated positive control peptide and epitopes from Lactobacillus 
curvatus, Lactobacillus sakei and Campylobacter coli. Binding experiments were performed three 
times. The error bars show the variation between the different experiments. (d-g) Side views of 
HLA-DQ8 complexed with the vinculin-DERAA peptide (d) and peptides derived from Lactobacillus 
curvatus (e), Lactobacillus sakei (f) and Campylobacter coli (g) in space-filling mode at pH 7.4 (extracel-
lular), obtained by energy minimization as described in the methods section. The peptide is shown in 
atomic color code: oxygen, red; nitrogen, blue; hydrogen, white; carbon, green; sulfur, yellow.


















































































































































































(Figure 6A). Peptide-binding studies revealed that these three peptides bind with 
an intermediate binding affinity to HLA-DQ7 and HLA-DQ8 (Figure 6B-C).Molecular 
models of these bacterial peptides in HLA-DQ8 illustrate the similarities with VCL-
DERAA (Figure 6D-G, Figure S18-20).
Thus, these data show that the RA susceptibility alleles HLA-DQ7 and HLA-DQ8 can 
present both VCL-DERAA and related microbe-derived epitopes to T cells and that 
such T cells can be cross-reactive to vinculin and bacterial epitopes, thereby provi-
ding an explanation for the presence of activated self-reactive CD4+ T cells directed 
to vinculin in peripheral blood.
DISCUSSION
The strong connection between the HLA locus and RA has been known for more 
than 35 years. The complex HLA class II associations and the diverse ACPA res-
ponses in RA patients suggest the presence of multiple etiological pathways. To 
unravel these pathways, identifying the relevant autoantigens is crucial. We here 
present evidence favouring the involvement of vinculin in the emergence of 
ACPA-positive disease. This cytoskeletal protein was recently found to be citrulli-
nated in vivo in the synovial fluid. We now show that it is recognized by ACPA as 
well, thereby adding it to a still selective list of targets. Moreover, we identified an 
epitope from vinculin recognized by CD4+ T cells restricted to HLA-DQ molecules 
predisposing to ACPA-positive RA. The core amino acid sequence (DERAA) is also 
present in many pathogens and in HLA-DRB1*13, a molecule encoded by an HLA-
locus associated with protection against ACPA-positive RA. We have also shown 
that a single TCR can recognize both a vinculin DERAA-epitope as well as DERAA-
epitopes from microbes, indicating the crossreactive nature of “DERAA”-directed T 
cell responses. More importantly, such T cell responses appear absent from donors 
carrying HLA-DRB1*13 as DERAA directed T cell responses to either pathogen- or 
vinculin-derived DERAA epitopes were lacking in these subjects. Even donors that 
harbored HLA-DRB1*13 next to predisposing HLA-alleles were unable to respond 
to vinculin DERAA.
Together, these data indicate a novel pathway that explains several of the pro-
tective- and predisposing HLA-effects associated with ACPA-positive RA (Figure 
7). In short, recognition of citrullinated vinculin by B cells will lead to the presen-
tation of the “VCL-DERAA” epitope in the context of HLA class II molecules. The 
HLA-DQ-molecules genetically linked to the predisposing HLA-SE-molecules are 
particularly good in presenting DERAA-containing peptides. The DERAA directed 
T cells primed against various pathogens harboring DERAA-containing proteins 
cross-react with the VCL-DERAA peptide and provide help to the B cells, ultimately 
leading to a strong ACPA-response. Subjects born with HLA-DRB1*13, will present 
the HLA-DRB1*13-derived DERAA-peptide in the thymus, leading to tolerization 





of the DERAA-reactive T cell response and hence the inability to provide help to 
ACPA-producing B cells via this pathway and thereby the emergence of ACPA-po-
sitive RA (Figure 7). The variation of HLA-DR and HLA-DQ molecules in the human 
population is enormous. We have shown that predisposing HLA-DQ molecules are 
particularly good at presenting the VCL-DERAA epitope. Interestingly, the absence 
of VCL-DERAA affinity for a wide variety of other tested HLA-DR or HLA-DQ mole-
cules could indicate a selective presentation by these HLA risk-molecules. Next 
to role of predisposing haplotypes, we also focussed on the protective effect of 
HLA-DRB1*13 alleles. However, the DERAA sequence can also be found in other 
HLA-DRB1 alleles (*04:02, *11:02, *11:03), which are rare in Caucasian popula-
tions. These alleles have previously been implicated in protection from ACPA+ RA, 
but their allele frequency hampers functional studies [43-45]. Interestingly, it has 
been previously reported that the processing of these alleles results in the genera-
tion of a similar HLA-DERAA epitope suggesting that these alleles could all protect 
via the pathway that we have described [22].
The place in time at which HLA-DR13 mediates protection from the development 
of ACPA and/or ACPA-positive disease, or its relation to epitope spreading of the 
ACPA response is currently not known and would be relevant to determine in future 
studies. Recent evidence showed that the ACPA response matures prior to disease 
onset and that the HLA system could be involved in this [13, 46]. It is intriguing to 
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Figure 7 Schematic representation of the role of DERAA directed CD4+ T cells in ACPA-positive RA. 
DERAA directed T cells are restricted to RA predisposing HLA-DQ5, -DQ7.3 and –DQ8 molecules. In 
carriers of these HLA-DQ molecules, DERAA directed T cells can become activated upon contact with 
microbes. These activated T cells can subsequently cross-react with a DERAA epitope derived from 
vinculin resulting in the activation of citrulline-directed B cells and the production of ACPA directed to 
citrullinated vinculin or vinculin-linked proteins. Citrullinated vinculin is present in the synovial com-
partment and is a target of ACPA. Binding of ACPA to its target can induce antibody mediated effector 
mechanisms thereby contributing to synovial inflammation. In HLA-DRB1*13 positive individuals, a 
HLA-DRB1*13 derived DERAA epitope is presented by predisposing HLA-DQ molecules to CD4+ T cells 
resulting in their negative selection, thereby protecting against the development of ACPA-positive RA.
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speculate that viral infections such as by DERAA containing microbes are involved 
in this expansion. Molecular mimicry of self-proteins with pathogenic proteins was 
proposed as a mechanism to break T cell tolerance, allowing the development of 
autoimmune disease [26,27]. Interestingly, the DERAA sequence is also present 
in proteins from many (common) microbes allowing priming of DERAA directed T 
cells. In mouse models, it was shown that low-avidity T cells to tissue-restricted 
antigens can persist without signs of anergy and unresponsiveness. Infection lowers 
the threshold for T cell activation resulting in the induction of autoimmunity and 
memory formation [47]. Infection could also induce autoimmunity via molecular 
mimicry of microbial proteins with self-proteins. We now identified crossreactive 
epitopes from the gut-residing bacteria L. sakei, L. curvatus and C. coli. It was shown 
that acute gastrointestinal infections can induce loss of T cell tolerance to (com-
mensal) gut microbes, resulting in the activation of microbiota-specific T cells, their 
differentiation to inflammatory effector cells, and formation of memory T cells [48]. 
A recent study on the fecal microbiota of RA patients compared to controls demon-
strated a significant increase in Lactobacillus species, together providing a rationale 
for a role of such bacterial species in the formation of DERAA-directed T cell res-
ponses [49].
Together, our study provides a mechanistic clue on the HLA-RA connection, inclu-
ding both predisposing and protective HLA-effect, and warrants further studies 
addressing the possibility to target DERAA-directed T cells in the prevention of 
ACPA-positive RA.
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Figure S1. Vinculin is an autoantigen recognized by circulating CD4+ T cells. IFN-γ ELISPOT of PBMC 
from healthy individuals stimulated for 24h with VCL-DERAA peptide REEVFDERAANFENH. Each dot 
represents a unique donor.
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Figure S2. Vinculin is an autoantigen recognized by circulating CD4+ T cells of HLA-DRB1*13 negative 
donors. IFN-γ ELISPOT of PBMC from healthy individuals stimulated for 4d with VCL-DERAA peptide 
REEVFDERAANFENH (Left panel). Stratification of donors in two distinct groups based on the presence 
or absence of HLA-DRB1*13:01 (Right panel). Each dot represents a unique donor. Two-sided statis-
















































Figure S3. Presentation to vinculin-DERAA directed T cells is restricted to RA predisposing HLA-DQ 
molecules. Competitive binding of a non-binding negative control peptide, an unbiotinylated positive 
control peptide and the VCL-DERAA peptide to HLA-DRB1*01:01 (a), HLA-DRB1*04:01 (b), HLA-DQ5 
(c), HLA-DQ7.3 (d), HLA-DQ8 (e), HLA-DRB1*13:01 (f), HLA-DRB1*13:02 (g), HLA-DQ6.2 (h), HLA-DQ6.3 
(i), HLA-DQ6.4 (j) or HLA-DQ7.5 (k). IC50 is the concentration of test-peptide (μM) where 50% of bio-
tinylated peptide is bound, ND = non-detectable (IC50 > 300 μM). All experiments were performed at 































































































































































































































Figure S5. Activated JP-T57 cells can activate ACPA producing B cells (a) Flow cytometry analysis of 
CD40L expression on JPT57 cells stimulated with VCL-DERAA pulsed APCs, CD40L transfected fibro-
blasts and EBV transformed B cells. (b) Co-culture of VCL-DERAA pulsed HLA-DQ8 positive B cells from 
healthy subjects with increasing numbers of JPT57 cells in the presence of anti-IgM. The experiment 
was repeated three times and the plot shows a representative experiment. (c) Co-culture of VCL-
DERAA pulsed HLA-DQ8 positive B cells from three ACPA positive RA patients with JPT57 (1:1) in the 
presence of anti-IgM. Activation of ACPA producing B cells was determined by CCP2 ELISA. Each dot 
represents a different well. Statistical analysis was performed using a student’s t-test with ** indicating 
P > 0,001.
Figure S4. T cell clone JPT57 specifically recognized the VCL-DERAA epitope. 3H-thymidine incorpora-
tion and IFN-γ production upon stimulation of T cell clone JPT57 with unpulsed and VCL-DERAA pulsed 
autologous APCs. Data are representative of at least three independent experiments. Two-sided statis-








































































































































































Figure S6. Vinculin-DERAA directed T cell clone JPT57 is HLA-DQ restricted. 3H-thymidine incorpora-
tion of JPT57 stimulated with feeders, pulsed or unpulsed with VCL-DERAA in the presence of HLA-II 
blocking antibodies. Data are representative of at least three independent experiments. Two-sided 
statistical analysis was performed using a student’s t-test with ** indicating P < 0.001.
Figure S7. Vinculin-DERAA directed T cell clone JPT57 is restricted to HLA-DQ7.3 and HLA-DQ8. IFN-γ 
production by JPT57 cells stimulated with HLA-DQ7.3 or HLA-DQ8 homozygous EBV-transformed B 
cells. Data are representative of at least three independent experiments. Two-sided statistical analysis 
was performed using a student’s t-test with ** indicating P < 0.001.
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Figure S8. Identification of a Pathmix directed T cell clone in an HLA-DRB1*13 negative donor. 3H-thy-
midine incorporation upon stimulation of T cell clone D2C18 with unpulsed and salmonella-DERAA 
pulsed autologous monocytes. The experiment was repeated two times and the plot shows a repre-
sentative experiment. Two-sided statistical analysis was performed using a student’s t-test with ** 
indicating P > 0.001.
Figure S9. Truncation of Phe633 results in loss of binding to HLA-DQ8. Competitive binding of HLA-DQ8 
to an unbiotinylated positive control peptide and C-truncated VCL-DERAA peptides. The experiment 
was repeated three times and plots show a representative experiment.





Figure S10. Arginine substuting Phe633 negatively impacts binding affinity to HLA-DQ8. Competitive 
binding of a negative control peptide, the native VCL-DERAA peptide and the VCL-DERAA peptide with 
Phe633 substituted to arginine. Experiments were performed three times and plots show a represen-
tative experiment.
Figure S11. N-terminal truncation of Val625 lowers the binding affinity to HLA-DQ8. Competitive 
binding of HLA-DQ8 to an unbiotinylated positive control peptide and N-truncated VCL-DERAA 
peptides. The experiment was repeated three times and plots show a representative experiment.
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Figure S12. Arginine substitutions of residues implicated to interact with binding pockets negatively 
impacts binding to HLA-DQ8. Competitive binding of a negative control peptide, the native VCL-DERAA 
peptide and the VCL-DERAA peptide with Glu628, Ala630 and Ala631 substituted to alanine or arginine. 
Experiments were performed three times and plots show a representative experiment.
Figure S13. HLA-DQ7.3 presents VCL-DERAA in a similar binding register as HLA-DQ8. Competitive 
binding of HLA-DQ7.3 to an unbiotinylated positive control peptide and C-truncated and N-truncated 
VCL-DERAA peptides. The experiment was repeated three times and plots show a representative expe-
riment.





Figure S14. Interaction free-energies (in kcal/mol) for selected peptide – ligand residue pairs, averaged 
over the MD trajectories. The left and right panels correspond, respectively, to polar (GB+Coulomb) 
and non-polar (vW + SA) interactions, computed with Eq. (1) of the supplementary methods. Rows 
from top to bottom correspond, respectively, to the DQ8:VCL-DERAA and DQ8:insulin complexes.
Figure S15. Hydrogen bonds between the VCL-DERAApeptide mainchain and DQ8.The peptide main-
chain is shown in thick licorice and its sidechains are displayed in blue lines. DQ8 groups are shown in 
thin licorice. Hydrogen bonds with occupancy smaller than 20% are omitted. A comprehensive list of 
all hydrogen bonds is included in Table S1.
Figure
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Figure S17. TCR view of the complex of HLA–DQ8 with the VCL-DERAA epitope in the groove at pH 7.4 
(extracellular). Depiction and colour conventions as in Figure S16. Anchors P1V and P9F point into the 
plane of the paper (screen) and are only partly seen. In vivo, P5R may not interact with P2F (cation-π 
interaction) because the former might more favorably interact with water molecules from the solvent.
Figure S16. TCR view of the complex of HLA-DQ7.3 with the VCL-DERAA epitope in the groove at pH 
7.4 (extracellular). The α1β1 domain of the modelled HLA-DQ molecule is in van der Waals surface 
representation, colored according to atomic charges (negative = red, positive = blue, neutral = gray, 
partial charges shades in-between). Several visible residues from the HLA-DQ molecule in contact with 
the antigenic peptide and potential contact with a cognate TCR in canonical orientation are shown in 
stick form with a transparent surface (atomic color code: oxygen, red; nitrogen, blue; hydrogen, white; 
carbon, green; sulfur, yellow). The antigenic peptide in the groove is shown in space-filling form, with 
identical colour conventions as in Fig. 6d-g. Anchors p1V and p9F point into the plane of the paper 
(screen) and are only partly seen. In vivo, p5R may not interact with p2F (cation-π interaction) because 
the former might more favorably interact with water molecules from the solvent. In this allele p4E 
makes an even weaker anchor than in DQ8, because of β13Gly→Ala and β26Leu→Tyr substitutions 
(DQ8→DQ7) that leaves less space available at the base of pocket 4.





Figure S18. TCR view of the complex of HLA-DQ8 with the L. curvatus epitope in the groove at pH 7.4 
(extracellular). Depiction and colour conventions as in Figure S16. Anchors P1P and P9F point into the 
plane of the paper (screen) and are only partly seen.
Figure S19. TCR view of the complex of HLA–DQ8 with the L. sakei epitope in the groove at pH 7.4 
(extracellular). Depiction and colour conventions as in Figure S16. Anchors P1P and P9F point into the 
plane of the paper (screen) and are only partly seen.
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Figure S20. TCR view of the complex of HLA–DQ8 with the C. Coli epitope in the groove at pH 7.4 
(extracellular). Depiction and colour conventions as in Figure S16. Anchors P1F and P9F point into the 
plane of the paper (screen) and are only partly seen.





Table S1. Statistics of intermolecular hydrogen bonds in the DQ8:VCL-DERAA complex. Hydrogen 
bonds were considered present if the D – A distance lDA was smaller than 3.5 Å, and the angle θD-H…A 
was larger than 150o. The (*) denotes water-mediated interactions; “sc” and “mc” denote side-chain 
and main-chain groups.
Donor Acceptor Occupancy 
(%)
Water P-2E (sc) 381
P-2E (Nter) Water 188
βArg88 (sc) P-2E(sc) 165
αArg53 (mc) P-2Ε (mc) 42.7
αArg53 (sc) P-2Ε (sc) 41.3
aPhe51 (mc) P-2E (sc) 29.8*
αPhe51 (mc) P-2E (Nter) 18.1*
Water P-1E(sc) 535
Water P-1E (mc) 62.9
P-1E (mc) Water 56.7
βAsn82 (sc) P-1E(mc) 20.5*
βHis81-Side P-1Ε(mc) 16.6*
Water P1V (mc) 79.3
P1V(mc) αArg53 (mc) 76.9
P2F(mc) βAsn82 (sc) 85.6
βAsn82 (sc) P2F (mc) 68.5
Water P3D(sc) 301
Water P3D (mc) 64.2
αAsnN62 (sc) P3D (sc) 46.9*
αTyr22 (sc) P3D (sc) 36.6*
Water P4E(sc) 269
βArg70 (sc) P4E (sc) 160.4
βThr71 (sc) E6 (sc) 64.7*
βThr28 (sc) E6 (sc) 38.5*
αAsn62 (sc) P4E(mc) 36
Donor Acceptor Occupancy 
(%)
P5R (sc) Water 118
Water P5R (mc) 98.3
P5R(sc) αThr61 (sc) 76.9
P5R (sc) αPhe58 (mc) 74.1
Water P6A(mc) 118
P6A(mc) αAsn62 (sc) 88.5
P7A(mc) βTyr30 (sc) 65.4
P8N (mc) Water 70.4
Water P8N (sc) 70.4
Water P8N (mc) 47.5
βTrp61 (sc) P8N(mc) 41.9
P8N (sc) Water 38.7
P8N (sc) αAsn69 (sc) 35.0
αHis68 (sc) P8N (sc) 19.2
Water P9F (mc) 65.6
P9F(mc) αAsn69 (sc) 38.8
Water P10E (sc) 555
Water P10E (mc) 62.8
P10E (mc) Water 48.6
Water P11N (Cter) 461
Water P11N (sc) 117.5
P11N (mc) Water 54.7
P11N (sc) Water 44.0
P11N(sc) αHis68 (sc) 21.3
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CHAPTER 9
The HLA-DRB1*14:02 allele predisposes 
indiginous North American populations to rheu-
matoid arthritis based on a unique molecular 
mechanism. 
Jurgen van Heemst*, Stephen W. Scally*, Jeremy Sokolove, Aaron Deutsch, Diederik 
Wieles, Antonis K. Moustakas, George K. Papadopoulos, Diane van der Woude, 
Irene Smolik, Carol A. Hitchon, David B. Robinson, Elizabeth D. Ferucci, Tom W.J. 
Huizinga, Hugh H. Reid, Soumya Raychaudhuri, Ranjeny Thomas, René E.M. Toes*, 




HLA-DR*14:02 is an HLA molecule, prevalent in indigenous North Americans 
(INA), that contains the rheumatoid arthritis (RA) associated shared epitope (SE) 
sequence. This sequence forms an electropositive pocket that was shown to 
preferentially accommodate citrulline residues in contrast to RA-resistant HLA-mo-
lecules, providing an explanation for the link between the HLA-system, RA and 
citrullination. Recent studies suggested an additional role for specific HLA-DRB1-re-
sidues at position β11 and β13 that are not carried by HLA-DRB1*14:02. We show, 
using a large cohort of INA RA patients, a significant association between HLA-
DRB1*14:02 and seropositive RA (OR=2.46). In contrast to other HLA-SE-alleles, 
HLA-DRB1*14:02 does not prefer citrulline in its electropositive pocket 4 or any of 
its other pockets as revealed by HLA-peptide-binding studies. Solved structures of 
HLA-DRB1*14:02 in complex with citrulline/arginine containing vimentin-epitopes 
revealed that citrulline and arginine residues are presented in a different orien-
tation in pocket 4, allowing for the citrulline to interact with T cell receptors. The 
differences between the SE alleles are attributable to the β11/β13 polymorphisms 
influencing the packing of P4 residues
These findings deepen our understanding of the association between the HLA-
system and RA by showing that different HLA-SE molecules present citrullinated 
ligands in structurally different ways, that nonetheless allow the unique presenta-
tion of citrullinated ligands to T cells.






Rheumatoid arthritis is a chronic systemic inflammatory disease characterized by 
extensive inflammation of synovial joints[1]. The presence of Anti-citrullinated 
protein antibodies (ACPA) is an important hallmark of RA[2]. These autoantibodies 
specifically target proteins that have undergone a post-translational modification 
converting positively charged arginine residues in uncharged citrulline residues[3, 
4].
The HLA class II locus is the most important risk factor for ACPA+ RA and contains 
genes encoding for the alpha and beta chains of HLA-DR and HLA-DQ mole-
cules[5-7]. It was previously hypothesized that the contribution of the HLA class 
II region is explained by the HLA-DR locus when it was shown that RA risk associ-
ates with HLA-DRB1 alleles that encode the amino-acids (aa) sequences QKRAA, 
QRRAA and RRRAA in position 70-74. This sequence is known as the shared epitope 
(SE) motif [8, 9]. SE-residues β70, β71 and β74 shape peptide binding pocket 4 of 
HLA-DR molecules and it was proposed that the SE are directly involved in the pre-
sentation of a shared (type of) antigen to CD4+ T cells[8, 9]. To date, such an antigen 
has not been identified. However, accumulating data have shown that pocket 4 of 
different SE-alleles display an increased affinity for citrulline over arginine residues, 
thereby permitting enhanced presentation of citrullinated peptide-ligands[10-16]. 
Most of this work is centered around HLA-DRB1*04:01, the strongest risk allele in 
Caucasians.
Recently the genetic association of individual amino acids in the HLA-DRB1 locus 
with ACPA+ RA was studied in a large cohort of Caucasians. This study identified 
that next to SE-residues β70 and β71, also β11 and β13, that are in tight LD, are 
associated with RA risk[17]: β13His (e.g. present in SE-allele HLA-DRB1*04:01) and 
β13Phe (e.g. present in SE-allele HLA-DRB1*01:01) are most strongly associated 
with risk, while β13Ser is not associated with predisposition[17]. Interestingly, β13 
is, like the SE-motif, involved in shaping the peptide binding properties of pocket 4.
To understand and uncouple the relative contribution of the SE-motif and β13 to 
presentation of citrullinated peptides, we wished to study HLA-DRB1*14:02. HLA-
DRB1*14:02 is an SE-allele that is rare in Caucasians, but prevalent in indigenous 
North Americans (INA). Interestingly, this SE-allele carries the non-predisposing 
β13Ser residue. We aimed to assess if HLA-DRB1*14:02 associates with seropo-
sitive RA as well as the relative capacity of the HLA-DRB1*14:02 to accommodate 




Study participants, both RA cases and controls, were recruited from INA popula-
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tions in Central Canada (Cree, Ojiway, and Ojicree People) and Alaska Native people 
(from Southcentral and Southeast Alaska). The study and consent forms were 
approved by the Research Ethics Board of the University of Manitoba, and by the 
Alaska Area Institutional Review Board. In addition, written community agreements 
to undertake studies of RA risk were developed with communities in Manitoba 
(Norway House and St Theresa Point communities), and the study was approved by 
the tribal health organizations of the study communities in Alaska. The study parti-
cipants signed consent documents after the study was explained to them in detail, 
with the help of an INA translator from their community, where necessary.
In total, 303 RA patients were recruited from the Cree/Ojibway/Ojicree popu-
lation, along with 351 INA controls from the same geographic locations. In total, 
69 RA patients were recruited from the Alaska Native population, along with 52 
controls from the same geographic location. In all cases, RA patients met the 1987 
ACR criteria for RA, and the controls had no personal or family history of RA or 
any related autoimmune diseases, including systemic lupus erythematosus, sclero-
derma, polymyositis, vasculitis, spondylarthritides, multiple sclerosis, inflammatory 
bowel disease, type 1 diabetes mellitus, or thyroid disease.
HLA-DRB1*1402 expression and purification
The extracellular domains of HLA-DRB1*1402 (HLA-DRA*0101 and HLA-DRB1*1402) 
were cloned into pHLSec for transient expression in HEK293S (GnTI-) cells[15, 18, 
19]. HLA-DRB1*1402 was expressed with the class II associated invariant peptide 
(CLIP) covalently attached via a Factor Xa cleavable flexible linker to the N-ter-
minus of the β-chain, which was preceded by an N-terminal strep II tag. In addition, 
the constructs contained enterokinase cleavable C-terminal fos/jun zippers that 
promoted dimerization, as well as a BirA biotinylation site and a His tag attached to 
the C-terminus of the β-chain.
HLA-DRB1*1402-CLIP was expressed and purified as previously described[15]. 
Briefly, HLA-DRB1*1402-CLIP was transiently expressed in HEK 293S (GnTI-) and 
purified via IMAC and size exclusion chromatography. HLA-DRB1*1402-CLIP was 
cleaved by Factor Xa for 6 h at 21 °C and then loaded with either Vimentin-64Arg59-71 
or Vimentin-64Cit59-71 for 16 h at 37 °C with a 20-fold excess of the peptide in 100mM 
Sodium Citrate pH 5.4 in the presence of HLA-DM at a DR:DM ratio of 5:1. Peptide 
loaded HLA-DRB1*1402 was then purified via Strep-Tactin Sepharose (IBA; Göt-
tingen), and the C-terminal fos/jun zippers removed via enterokinase (Genscript) 
digest. Cleaved and peptide loaded HLA-DRB1*1402 was then purified further anion 
exchange chromatography (HiTrap Q HP; GE Healthcare), buffer exchanged into 10 
mM Tris pH 8, 150 mM NaCl, and concentrated to 6mg/mL for crystallization trials.
Crystallization and structure determination
Crystal trays were set up using the hanging-drop vapour diffusion method at 20°C. 
Protein and a mother liquor of 100 mM BTP pH 7.3, 22-28% (vol/vol) PEG3350, 0.2 





M KNO3 were mixed in a 1:1 ratio and plate like crystals typically grew within 5 days. 
Crystals were flash frozen in 16% ethylene glycol prior to data collection. Data were 
collected at the MX1 beamlines at the Australian Synchrotron and processed using 
the program Mosflm. The structures were determined by molecular replacement 
using the program Phaser and subsequently refined using Phenix and iterations of 
manual refinement using Coot. The structures were validated using MOLPROBITY.
Cell lines
The following EBV-transformed lymphoblastoid B cell lines were used: BC1402 
(HLA-DRB1*14:02), BOLETH (HLA-DRB1*04:01), BSM (HLA-DRB1*04:01), and 
KAS116 (HLA-DRB1*01:01). Cells were maintained in IMDM (Lonza) supplemented 
with 10% heat-inactivated FCS.
Peptides
Peptides were synthesized according to standard Fmoc (N-(9-fluorenyl)methoxy-
carbonyl) chemistry using a SyroII peptide synthesizer (MultiSynTech, Witten, 
Germany). The integrity of the peptides was checked using reverse phase HPLC and 
MS. For HLA-peptide affinity studies, we used Influenza-peptide HA305-319 CPKYVK-
QNTLKLATG. The anchors are depicted in bold. To assess citrulline or arginine 
accommodation, peptides with an arginine or a citrulline at the indicated anchor 
positions were generated. As negative control peptide, we have used a peptide that 
did not bind to the respective HLA molecules, the previously described A4KA5-pep-
tide[20]. We also assessed the binding of vimentin peptides Vimentin-64Arg/Cit59-71 
(GVYATRSSAVRLR) and Vimentin-71Arg/Cit66-78 (SAVRARSSVPGVR). The arginine’s in 
bold were substituted for citrulline.
HLA class II competitive peptide binding assay
Peptide-binding assays were performed, as described previously[21]. In short, cell 
lysates from HLA-class II homozygous B-lymphoblastoid cell lines were incubated 
on B8.11.2- (anti-HLA-DR) coated (10 μg/ml) FluoroNunc 96-well plates at 4C over-
night. Titration ranges of the tested peptides (0 to 300 μM) were mixed with a fixed 
concentration (0.6 μM) of biotinylated indicator peptide and added to the wells. 
Bound indicator peptide was detected using europium-streptavidin (Perkin Elmer, 
Boston, MA) and measured in a time-resolved fluorometer (PerkinElmer, Wallac 
Victor2). IC50 values were calculated based upon the observed binding of the test 
peptide against the fixed concentration indicator peptide. The IC50 value depicts 
the concentration of test peptide required for a loss of 50% of the indicator peptide 
signal. IC50 values greater than 300 μM were classified as non-detectable binding 
affinity.
Statistical analysis
Wilcoxon’s signed rank test was used to assess differences in IC50 values between 
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citrulline and arginine containing peptides. P-values below 0.05 were considered 
to be statistically significant. Logistic regression analysis was used to calculate odds 
ratios (OR) and 95% confidence intervals (CIs) for the development of RA. Healthy 
controls were used as comparator group.
RESULTS
SE-allele HLA-DRB1*14:02 is a risk factor for RA in INA.
HLA-DRB1*14:02 is rare in Caucasians, but prevalent in INA populations[22-24]. 
Interestingly, HLA-DRB1*14:02 carries both the predisposing SE-motif and the 
non-predisposing β13S-residue. Previously it was shown that the SE-alleles in INA, 
associate with RA risk. HLA-DRB1*04:04 is the most frequent SE-allele in these 
populations, followed by HLA-DRB1*14:02. Because HLA-DRB1*14:02 has the SE-se-
quence it was postulated that HLA-DRB1*14:02 is implicated in RA risk. However, 
this has not been shown as these studies lacked the proper size to provide a sta-
tistically significant answer to the association of HLA-DRB1*14:02 with RA risk[22, 
24-26].
We have now analyzed a group of 344 INA RA patients and 352 controls, the largest 
cohort of HLA-typed INA RA patients and controls available. For 68% of the RA 
patients (241/352), RF and ACPA status was known. 90% (218/241) of RA patients 
were seropositive (positive for RF and/or ACPA). Both in total RA patients (OR = 
2.48, 95% CI = 1.70-3.60, P< 0.0001) and in confirmed seropositive RA (OR = 2.46, 
95% CI = 1.58-3.81, P=0.0001) patients, SE-positivity associated with RA risk (Table 
S1).
In total 293 of 344 RA patients carried a SE-allele, 176 carried a single SE-allele 
and 117 were SE homozygous. Thus, in total we identified 410 SE-alleles. 32% of 
these SE-alleles (132/410) were HLA-DRB1*14:02, and 61% HLA-DRB1*04, mostly 
HLA-DRB1*04:04 (185/410). The remaining SE-alleles were HLA-DRB1*01 and HLA-
DRB1*10. To study the predisposing effect of HLA-DRB1*14:02 separately from the 
other SE-alleles, we stratified RA patients according to HLA-status (Table 1). Both in 
total and in seropositive RA patients, we demonstrated that HLA-DRB1*14:02 is a 
risk factor for seropositive RA independent of other SE-alleles (Table 1). In addition, 
the other SE-alleles (mainly HLA-DRB1*04) also associate with the risk to develop 
seropositive RA independent of HLA-DRB1*14:02 (Table 1).
Together these data show that HLA-DRB1*14:02 is a risk allele for the development 
of (seropositive) RA in INA.
HLA-DRB1*14:02 shapes the ACPA autoantibody response
Previously, we have shown that SE-alleles, mainly HLA-DRB1*04:01 and *01:01, 
influence both the level and epitope-recognition profile of the ACPA-response in 
Dutch RA-patients[27-29]. To investigate whether HLA-DRB1*14:02 has an impact 





on the ACPA response, sera of 232 INA RA patients were tested in a multiplex ACPA 
antigen array[30]. We evaluated the depth of the ACPA response using an ACPA 
score (sum of all normalized ACPA titers divided by number of epitopes) as pre-
viously described [30]. These analyses revealed that HLA-DRB1*14:02-positive RA 
patients display a more diverse ACPA response, as compared to HLA-SE negative, 
but ACPA positive patients (data not shown).
Together, these data show that HLA-DRB1*14:02 is not only a risk factor for RA, but 
also that HLA-DRB1*14:02 impacts the constitution of the ACPA-response, mimic-
king the effects observed for other HLA-SE alleles.
HLA-DRB1*14:02 present arginine and citrulline residues with a similar peptide 
binding capacity.
SE-allele HLA-DRB1*14:02 associates with RA risk and a broadened ACPA-response 
despite the presence of the non-predisposing β13Ser-residue. The latter residue is 
known to influence the characteristics of binding pocket 4 and pocket 6. To better 
comprehend the ability of HLA-DRB1*14:02 to present citrullinated ligands, we next 
assessed the ability of HLA-DRB1*14:02 to accommodate arginine and citrulline 
in the various peptide binding pockets. For comparison, similar experiments were 
performed for HLA-DRB1*01:01 and HLA-DRB1*04:01, the two most common SE+ 
HLA-DR molecules in Caucasians[17, 31]. To systematically compare the capacity 
of the different binding pockets to accommodate citrulline and arginine residues, 
we made use of the influenza-derived HA305-319 peptide. This peptide has previously 
been crystallized and studied in the context of different HLA-DR molecules and the-
refore its binding register is known[10, 20, 32, 33]. The accommodation of citrulline 
and arginine residues in peptide binding pockets was determined by substituting 


























































Table 1: Association of HLA-DRB1*14:02 with total and seropositive RA in INA RA patients and controls. 
Patients and controls were stratified according to the presence of SE. SE-positive individuals were 
further stratified in those that carry 14:02, those that carry other SE-alleles (DRB1*01:01, *01:02, 
*04:01, *04:04, *04:05, *04:08, *04:10, *04:13, and *10:01), or those that are positive for 14:02 and 
another SE-allele.
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arginine to citrulline conversion in the different position of the peptide (P1, 4, 6 and 
9) interacting with the different binding pocket of the HLA-molecule is assessed, 
as previously described[10, 34-37]. Using this approach, we could demonstrate, as 
expected, that the conversion of arginine to citrulline at peptide-positions interac-
ting with pocket 4 enhanced peptide binding affinity to HLA-DRB1*01:01 (Figure 
1A) and *04:01 (Figure 1B). In addition, we also demonstrated a preference for cit-
rulline in pocket 6 and 9 of HLA-DRB1*01:01 (Figure 1A) and in pocket 7 of *04:01 
(Figure 1B). Intriguingly, our analyses of the HLA-DRB1*14:02 allele indicated that 
peptides containing an arginine or citrulline residue at a position interacting with 
peptide binding pocket 4 are presented with a similar binding affinity (Figure 1C). In 
addition, we could not demonstrate a preference for citrulline in any of the other 
peptide binding pockets. In contrast, for pocket 6 and pocket 9 we demonstrated an 
increased affinity for arginine residues (Figure 1C).
Thus using this approach, we confirmed previous findings describing a preference 
for citrulline in pocket 4 of HLA-DRB1*01:01 and HLA-DRB1*04:01. Moreover, our 
data indicate that HLA-DRB1*01:01 and *04:01 also prefer citrulline over arginine 
residues in other pockets albeit in a distinct pattern. In contrast, HLA-DRB1*14:02 
displays no preference for citrulline residues in pocket 4 or any of its other peptide 
binding pockets.
To further support these data, we next analyzed the binding affinity of two previously 
studied vimentin peptides, Vimentin59-71 and Vimentin66-78, that carry a citrulline at a 
Figure 1: Accommodation of arginine and citrul-
line residues by HLA-DRB1*01:01, DRB1*04:01 
and DRB1*14:02. (A-C) Competitive binding of 
a biotin-labeled HA peptide with an unlabeled 
HA peptide or HA-variants with citrulline or 
arginine residues in p1, p4, p6, p7 and p9 to HLA-
DRB1*01:01 (A), DRB1*04:01 (B) and DRB1*14:02 
(C). Graph depicts the IC50-values (μM). ND = 
Non-detectable binding affinity. Binding experi-
ments were performed at least three times and 
plots show pooled experiments. The error bars 





































































































































position interacting with pocket 4[12, 15, 16, 38]. By using these vimentin-peptides, 
we demonstrated an increased affinity of the citrulline variant for SE-alleles HLA-
DRB1*01:01 and *04:01, whereas HLA-DRB1*14:02 presented both the arginine 
and citrulline variant with a similar affinity (Table 2).
Thus, together these data indicate that different SE-alleles (HLA-DRB1*01:01, 
*04:01 and *14:02) have distinct capacities to present citrullinated ligands and, 
most importantly, that a preference for citrulline residues in pocket 4 is not a shared 
characteristic of all SE-alleles.
Structural determination of citrullinated ligand presentation by HLA-DRB1*14:02 
shows a joint role for β11/13 and the SE-motif in the accommodation of arginine 
residues in pocket 4.
The HLA-DRB1 chain contains 12 different polymorphic residues that have been 
directly implicated in peptide accommodation[35]. HLA-DRB1*01:01 differs from 
*04:01 and *14:02 in 8 out of these 12 polymorphic residues (Figure 2A). These 
different residues are involved in shaping peptide binding pocket 4 (β13, β26, β28 
and β71), pocket 6 (β11 and β30), pocket 7 (β28 and β71) and pocket 9 (β9 and β37, 
Figure 2B). Despite these differences, all these SE-alleles are strongly associated 
with susceptibility to seropositive RA[17, 27]. Minor differences in the polymorphic 
residues of MHC molecules have been described to greatly influence the nature of 
the ligand binding repertoire[36-40]. To determine how structural differences in 
pocket 4 of HLA-DRB1*14:02 explain our results, we aimed to solve the structure 
of HLA-DR*14:02 in complex with a citrullinated ad native epitope. We therefore 
cloned HLA-DR*14:02 and loaded the HLA-molecule with native Vimentin59-71, 
Vimentin-64Cit59-71, Vimentin-64,69,71Cit59-71, Vimentin66-78 and Vimentin71Cit66-78. 
Interestingly, we could only make stable complexes of Vimentin59-71 and Vimen-
tin-64Cit59-71 supporting our HLA-peptide binding studies (Figure S1, Table 2).
We next solved the structures of Vimentin-64Arg59-71 (Figure 3A and 3C) and Vimen-
tin-64Cit59-71 (Figure 3B and 3D) in HLA-DRB1*14:02 (Table S2). Both these epitopes 
were bound in a linear extended manner with P1-Tyr, P6-Ser and P9-Arg occupying 
Peptide Variant DRB1*01:01 DRB1*04:01 DRB1*14:02
Vim59-71 64Arg 43 >300 19
64Cit 34 197 19
Vim66-78 71Arg >300 187 >300
71Cit 51 21 >300
Table 2: Presentation of (citrullinated) vimentin peptides by different SE-alleles.
Competitive binding of a biotin-labeled HA peptide with unlabeled Vim59-71-64Arg, Vim59-71-64Cit, Vim66-
78-71Arg and Vim66-78-71Cit to HLA-DRB1*01:01, *04:01 and *14:02. Table depicts average IC50-values 
(μM). ND = Non-detectable binding affinity. Binding experiments were performed at least three times 
and pooled experiments are shown.
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respectively pocket 1, 6 and 9. P-1-Val, P2-Ala, P5-Ser, P7-Ala, P8-Val and P11-Arg 
represented potential TCR contact sites. These structures clearly show that for both 
ligands P4-Arg and P4-Cit are presented in an alternative orientation: The arginine 
is projecting inwards, whereas the citrulline projects outwards. In Figure 4A the 
interactions between the HLA-DR molecule and the P4-Arg residues are shown for 
Vimentin59-71. The p4-Arg is buried in the pocket to avoid interactions with the posi-
tively charged β71Arg-residue. This orientation is promoted by β11Ser and β13Ser, 
two small hydrophobic residues that allow the accommodation of Arginine by provi-
ding necessary space. Larger residues in HLA-DRB1*04:01 (β11Val and β13His) and 
HLA-DRB1*01:01 (β11Leu and β13Phe) prevent the accommodation of arginine, 
thereby explaining observed differences between SE-alleles. β11Ser and β13Ser 
also contribute by providing hydrogen bonds with the P4-Arg residue. The arginine 
residue is further stabilized by an hydrogen bond with β30Tyr and a salt bridge with 
β28Glu.
In contrast to P4-Arg, the P4-Cit sits upright in the pockets, similar to what was 
shown for HLA-DRB1*04:01/04:04[15]. The citrulline forms hydrogen bonds with 
β71Arg and β70Gln. The upright position of P4-Cit could potentially be a target for 
citrulline-directed T cell receptors (Figure 4B).
Together, these structures provide a detailed understanding of the accommodation 
of arginine and citrulline residues in pocket 4. Observed differences between SE 
alleles are explained by structural differences, in particular by residues β11 and 
β13. We believe that the upright position of citrulline in pocket 4 allows interactions 
with possible citrulline specific T cells, thereby providing a molecular basis for the 
association of HLA-DRB1*14:02 with seropositive RA.





--------WQ LKF------- -----L-E-C IYN---SV-F ---------- ---------- ---------Q RRAA------ ----------
--------EQ VKH------- -----F-D-Y FYH---YV-F ---------- ---------- ---------Q KRAA------ ----------
DRB1*14:02 --------EY STS------- -----F-E-Y FHN---NV-F ---------- ---------- ---------Q RRAA------ ----------
β85 β86 β89 β90 β13 β26 β28 β70 β71 β74 β78 β11 β30 β28 β47 β61 β67 β71 β9 β37 β57
*01:01 V G F T F L E Q R A Y L C E Y W L R W S D
*04:01 V G F T H F D Q K A Y V Y D Y W L K E Y D
*14:02 V G F T S F E Q R A Y S Y E Y W L R E N D
Pocket1 Pocket 4 Pocket 6 Pocket7 Pocket 9
Figure 2: Characteristics of the tested SE-alleles. (A) Schematic representation of differences in amino 
acids between SE-alleles HLA-DRB1*01:01, *04:01 and *14:02. Positions important for interaction 
with the peptide side chains are highlighted in yellow and green. Polymorphic residues are highlighted 
in yellow. (B) Schematic representation of the differences in pockets between HLA-DRB1*01:01, 
*04:01 and *14:02. Aa residues are color coded according to their properties (white = hydrophilic, 
gray = hydrophobic, red = basic, blue = acidic).






The INA RA patient population is characterized by a high prevalence of ACPA. It was 
previously demonstrated that SE-alleles are a risk factor for RA in INA, but these 
studies were underpowered to draw conclusions on the contribution of individual 
SE-alleles to RA predisposition[22-24, 26]. We now demonstrated in a large cohort 
of INA, that SE-allele HLA-DRB1*14:02 is associated with predisposition to sero-
positive RA. Interestingly, the presence of HLA-DRB1*14:02 is also reflected in a 
broader ACPA repertoire as was previously reported for other SE-alleles present in 
the Caucasian population.
More than 10 years ago, it was first proposed that the SE-alleles could predispose 
to RA through the increased ability to present citrullinated ligands via the exqui-
site ability of pocket 4 of HLA-DRB1*04:01 to interact with citrulline[16]. However, 
the amino acids encompassing the SE sequence are not only taking part in the 
formation of pocket 4, but also of pocket 7. Likewise, also other now performed 
a systematic analysis of the capacity of three different predisposing SE-alleles to 
present citrulline- and arginine residues in their different peptide binding pockets 
(HLA-DRB1*01:01, *04:01 and *14:02). Interestingly, all three SE-alleles show diffe-
rent patterns of citrulline “presentation”. Our data document that HLA-DRB1*01:01 
prefers citrulline residues in 4, 6 and 9, while HLA-DRB1*04:01 prefers citrulline 
over arginine in pocket 4 and 7. Interestingly, HLA-DRB1*14:02 has no preference 
for citrulline residues in any of its peptide binding pockets. When the sequences 
Figure 3: Crystal structure of HLA-DRB1*1402 in complex with vimentin59-71 and vimentin-64Cit59-71 
(A) HLA-DRB1*1402 in complex 
with vimentin59-71 and (B) 
vimentin-64Cit59-71. The 
α- and β-chains are shown in 
cartoon representation and 
coloured in light green and 
light blue respectively, while 
the vimentin peptides are dis-
played as sticks. The carbons 
are coloured deep salmon and 
light orange for vimentin59-71 
and vimentin-64Cit59-71, respec-
tively, nitrogens are coloured in 
blue and oxygens are coloured 
in red. Side view of (C) HLA-DR-
B1*1402-Vimentin59-71 and 
(D) HLA-DRB1*1402-Vimen-
tin-64Cit59-71. The β-chain is 
transparent to help visualize 
the peptide. The unbiased 
2Fo-Fc electron density map of 
the peptides is shown in blue 
and contoured to 1 σ.
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of different SE-alleles are compared it becomes clear that HLA-DRB1*14:02 differs 
from other SE-molecules in residues important for shaping peptide binding pockets 
4 and 6, most notably in β11 and β13[17, 35]. Indeed our structural analysis of 
the p4 pocket of HLA-DRB1*14:02 showed that differences in β11/β13 allowed for 
an enhanced affinity for arginine residues compared to the other tested SE-mole-
cules. Together, these findings indicate that it is unlikely that a common mechanism 
related to binding of citrullinated residues in p4 or other pockets of SE-molecules 
explains the HLA-RA connection.
Intriguingly, however, our data also indicate that while the structural basis for cit-
rullinated ligand presentation is different, the outcome for the presentation of 
citrullinated ligands is highly similar. We show that, although, HLA-DRB1*14:02 can 
accommodate both arginine and citrulline residues in pocket 4 with a similar affinity, 
the citrulline, in contrast to arginine, was accommodated in an upright position 
allowing interaction with possible citrulline-specific T cells. Thus, it is highly concei-
vable that the conversion of an arginine to a citrulline residue in pocket 4 generates 
a neo-epitope for HLA-DRB1*14:02-restricted CD4+ T cells, thereby mimicking the 
effects of citrullination for presentation of ligands in the context of HLA-DRB1*04:01 
and 04:04[15]. We, therefore, believe our data provide a similar molecular basis 
for the HLA-DRB1*14:02-RA association as described for other SE-allomorphs and 
warrant future efforts to identify and characterize citrulline-directed T cells in 
HLA-DRB1*14:02-positive RA patients. Our data provide an important step forward 
for the structural requirements of an RA-inducing antigen that induces seropositive 
RA regardless of ethnic background.
Figure 4: Interactions in the P4 pocket of HLA-DRB1*1402 with vimentin59-71 and vimentin-64Cit59-71 
The P4 pocket of HLA-DRB1*1402 bound to (A) vimentin59-71 and (B) vimentin-64Cit59-71. The P4-Arg in 
the vimentin59-71 peptide is buried in the P4 pocket, away from the electropositive Arg71β, and forms 
a salt bridge with Glu28β and a number of hydrogen bonds with Ser11β, Thr12β, Ser13β, Tyr30β, and 
a water-mediated hydrogen bond with the main chain carbonyl of Gln9α. The P4-Cit of the vimen-
tin-64Cit59-71 peptide adopts an upright conformation and forms hydrogen bonds with Arg71β and 
Gln70β and a water-mediated hydrogen bond with Thr77β. A water occupies the space below the 
P4-Cit.
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Table S1: Association of the shared epitope with total and seropositive RA in INA RA patients and 
controls. Patients were stratified according to the presence of SE. SE-positive were classified as SE-po-
sitive when positive for DRB1*01:01, *01:02, *04:01, *04:04, *04:05, *04:08, *04:10, *04:13, and 
*10:01 and *14:02.









Space group P12(1)1 P12(1)1
Cell dimensions 
a,b,c (Å) 67.0, 77.7, 94.5 67.3, 76.9, 94.1
α,β,γ (°) 90, 109.5, 90 90, 109.5, 90
Resolution (Å)a 35.64-1.90 (2.0-1.90) 35.31-1.98 (2.09-1.98)
No. molecules in ASU 2 2
Total no. observations 262810 (35904) 229839 (31923)
No. unique observations 72027 (10379) 63444 (9163)
Multiplicity 3.6 (3.5) 3.6 (3.5)
Rmerge (%)
b 9.3 (37.9) 9.1 (30.8)
Rpim (%)
c 5.6 (23.6) 5.6 (19.5)
<I/σI> 10.6 (3.3) 9.1 (4.3)
Completeness (%) 99.7 (98.9) 99.9 (99.3)
Refinement Statistics







Rms deviations from ideality
Bond lengths (Å) 0.003 0.004
Bond angles (°) 0.86 0.89
Dihedrals (°) 14.0 13.2
Ramachandran plot
Favoured regions (%) 98.3 98.7
Allowed regions (%) 1.7 1.3
B-factors (Å2)
Average B-factors 20.4 22.0
Average macromolecule 18.1 20.6
Average ligand 40.9 33.4
Average water molecule 32.1 31.1
a Values in parentheses refer to the highest resolution bin. b Rmerge = Σhkl Σi | Ihkl, i - <Ihkl> | / Σhkl <Ihkl>
c Rpim = Σhkl [1/(N – 1)]
1/2 Σi | Ihkl, i - <Ihkl> | / Σhkl <Ihkl>. 
d Rfactor = (Σ | |Fo| − |Fc| |) / (Σ | |Fo|) - for all data except as 
indicated in footnote e. e 5 % of data were used for the Rfree calculation.




The increased ability to present citrulinated 
peptides is not unique to HLA-SE molecules: 
Arginine to citrulline conversion enhances 
peptide affinity for HLA-DQ molecules. 




Objective. Presentation of citrullinated neo-epitopes by HLA-DRB1 molecules that 
carry the shared epitope (SE) sequence was proposed to explain the association 
between HLA and seropositive RA. Although it is shown that several HLA-DRB1-SE 
molecules display enhanced binding affinities for citrullinated ligands, it is not 
known whether this feature is confined to these HLA-molecules. To better under-
stand the HLA-RA-connection, we aimed to investigate if the enhanced capacity to 
present arginine to citrulline converted peptides is unique for HLA-SE alleles.
Methods. We selected four HLA-molecules (one HLA-DR and three HLA-DQ mole-
cules) that could potentially prefer citrulline over arginine residues. The affinity 
of peptides containing arginine/citrulline residues at positions interacting with 
the various peptide-binding pockets was compared by HLA class II peptide affinity 
assays.
Results. HLA-DRB1*03:01 did not display an enhanced affinity for peptides con-
taining a citrulline. In contrast, several peptide-binding pockets of the HLA-DQ 
molecules analyzed showed enhanced affinities for citrulline residues: i.e. Pocket 4, 
7 and 9 for HLA-DQ2 and pocket 1, 6 and 9 for HLA-DQ7 and HLA-DQ8.
Conclusion. Arginine-to-citrulline conversion of peptides can also enhance the 
binding affinity for non-HLA-SE molecules and hence the capacity to present citrul-
linated neo-epitopes is not an unique feature of HLA-SE molecules.







Rheumatoid arthritis (RA) patients can be divided in two distinct disease subsets 
based on the presence of anti-citrullinated protein antibodies (ACPA)[1, 2]. These 
autoantibodies target proteins that have undergone post-translational modifica-
tions converting positively charged arginine to uncharged citrulline residues[3].
The most important risk factor for ACPA+ RA is the HLA class II locus[2]. This locus 
contains genes encoding the beta chain of HLA-DR (HLA-DRB1) and the alpha and 
beta chain of HLA-DQ (HLA-DQA1 and HLA-DQB1) that inherit together in haplo-
types. In 1987 it was proposed that risk is explained by the HLA-DRB1 locus, in 
particular by those alleles that carry the sequence QKRAA, QRRAA or RRRAA in 
position 70-74 of the DRB1 chain, also known as the shared epitope (SE) motif[4, 
5]. About 80% of ACPA+ RA patients carry “HLA-SE” alleles, illustrating that these 
alleles are highly prevalent, but not required to develop seropositive disease[2].
HLA class II molecules are composed of an alpha and beta chain that create a 
ligand-binding groove that is involved in the presentation of peptides to CD4+ T 
cells. These ligands vary in length, but the part that interacts with this groove is 
9 amino acids (aa) in length. The ligand-binding groove contains peptide-binding 
pockets allowing the interaction with amino acids from the peptide presented. 
These pockets accommodate the side chains of peptide residues 1, 4, 6 , 7 and 9 
and are respectively named: pocket 1, 4, 6, 7 and 9[6].
The amino acid residues that shape the pockets are highly polymorphic, thereby 
dictating the preferences for particular amino acids that can be accommodated in 
the pockets of different HLA class II alleles. In this way, the compared characteris-
tics of the peptide-binding pockets shape the repertoire of ligands presented by 
the HLA-molecule. The amino acids forming the SE motif are part of pocket 4 of 
the HLA-DRB1-molecule [4, 6]. It was proposed that the SE motif associates with 
risk because the positively-charged SE residues would prevent the accommoda-
tion of positively-charged arginine residues while favoring the accommodation of 
uncharged citrulline residues. The conversion of arginine to citrulline could thereby 
result in the presentation of a peptide that would otherwise not be presented [7]. 
Indeed, several studies have shown that pocket 4 of HLA-SE alleles HLA-DRB1*01:01, 
*04:01, *04:04 and *10:01 prefers citrulline over arginine residues[7-9]. It was pos-
tulated that this preference for citrulline over arginine residues would be unique 
to HLA-SE alleles, but this was never analyzed[7]. We aimed to study if also non-
HLA-SE alleles can present citrullinated peptides with an enhanced affinity.
METHODS
Cell lines. Lysate of EBV-transformed lymphoblastoid B cell lines were used as a 
source for HLA-DQ/DR molecules: BOLETH (DQA1*03:01/DQB1*03:02), BSM 
(DQA1*03:01/DQB1*03:02), DUCAF (DRB1*03:01/DQA1*05:01/DQB1*02:01), 
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JSM (DQA1*03:02/DQB1*03:01) Cells were maintained in IMDM (Lonza) supple-
mented with 10% heat-inactivated FCS.
Peptides. Peptides were synthesized according to standard Fmoc (N-(9-fluorenyl)
methoxycarbonyl) chemistry using a SyroII peptide synthesizer (MultiSynTech, 
Witten, Germany). The integrity of the peptides was verified using reverse phase 
HPLC and MS. For binding studies on HLA-DR3 molecules we used myoglobin-peptide 
LFRKDIAAKYK, for HLA-DQ2 deamidated alpha-gliadin-peptide LQPFPQPELPYPQ, 
and for HLA-DQ7 and HLA-DQ8 Herpes Simplex Virus 2 (HSV-2)-peptide VP16432-
444 VDMTPADALDDFD. The anchors are depicted in bold. These peptides were 
previously described in the context of the studies HLA-molecules[10-12]. To assess 
arginine or citrulline accommodation, peptides with an arginine or a citrulline at the 
indicated anchor positions were generated. As negative control peptides, we used 
peptides that do not bind to the respective HLA molecules. For HLA-DR3 we used 
AAAAKAAAAA, for HLA-DQ2 AKPFPQPEAPYKA, and for HLA-DQ7.3 and HLA-DQ8 
AADTNRWSKMDAA.
HLA class II competitive peptide-binding assay. Peptide-binding assays were 
performed, as previously described[13]. In short, cell lysates from HLA- class II 
homozygous B-lymphoblastoid cell lines were incubated on SPV-L3- (anti-HLA-DQ) 
or B8.11.2- (anti-HLA-DR) coated (10 μg/ml) FluoroNunc 96-well plates at 4°C over-
night. Titration ranges of the tested peptides (0 to 300 μM) were mixed with a fixed 
concentration (0.6 μM) of biotinylated indicator peptide and added to the wells. 
Bound indicator peptide was detected using europium-streptavidin (Perkin Elmer, 
Boston, MA) and measured in a time-resolved fluorometer (PerkinElmer, Wallac 
Victor2). IC50 values were calculated based upon the observed binding of the test 
peptide against the fixed concentration indicator peptide. The IC50 value depicts 
the concentration of test peptide required for a loss of 50% of the indicator peptide 
signal. IC50 values greater than 300 μM were classified as non-detectable binding 
affinity. 
Statistical analysis. Wilcoxon’s signed rank test was used to assess differences in 
IC50 values between citrulline and arginine containing peptides. P-values below 
0.05 were considered to be statistically significant.
RESULTS
Presentation of arginine and citrulline residues by HLA-DR3
The genes encoding for HLA-DRB1, HLA-DQA1 and HLA-DQB1 are highly poly-
morphic and many different alleles have been identified in the human population. 
The residues within the HLA-molecules involved in shaping peptide-binding pockets 






are known[6]. To select for HLA-DRB1 alleles that could potentially prefer citrulline 
over arginine residues, we made use of MHC motif viewer[14], a web server that 
displays peptide-binding motifs for all HLA-DR alleles using a predictive algorithm. 
We searched for non-SE alleles that are common in Caucasians and that display a 
predicted preference for negatively-charged amino acids. In this way, we selected 
HLA-DR3 (HLA-DRB1*03:01), one of the most common HLA-DR-molecules in Cau-
casians, for further studies. HLA-DR3 was predicted to have a strong preference 
for negatively charged amino acids in pocket 4. Figure 1A depicts the amino acid 
residues of HLA-DRB1*03:01 involved in shaping the various binding pockets and 
indicates that pocket 4 has a net-positive charge, thereby explaining the predicted 
preference for negatively-charged aa residues.
To systematically analyze if arginine-to-citrulline conversions of peptides enhanced 
the affinity for HLA-DR3, we selected a myoglobin-peptide that was previously des-
cribed to be accommodated by this allele and for which the peptide-binding register 
is known[11]. Next, we substituted each of the peptide positions interacting with 
peptide-binding pockets of the HLA-molecule for arginine or citrulline residues. The 
effect of these substitutions was subsequently studied in peptide-binding assays. In 
this way a systematic characterization of the ability of each of the peptide-binding 
pockets to accommodate arginine or citrulline residues was performed.
As depicted in Figure 1B, HLA-DR3 was unable to accommodate either arginine or 
citrulline in pocket 4. Also for the other peptide-binding pockets, arginine-to-citrul-
line conversion did not result in enhanced peptide-binding affinities. In contrast, in 
pocket 6 and 9 arginine- was preferred over citrulline-residues.














































β85 β86 β89 β90 β13 β26 β28 β70 β71 β74 β78 β11 β30 β28 β47 β61 β67 β71 β9 β37 β57
*03:01 V V F T S Y D Q K R N S Y D F W L K E N D
Pocket1 Pocket 4 Pocket 6 Pocket7 Pocket 9
Figure 1: Accommodation of citrulline and 
arginine residues by HLA-DR3 molecules. 
(A) Schematic representation of the pepti-
de-binding pockets of HLA-DR3. Aa residues 
are color coded according to their properties 
(white = hydrophilic, gray = hydrophobic, red 
= basic, blue = acidic). (B) Competitive binding 
of a biotin-labeled myoglobin-peptide with an 
unlabeled myoglobin-peptide or myoglobin-va-
riants with citrulline or arginine residues in p1, 
p4, p6, p7 and p9 to HLA-DR3. Graph depicts 
the IC50-values (μM). ND = Non-detectable 
binding affinity. Binding experiments were 
performed at least three times and plots show 
pooled experiments. The error bars show the 
variation between the different experiments.
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ne-residues in pocket 4 or any of its other peptide-binding pockets. It is therefore 
unlikely that HLA-DR3 would prefer peptides that contain a citrulline over their 
arginine counterparts.
Presentation of arginine and citrulline residues by HLA-DQ molecules.
Genes encoding for HLA-DR and HLA-DQ molecules are in tight linkage disequilibrium 
(LD) and inherit together in haplotypes. The ability of predisposing and non-predis-
posing HLA-DQ molecules to accommodate arginine and citrulline residues has not 
been studied, although it was described for different HLA-DQ molecules that they 
prefer negatively-charged amino acid residues, e.g. for HLA-DQ2 (DQB1*02:01/
DQA1*05:01), HLA-DQ7 (DQB1*03:01/DQA1*03:02) and HLA-DQ8 (DQB1*03:02/
DQA1*03:01). The latter two HLA-molecules are particularly interesting as these 
are encoded by genes that are in tight LD with SE alleles and hence also associate 
with RA-risk. Figure 2A shows the amino acids shaping the various peptide-binding 
pockets of these HLA-DQ molecules.
To systematically analyze if arginine to citrulline conversion of peptides enhanced 
their affinity for HLA-DQ molecules, we used a similar approach as applied for 
HLA-DR3. As the myoglobin-peptide cannot be presented by these HLA-DQ mole-
cules, we arginine- or citrulline-substituted two previously described epitopes 
derived from alpha-gliadin (HLA-DQ2) and from herpes simplex virus VP16-protein 
(HLA-DQ7 and HLA-DQ8) for which the binding register has been established[10, 12], 
Our data show that all three HLA-DQ molecules preferred citrulline over arginine 
residues in different peptide-binding pockets of the HLA-molecules. HLA-DQ7 
(Figure 2B) and HLA-DQ8 (Figure 2C) preferred citrulline over arginine residues in 
peptide-binding pocket 1, 6 and 9, whereas HLA-DQ2 (Figure 2D) molecules pre-
ferred citrulline residues in pocket 7 and 9.
Together these data demonstrate that an arginine to citrulline conversion can also 
enhance peptide-binding affinity for several HLA-DQ molecules thereby indica-
ting that this property is not confined to HLA-SE alleles. These data are important 
as they indicate that also HLA-DQ molecules could contribute to the induction of 
citrullinated-peptide-directed T cell immunity thought to contribute to the auto-im-
mune response underlying RA.
DISCUSSION
Over a decade ago, it was first demonstrated that arginine-to-citrulline conversion 
enhances the affinity of peptides for HLA-SE alleles[7]. It was suggested that this 
feature is unique to HLA-SE alleles and could thereby, explain the HLA-RA con-
nection. We now also analyzed non-SE alleles and demonstrate that also several 
HLA-DQ molecules have the enhanced capacity to present citrullinated peptides 






as we can clearly show that peptides that harbor a citrulline instead of arginine in 
positions interacting with peptide-binding pockets have an enhanced affinity.
Determining the capacity to present citrullinated neo-epitopes for all different 
HLA-molecules would require a large-scale approach given the fact that hundreds 
of different HLA-DR and HLA-DQ molecules have been described. However, the 
amino acid positions important for shaping peptide-binding pockets have been 
elucidated, thereby allowing us to predict HLA-DQ and HLA-DR molecules that are 
likely to display the capacity to present citrullinated neo-epitopes. In this study we 
α9 α24 α31 α32 α43 α52 β85 β86 β89 β90 β13 β26 β28 β70 β71 β74 β78
DQ2 Y H Q F W R L E T T G L S R K A V
DQ7 Y H E F W R L E T T A Y T R T E V
DQ8 Y H E F W R L E T T G L T R T E V
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α11 α62 α65 α66 α69 β11 β30 β28 β47 β61 β67 β71 α68 α69 α72 α73 α76 β9 β37 β57
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Figure 2: Accommodation of citrulline and arginine 
residues by HLA-DQ molecules (A) Schematic 
representation of the differences in peptide-bin-
ding pockets between HLA-DQ2, HLA-DQ7 and 
HLA-DQ8. Aa residues are color coded according to 
their properties (white = hydrophilic, gray = hydrop-
hobic, red = basic, blue = acidic). (B-C) Competitive 
binding of a biotin-labeled VP16-peptide with an 
unlabeled VP16-peptide or VP16-variants with cit-
rulline or arginine residues in p1, p4, p6, p7 and p9 
to HLA-DQ7 (B) and HLA-DQ8 (C). (D) Competitive 
binding of a biotin-labeled alpha-gliadin-peptide 
with an unlabeled alpha-gliadin-peptide or alpha-gliadin-variants with citrulline or arginine residues in 
p1, p4, p6, p7 and p9 to HLA-DQ2. Graphs depict the IC50-values (μM). ND = Non-detectable binding 
affinity. Binding experiments were performed at least three times and plots show pooled experiments. 
The error bars show the variation between the different experiments.
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focused on only a few SE-negative HLA class II molecules that are likely able to 
present citrullinated neo-epitopes. However, it is highly conceivable that also other 
unstudied HLA-DR or HLA-DQ molecules share similar capacities.
To the best of our knowledge the capacity of HLA-DQ molecules to present cit-
rullinated ligands has not been studied. Interestingly, in a recent study, it was 
shown that T cells of collagen-type II (CII)-immunized HLA-DQ8 transgenic mice 
respond better to citrullinated CII than to native CII, which could be explained by 
an enhanced capacity of HLA-DQ8 to present citrullinated neo-epitopes[15]. Our 
data demonstrate that the presentation of citrullinated ligands by HLA-DQ mole-
cules is not confined to those HLA-molecules associated with predisposition. The 
hypothesis that predisposing HLA-molecules associate with predisposition because 
of their capacity to present arginine-to-citrulline converted epitopes with an 
enhanced affinity is conceivably not explaining the complete molecular basis for 
the association between HLA-SE haplotypes and RA. It would, therefore, be interes-
ting to better comprehend the additional contribution of the molecules encoded by 
the HLA-SE-haplotypes to seropositive RA. Together, this study provides a further 
refinement of the SE-hypothesis and the possible contribution of citrulline-specific 
T cells in the pathogenesis of ACPA-positive RA.
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Expression of HLA class II molecules
HLA class II molecules are well-known for their role in the adaptive immune system. 
Particularly, these molecules are involved in presenting peptide-ligands that can be 
epitopes for CD4+ T cells. The expression of HLA class II molecules is restricted to 
professional antigen-presenting cells (e.g. macrophages, B cells and dendritic cells) 
and to specialized cells in the thymus involved in T cell education. In inflammation, 
these cells can increase their HLA-class II expression under the influence of IFN-
gamma and IFN-gamma can also induce the expression of HLA-class II molecules 
by non-professional cells[1]. In Chapter 2, we now describe for the first time HLA 
class II expression by mast cells, which is sufficient to activate CD4+ memory T cells. 
The expression of HLA-class II molecules is largely influenced by the presence of 
IFN-gamma. Interestingly, we also show that mast cells can internalize antigen and 
process antigen to T cell epitopes. This is particular interesting because mast cells 
are located at strategic locations throughout the body (e.g. the skin and the gut) 
and can therefore be one of the first cells that present antigens to nearby memory 
CD4+ T cells.
Presentation of ligands by HLA class II molecules
Since the early 90s ligands have been eluted from different HLA class II mole-
cules[2-7]. These studies have provided numerous information on the nature of HLA 
class II ligands and have clearly demonstrated that these ligands are very different 
from HLA class I ligands, both in their origin, the pathway of antigen-processing, 
as well as in length and in restriction. Also, these studies have provided insights 
in how structural difference between different HLA class II alleles are reflected in 
distinct peptide-binding repertoires. In Chapter 3 and 4, we describe two distinct 
HLA-class II molecules: HLA-DQB1*06:03 and HLA-DRB1*03:01 and correlate iden-
tified ligands to functional characteristics of the peptide-binding pockets.
In the last 25 years, there has been an enormous development in the instruments 
capable of measuring HLA-ligands. Whereas in the 90s, the number of ligands 
isolated from a single HLA class II molecules were generally below a hundred, in 
Chapter 3, we isolated over 13.000 ligands from a single HLA class II molecule, 
HLA-DRB1*03:01. This is the largest set of identified ligands that have ever been 
described and allowed us to perform analyses that were previously not possible. 
These analyses have provided novel insights into the nature of HLA class II ligands. 
For instance, we have shown that HLA class II ligands are not only conserved in 
amino acid positions involved in interacting with the HLA molecules peptide binding 
pockets, but also in N- and C-terminal residues projecting outside the HLA class II 
molecule.
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TOWARDS A MODEL FOR RA RISK.
Rheumatoid arthritis patients are a highly heterogeneous population[8]. Inte-
restingly, ACPA autoantibodies can subdivide RA patients in two distinct disease 
subsets, ACPA-negative and ACPA-positive RA patients. These patient subsets 
strongly differ with regard to important disease outcome measures (disease pro-
gression, chance for remission and radiographic damage), and risk factors (both 
genetic and environmental) (discussed in Chapter 5)[9-14].
The HLA class II locus is the most important risk factor for the development of RA, 
but the associated haplotypes differ between ACPA-positive and ACPA-negative 
RA (discussed in Chapter 6)[9, 11, 15, 16]. In Caucasians, HLA-DRB1*01/10:DQ5- 
and HLA-DRB1*04:DQ7/DQ8-encoding haplotypes are strongly overrepresented 
in ACPA-positive RA patients compared to healthy controls or ACPA-negative RA 
patients[17-19]. In addition to predisposing haplotypes, the HLA-DRB1*13:DQ6 
haplotypes associates with protection from ACPA-positive RA[14, 20, 21].
Only a small percentage of donors carrying risk haplotypes will develop ACPA-posi-
tive RA. This shows that their presence is not sufficient for disease development and 
that other factors are required and these findings suggest that the development of 
ACPA+ RA involves multiple hits. This is further supported by reports demonstra-
ting that ACPA-positivity can precede the onset of RA by up to ten years and that 
different environmental/genetic risk factors underlie the development of ACPA-po-
sitivity and the transition to ACPA-positive RA (Chapter 7)[22, 23].
Positivity for risk haplotypes is not required for the development of ACPA-positive 
RA as about 15% of patients are negative for these haplotypes. These patients are 
homozygous for a wide variety of other HLA-DR subtypes. The difference in the 
relative distribution of HLA-DR genotypes between ACPA+ RA patients and healthy 
controls (generally presented as odds ratios) could therefore best be explained by 
the sum of the risk to undergo the multiple hits required for disease development. 
This sum could be influenced by different factors (Figure 1):
(1)  Hit number. Etiological pathway in individuals positive for high-risk 
 haplotypes possibly require less hits (or less rare hits) (Figure 1A).
(2)  Hit risk: Etiological pathways in those positive for high-risk haplotypes   
 might require more prevalent hits (Figure 1B).
(3)  Multiple pathways: Individuals positive for high-risk haplotypes 
 might develop ACPA-positive RA via more different routes (Figure 1C).
The distribution of HLA-DR haplotypes in ACPA-positive RA patients is most likely 
explained by a combination of the three factors (Figure 1D).
TOWARDS A MOLECULAR BASIS
For this thesis we aimed to further elucidate the molecular basis of RA with a 







Initial loss of B cell tolerance.
ACPA autoantibodies can be detected in the serum of healthy donors up to ten 
years before disease onset without any clinical signs of arthritis[23]. Interestingly, 
the ACPA-response of healthy donors is characterized by low levels, little cross-reac-
tivity and low isotype usage[24]. Recently, it became increasingly clear that the HLA 
locus is playing only a minor role in the development of ACPA-autoantibodies as it 
was shown for both predisposing and protective HLA alleles that these do not asso-
ciate with the presence of ACPA in healthy donors (Chapter 7)[22]. In contrast these 
HLA alleles associate more with the transition from ACPA-positive to ACPA-positive 
disease (Chapter 7). This indicates that the initial development of ACPA is triggered 
by HLA-independent risk factors. These independent risk factors could be genetic 
factors that shape the threshold for B cell activation (e.g. PTPN22) or perhaps factors 
that increase “citrulline load”, e.g. polymorphisms in the PADI4 gene, anti-PAD anti-
bodies that enhance PAD function, chronic infection with PAD-containing bacteria 
or environmental factors like smoking and silica exposure that promote citrullina-
tion in the lungs[13, 22, 25-28].
Loss of T cell tolerance
The transition from ACPA-positivity to ACPA-positive RA is characterized by strong 
changes in the ACPA-response, including a rise in ACPA-levels, isotype-expansion 
and a more diverse fine-specificity profile[24]. These changes in the ACPA-pro-
file are likely the result of germinal center formation that are induced by T cell 
dependent B cell activation[29, 30]. A role for T cells during this phase is further 



























Figure 1: Schematic model explaining the HLA-RA connection. The risk of an HLA-genotype for RA 
development could be influenced by several factors including the number of required hits(A), the 
chance for a hit to occur (B) or the number of etiological pathways (C) Red lines indicate common hits, 
blue lines indicates rare hits.
Chapter 11190
supported by the observation that the HLA class II molecules associated with RA are 
mainly involved during this particular phase. In this thesis, three different potential 
pathways were studied (Chapter 8-10) that are summarized in Figure 2. Interes-
tingly, the molecular basis for all these pathways is different. The studied pathways 
will now be shortly summarized.
Molecular mimicry
In Chapter 8, we provide a first molecular basis for the role of both predisposing 
and protective HLA-alleles in ACPA-positive RA. As discussed, HLA-DRB1*13-posi-
tive donors are protected. HLA-DRB1*13 is particularly interesting as it was also 
shown to protect in the presence of shared epitope alleles indicating that HLA-
DRB1*13 could act in the same biological pathway as risk alleles, possibly by 
preventing a particular hit to occur[14, 31]. In Chapter 7, we studied the protective 
role of HLA-DRB1*13 during different phases of disease development. We could 
show that HLA-DRB1*13 does not protect from ACPA-positivity, only from ACPA-po-
sitive disease. These data indicate that this allele exerts (part of) its effect in the 
time-frame between ACPA-positivity and the development of ACPA+ RA. In Chapter 
8, we provide an explanation for the protective effect HLA-DRB1*13 alleles in the 
presence of SE alleles. We could show that predisposing HLA-DQ molecules (those in 
Figure 2: Summary of the studied molecular bases for the association between HLA, RA and citrullination
ARG
ARGCIT CIT DERAA
Citrulline-directed T-cells DERAA-directed T-cells
















LD with SE-alleles) have an exceptional capacity to present a group of peptides with 
the core sequence DERAA that are derived from microbes, vinculin and from HLA-
DRB1*13. Our data indicate a role for vinculin directed T cells, primed by pathogens 
in providing help to ACPA-producing B cells and a role for HLA-DRB1*13 in tolerizing 
this T cell population. Together this pathway explains part of the risk mediated by 
risk and protective haplotypes. Thus, this elegant pathway can explain a large part 
of the risk of SE-alleles and the protective effect of HLA-DRB1*13 alleles.
Enhanced HLA-affinity
It was previously shown for “Caucasian” SE alleles that these can present citrulli-
nated peptides with an enhanced affinity over their native counterpart[32-38]. In 
Chapter 10, we show that this capacity is not specific for SE alleles as it can also be 
found for several predisposing and non-predisposing HLA-DQ molecules, thereby 
providing a further refinement of the association between HLA-SE alleles, RA and 
citrullination.
Enhanced TCR-avidity
In Chapter 9, we show that not all HLA-SE alleles can present citrullinated epitopes 
with an enhanced HLA-affinity. SE-allele HLA-DRB1*14:02, frequent in indigenous 
North Americans, has no enhanced affinity for citrullinated epitopes over their 
arginine counterpart. However, we could demonstrate that HLA-DRB1*14:02 
presents citrulline residues in an orientation different from arginine residues, which 
could be a target of citrulline-directed T cells, thereby providing an alternative 
molecular basis for this HLA-SE allele.
CONCLUSION
In recent years, novel insights have been provided into the mechanisms underlying 
the association between the HLA system, RA and citrullination. Further elucidating 
the molecular basis for these associations will likely contribute to a better under-
standing of disease pathogenesis. The window between ACPA-positivity and disease 
development offers a unique opportunity for preventive treatment. As the HLA 
system plays a key role in disease development, elucidating the molecular basis for 
the association between HLA, ACPA and RA will be of pivotal importance. Excitingly, 
the data presented in this thesis together with other recent data, have provided 
novel insights into this long-known association.
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PRESENTATIE VAN PEPTIDEN DOOR HLA KLASSE II MOLECULEN
HLA klasse II moleculen spelen een belangrijke rol in het adaptieve immuunsysteem. 
Deze moleculen zijn gespecialiseerd in het presenteren van eiwitfragmenten, ook 
wel peptiden of liganden genoemd, op het oppervlak van cellen. Deze HLA-peptide 
complexen kunnen vervolgens herkend worden door CD4+ T cellen. Indien de T-cel 
receptor het HLA-peptide complex met voldoende aviditeit herkent, kan dit resul-
teren in T-cel activatie en bijbehorende effectormechanismen, zoals het primen van 
cytotoxische T cellen of het geven van hulp aan B cellen. Er zijn 3 typen HLA-klasse 
II moleculen: HLA-DQ, HLA-DR en HLA-DP. De genen die coderen voor deze mole-
culen bevinden zich op chromosoom 6 en zijn zeer polymorf. Dit betekent dat er 
verschillen zijn in de HLA klasse II moleculen tussen verschillende individuen. Deze 
verschillen bevinden zich met name in het gebied van het HLA klasse II molecuul 
dat betrokken is bij het presenteren van peptiden. Verschillende HLA klasse II mole-
culen presenteren dan ook een verschillend peptide-repertoire.
HLA klasse II moleculen komen tot expressie op professionele antigeen-presente-
rende cellen als macrofagen, B cellen en dendritische cellen. Daarnaast kunnen HLA 
klasse II moleculen tot expressie komen in gespecialiseerde cellen in de thymus, 
waar ze een rol spelen bij de positieve selectie van HLA klasse II gerestricteerde 
T cellen en de negatieve selectie van auto-reactieve T cellen. Tot slot kunnen ook 
andere cellen tijdens inflammatie HLA klasse II tot expressie brengen, zoals geac-
tiveerde T cellen en IFN-gamma gestimuleerde niet-hematopoietische cellen, zoals 
darmepitheelcellen, hepatocyten, pancreatische β-cellen en synoviocyten. In 
Hoofdstuk 2 beschrijven we dat ook humane mestcellen in lage hoeveelheden HLA 
klasse II tot expressie kunnen brengen, waarmee ze CD4+ memory T cellen kunnen 
activeren. De mate van expressie wordt in grote mate beïnvloed door de aanwezig-
heid van IFN-gamma.
In Hoofdstuk 3 en 4 hebben we HLA-peptide complexen geïsoleerd uit HLA klasse 
II homozygote cellen en de gepresenteerde peptiden geanalyseerd. In Hoofdstuk 3 
hebben we ons gefocust op HLA-DR0301 en in Hoofdstuk 4 op HLA-DQ0603. Het 
motief waaraan peptiden moeten voldoen om gepresenteerd te kunnen worden 
verschilt erg tussen deze twee moleculen. Dit kan verklaard worden doordat deze 
twee HLA-moleculen erg verschillend zijn in diverse posities die een rol spelen bij 
HLA-peptide interacties. HLA-DQ0603 heeft bijvoorbeeld een elektropositieve p6 
pocket, terwijl de p6 pocket van HLA-DR0301 elektronegatief is. De p6 pocket van 
DQ0603 heeft daarom een voorkeur voor zure aminozuren, terwijl de p6 pocket van 
DR0301 een voorkeur heeft voor basische aminozuren. Het gevolg is dat er weinig 
overlap is in de peptiden die gepresenteerd worden door deze twee moleculen.
Naast het bindingsmotief hebben we ook andere eigenschappen van de gepresen-
teerde peptides bestudeerd, zoals de lengte van de peptiden, fysisch-chemische 
eigenschappen en de eiwitten waarvan de peptiden afkomstig zijn. Deze studies 
hebben ons een goed beeld gegeven van de type peptiden die door HLA klasse II 
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moleculen gepresenteerd worden en hebben ons nieuwe inzicht verschaft in anti-
geen-processing en antigeen-presentatie.
ACPA-POSITIEVE REUMATOIDE ARTHRITIS
Het HLA klasse II locus is sterk geassocieerd met het ontwikkelen van auto-immuun-
ziekten. Dit suggereert een belangrijke rol voor antigeen-specifieke CD4+ T cellen 
in de ontwikkeling van deze aandoeningen. Tijdens ons onderzoek hebben wij ons 
met name gericht op reumatoïde artritis (RA). Dit is een systemische auto-immuun-
ziekte waarbij met name de synoviale gewrichten sterk aangedaan zijn. De mate 
van ontsteking is sterk afhankelijk van de aanwezigheid van een groep antilichamen, 
ACPA genoemd, die specifiek gericht zijn tegen gecitrullineerde eiwitten. Citrulline-
ring is een post-translationeel proces, waarbij arginine residuen worden omgezet in 
citrulline residuen. In de afgelopen 10 jaar is steeds meer duidelijk geworden dat 
er grote verschillen zijn tussen ACPA-negatieve en ACPA positieve RA patiënten. Zo 
verschillen deze patiënten in klinisch uitkomst, maar ook in genetische risicofac-
toren. Zo is het HLA klasse II locus de belangrijkste risicofactor voor de ontwikkeling 
van RA, maar speelt het vooral een rol bij het ontstaan van ACPA-positieve RA. Het 
begrijpen van deze associatie kan waardevolle inzichten verschaffen in de pathoge-
nese van ACPA-positieve RA.
Om ACPA-positieve RA goed te kunnen bestuderen is het belangrijk dat er goede 
tests zijn om ACPA te bepalen. In de kliniek wordt nu veel gebruik gemaakt van de 
anti-CCP-2 en anti-CCP-3 test. Deze tests kunnen met een hoge specificiteit ACPA+ 
RA patiënten identificeren. Echter, het is mogelijk dat toch een deel van de ACPA+ 
RA patiënten gemist wordt door de bestaande tests. Dit heeft geresulteerd in de 
ontwikkeling van multiplex-platforms, waarop serum van grote groepen patiënten 
getest kan worden op positiviteit voor een groot aantal gecitrullineerde antigenen. 
In Hoofdstuk 5 analyseren we de waarde van een multiplex-assay in vergelijking met 
bestaande ACPA tests of als mogelijke toevoeging. Uit deze analyses is gebleken dat 
deze multiplex-assay weliswaar goed het onderscheid kan maken tussen gezonde 
controles en RA patiënten, maar niet in staat is om onderscheid te maken tussen RA 
patiënten en patiënten met een andere reumatische aandoening. Deze test bleek 
dan ook niet geschikt als vervanging van of als toevoeging op de bestaande tests.
EEN MOLECULAIRE BASIS VOOR DE ASSIOCIATIE TUSSEN RA, ACPA EN HLA.
De genen die coderen voor HLA klasse II moleculen bevinden zich in een regio op 
chromosoom 6 met een sterk linkage-disequilibrium. Dit betekent dat deze genen 
in haplotypen overerven. De genen die geassocieerd zijn met RA zijn met name 
de genen die coderen voor de alfa en de bèta ketens van HLA-DQ (HLA-DQA1 en 
HLA-DQB1) en voor de bèta keten van HLA-DR (HLA-DRB1). Tot op heden is het niet 







Recentelijk zijn er diverse publicaties verschenen, waarbij middels een nieuw ont-
wikkelde statistische methode, gekeken kan worden naar individuele aminozuren 
binnen het HLA-molecuul en de associatie van die aminozuren met ziekte, waar-
onder met ACPA-positieve RA. De sterkst associërende aminozuren, geïdentificeerd 
met deze statistische methode, worden in causaal verband gebracht met de patho-
genese van RA. In Hoofdstuk 6 bediscussieerden we de uitkomsten en interpretatie 
van deze onderzoeken.
De analyses die we in Hoofdstuk 6 uitgevoerd hebben tonen opnieuw aan hoe 
lastig het is om middels genetische studies causaliteit binnen de HLA locus te 
onderzoeken en ondersteunen het idee dat dit causale verband alleen middels func-
tionele experimenten aan te tonen is. Het tweede deel van dit proefschrift is hier 
dan ook aan gewijd. De HLA klasse II locus speelt een dubbele rol in RA. Sommige 
haplotypen zijn sterk geassocieerd met predispositie (m.n. HLA-DRB1*04;DQ-
B1*03;DQA1*03), terwijl anderen sterk geassocieerd zijn met bescherming (m.n. 
HLA-DRB1*13-DQB1*06-DQA1*01). In Hoofdstuk 7 en 8 hebben we het bescher-
mende effect bestudeerd. Dit alles met de gedachte dat als we bescherming 
begrijpen, we mogelijk ook tot belangrijke inzichten komen wat betreft predispo-
sitie. In Hoofdstuk 7 hebben we bestudeerd wanneer de HLA-DRB1*13 moleculen 
hun beschermend effect uitoefenen. Het is bekend dat ACPA antistoffen soms 
wel 10 jaar voor het ontstaan van symptomen in het bloed van donoren terugge-
vonden kunnen worden. We hebben daarom bestudeerd of HLA-DRB1*13 vooral 
beschermt tegen het ontstaan van ACPA-positiviteit of tegen de transitie van 
ACPA-positiviteit naar ACPA+ RA. Uit deze studie blijkt dat HLA-DRB1*13 met name 
beschermt tegen de transitie naar ACPA-positieve RA. Dit is interessant omdat dit 
de fase is waar de ACPA respons een sterke maturatie laat zien, iets dat kan duiden 
op CD4-positieve T-cel hulp. Ook hebben de predisponerende haplotypen op dit 
moment hun effect, wat suggereert dat producten van de beschermende en pre-
disponerende haplotypen deel uit kunnen maken van dezelfde route. Dit versterkte 
onze gedachte dat het begrijpen van het beschermende effect van HLA-DRB1*13 
erg waardevol zou kunnen zijn. In Hoofdstuk 8 proberen we het mechanisme hier-
achter verder te begrijpen. In hoofdstuk 2 en 3, maar ook in eerdere studies, waar 
gekeken is naar peptiden gepresenteerd op HLA klasse II moleculen valt op dat veel 
gepresenteerde peptiden afkomstig zijn van andere HLA moleculen. Zo is er ook 
een peptide beschreven afkomstig van HLA-DRB1*13. Dit peptide heeft de ami-
nozuursequentie DERAA, een sequentie die naast HLA-DRB1*13 ook voorkomt in 
veel ziekteverwekkers en in vinculine. Vinculine is een eiwit dat voorkomt in de 
gewrichten, gecitrullineerd kan worden en waarvan we hebben aangetoond dat het 
in gecitrullineerde vorm herkend kan worden door ACPA. In hoofdstuk 8 beschrijven 
we een populatie CD4+ T cellen die specifiek gericht zijn tegen het DERAA-fragment 
van vinculine. Deze populatie CD4+ T cellen is afwezig in beschermde HLA-DRB1*13 
positieve donoren. Daarnaast laten we zien dat vinculine-DERAA specifieke T cellen 
kunnen kruisreageren met DERAA-bevattende peptiden van ziekteverwekkers. 
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Deze studie impliceert een rol voor vinculine-DERAA specifieke T cellen, geactiveerd 
tijdens infecties met DERAA bevattende ziekteverwekkers, in het ontstaan van anti-
stoffen tegen gecitrullineerd vinculine. Wanneer we verschillende HLA-moleculen 
vergeleken op hun capaciteit om DERAA-peptiden te presenteren ontdekten we 
dat deze peptiden erg goed gepresenteerd kunnen worden op predisponerende 
HLA-DQ moleculen. We hebben daarmee een moleculaire basis ontdekt voor het 
ontstaan van ACPA-positieve RA, die zowel het beschermende als het predispone-
rende effect kan verklaren.
De groep ACPA+ RA patiënten is erg heterogeen, bijvoorbeeld in ziekteactiviteit 
en in ACPA karakteristieken (zie ook hoofdstuk 7), maar ook in genetische predis-
positie. Zo is bijvoorbeeld een deel van de ACPA+ RA patiënten niet positief voor 
predisponerende haplotypen. Dit suggereert dat de route, zoals beschreven in 
hoofdstuk 8 niet de enige route kan zijn. We zijn daarom ook naar andere moge-
lijkheden gaan kijken. Zo is er een theorie dat de genetische predispositie deels 
verklaard kan worden door de presentatie van gecitrullineerde peptiden. In Hoofd-
stuk 9 en Hoofdstuk 10 hebben we hier verder onderzoek naar gedaan en op een 
systematische manier de capaciteit van verschillende HLA moleculen om gecitrulli-
neerde peptiden te presenteren vergeleken. We vonden zowel HLA-DR als HLA-DQ 
moleculen in staat zijn om gecitrullineerde peptiden te presenteren. Voor HLA-DR 
vonden we dat gecitrullineerde peptiden goed gepresenteerd worden door pre-
disponerende allelen, maar niet door alle predisponerende allelen. De capaciteit 
van predisponerende allelen om gecitrullineerde peptiden te presenteren wordt 
beïnvloed door bepaalde residuen in het HLA molecuul die betrokken zijn bij pepti-
de-presentatie en waarvan eerder gesuggereerd is dat ze betrokken zijn in RA.
Samenvattend verschaffen we in dit proefschrift nieuwe inzichten in anti-
geen-presentatie en in de contributie van HLA moleculen in de pathogenese van 
ACPA-positieve RA. Het verder begrijpen van de HLA-associatie zal naar alle waar-
schijnlijkheid zeer belangrijke inzichten verschaffen in de pathogenese van RA en 
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